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ABSTRACT
Human immunodeficiency virus (HIV) infection of macrophages in brain and other
tissues plays an important role in development of HIV-associated neurological disorders and
other aspects of disease pathogenesis. Macrophages express low levels of CD4, and macrophage-
tropic HIV strains express envelope glycoproteins (Envs) adapted to overcome this restriction to
virus entry by mechanisms that are not well characterized. One mechanism that influences this
phenotype is increased exposure of the CD4 or CCR5 binding site, which may increase
dissociation of soluble gp120 (sgp120) from Env trimers based on structural models. Little is
known about spontaneous sgp120 shedding from primary HIV Envs or its biological
significance. In this dissertation, we identify genetic determinants in brain-derived Envs that
overcome the restriction imposed by low CD4, examine spontaneous sgp120 shedding by these
Envs, and explore the biological significance of these findings. Sequence analysis of the gp120
3 strand of the CCR5-binding site bridging sheet identified D197, which eliminates an N-linked
glycosylation site, as a viral determinant associated with brain infection and HIV-associated
dementia (HAD), and position 200 as a positively-selected codon in HAD patients. Mutagenesis
studies showed that D197 and T/V200 enhance fusion and infection of macrophages and other
cells expressing low CD4 by enhancing gp120 binding to CCR5. Sgp120 shedding from primary
brain and lymphoid Envs was highly variable within and between patients, representing a
spectrum rather than a categorical phenotype. Brain Envs with high sgp120 shedding mediated
enhanced fusion and infection with cells expressing low CD4. Furthermore, viruses expressingiv
brain Envs with high sgp120 shedding had an increased capacity to induce lymphocyte activation
during PBMC infection, despite similar levels of viral replication. Genetic analysis demonstrated
greater entropy and positive selection in Envs with high versus low levels of sgp120 shedding,
suggesting that diversifying evolution influences gp120-gp41 association. Finally, we examined
V3 loop sequences from dual-tropic brain and lymphoid Envs and found that the frequency of
R5X4 HIV-1 is underestimated by most predictive bioinformatic algorithms. Together, these
studies provide a better understanding of how neurotropic HIV Envs adapt to target cells
expressing low CD4, and possible roles of these viral adaptations in disease pathogenesis.v
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The HIV/AIDS Pandemic
Since the first reports by the Centers for Disease Control of 5 cases of
Pneumocystis carinii pneumonia in young men in Los Angeles on June 5, 1981, acquired
immunodeficiency syndrome (AIDS) has become a worldwide pandemic (4). In 1984,
human immunodeficiency virus (HIV) was isolated from an AIDS patient and identified
as the causative agent of AIDS (5-7). Since that time, AIDS has resulted in more than 25
million deaths worldwide (UNAIDS 2011) and an estimated 34 million people are living
with HIV infection (UNAIDS 2011). There were 2.7 million new HIV infections reported
in 2010, down 21% from the peak of the global epidemic in 1997 (UNAIDS 2011).
Encouragingly, nearly 6.6 million people in low and middle income countries were
receiving HIV treatment at the end of 2010. As a consequence, HIV incidence in 33
countries, 22 of them in sub-Saharan Africa, continued to decline (UNAIDS Outlook
Report 2010) and the number of people dying from AIDS-related causes fell to 1.8
million, down from a peak of 2.2 million in the mid-2000s (UNAIDS 2011). However,
HIV incidence increased by more than 25% over this same period in 7 countries, 5 of
which are located Eastern Europe and Central Asia (UNAIDS 2009).
HIV is a lentivirus of family Retroviridae. Two types of HIV (HIV-1 and HIV-2)
circulate worldwide. HIV infection in humans is the result of several cross-species
transmission events of simian immunodeficiency viruses (SIV): HIV-1 from a single
chimpanzee to human transmission event (SIVcpz) and HIV-2 most likely from a sooty
mangaby transmission event (HIVsmm). HIV-1 is more common and virulent, with a
prevalence of almost 90%. In contrast, HIV-2 is less easily transmitted, occurring in a
few countries in Western Africa, Europe, and India (11-13) (hiv.lanl.gov).3
HIV-1 infection is characterized by high levels of genetic diversity due to error-
prone proofreading by the viral polymerase, high generation rate of viral particles,
recombination, and hypermutagenesis induced by APOBEC3G (12-14). HIV-1 exists as 3
distinct genetic groups: M (major),
O (outlier), and N (non-M or O)
(Fig. 1.1). The M group consists of
over 95% of global viral isolates
and consists of at least 12 distinct
phylogenetically associated
subtypes or clades (A1, A2, B, C,
D, E, F1, F2, G, H, J, and K) based
on sequences of complete viral
genomes (12-13). These clades
represent different lineages of HIV,
and have different geographical
distributions. HIV isolates within
a clade may exhibit nucleotide distances of up to 30%; interclade genetic variation can
range between 30-40% depending on the gene analyzed (12-13). Furthermore, all
retroviruses have a propensity to recombine, and in HIV-1 group M viruses this
propensity has resulted in at least 46 circulating recombinant forms (CRFs) that arose due
to infection of a single individual infected with 2 clades. Clade C viruses represent more
than 50% of infections worldwide and are most prevalent in sub-Saharan Africa, China,
Figure 1.1 Phylogenetic analysis of HIV and SIV
sequences from LANL.
A neighbor-joining phylogenetic tree was
constructed to examine relationships between HIV
and SIV sequences in the LANL database
(hiv.lanl.gov). Groups are indicated with curved lines.
Type sequences (HXB2 for HIV, SIVMM239 for
SIV, are shown in bold type. Adapted from (Calef et
al 2005) (8).4
and India. Clade B viruses are most prevalent in western Europe, the Americas, and
Oceania (12-13) (UNAIDS 2010) and are the most frequently studied clade.
Clinical Course of HIV infection
CD4+ T cells, macrophages, and other cells of the monocyte lineage are key
targets of HIV infection. HIV is transmitted either by mucosal exposure during sex or
breast feeding, or by direct blood-to-
blood contact. The clinical course of
HIV infection is characterized by an
acute infection with high levels of
viremia and irreversible damage to
the immune system, in particular the
gut-associated lymphoid tissue
(GALT). This is followed by a chronic
phase with persistent immune
activation and slow depletion of CD4+
T cells, ultimately resulting in the
progressive immune exhaustion and
profound immunodeficiency that
define AIDS (Fig. 1.2) (13, 16-18).
The acute stage of HIV infection,
which lasts from1-3 weeks post-
exposure, is characterized by a peak in
Figure 1.2. The clinical course of HIV infection.
Changes in mucosal and blood CD4+T cell numbers
and in viremia levels over the course of HIV infection
are shown schematically in relation to changes in the
relative level of immune activation. During acute
infection, mucosal T cells (purple) drop, viremia
(green) rapidly rises to a maximum peak, and CD4+ T
cell counts (blue) decline sharply at first but then begin
to rise to a moderately subnormal level. In the chronic
phase, immune activation slowly increases (red).
Mucosal CD4+ T cell numbers remain low, CD4+ T
cell count slowly declines, and viremia rises. As overt
AIDS is approached, changes seen in the chronic phase
accelerate. Over the course of the chronic phase and
into AIDS, the regenerative capacity of the immune
system is destroyed (+++ to +), and target cell
selectivity drops (++++ to +). Adapted from (van Marle
et al 2005) (15).5
viral replication and a dramatic decline in CD4+ T cells. CCR5+ CD4+ memory T cells
are depleted from mucosal effector sites due to direct infection, bystander effects, and
immune activation (17, 19). There is massive depletion of lamina propria CD4+ T cells in
the first 3-6 weeks after transmission, and this cell loss is constant throughout the chronic
stage of infection. After this peak in viremia, plasma RNA levels decrease over a 4-5
month period and CD4+ T cells subsets partially recover, though not to pre-infection
levels (18, 20-21).
In the weeks to months after acute HIV infection, most individuals enter a
clinically asymptomatic period characterized by low viremia (viral setpoint) and
seroconversion. This chronic stage then lasts for approximately 10 years (17-18). During
this time, steady-state viremia is fueled by rapid and continuous infection of target cells.
Viral loads remains relatively constant in a given patient over a long period as
equilibrium is reached between viral production and viral clearance. In reservoirs such as
lymphoid tissue, there is a sharp decline in frequency of productively infected cells.
Germinal center formation within lymphoid follicles becomes pronounced, and viral
RNA corresponding to extracellular virions complexed with antibody and complement is
detected in the network of follicular dendritic cell (FDC) processes. The massive
numbers of virions trapped within the FDC network as well as latently infected cells
(which harbor proviral DNA but do not express viral proteins) represent potentially
continuous sources of virus for de novo infection of CD4+ T lymphocytes that are
resident in or migrating through lymphoid tissues. Moreover, activation signals such as
those delivered by proinflammatory cytokines, which are found in abundance within
activated lymph nodes, are potent inducers of HIV replication in latently infected cells.6
Lymphoid tissue remains the most important reservoir of systemic HIV infection
throughout the course of disease. Thus, viral replication continues in the lymphoid
compartment, and transient peaks in viremia may be detected throughout this period (17-
18, 21).
During the course of the chronic stage of infection, there is a slow but steady
decline in CD4+ lymphocytes and resulting impairment of the immune system. CD4+ T
cells counts are an excellent marker of degree of immunodeficiency and can determine
the immediate risk of opportunistic infections and other AIDS-related complications (17).
Disease progression results in destruction of lymph node architecture as a consequence of
viral replication and chronic immune activation. This leads to an increase in virus
diffusion to surrounding CD4+ T-cells and favors HIV-1 spread within the local, regional
and systemic lymphoid environment. Particularly at this stage, HIV infection is
associated with an extensive replication in the gut lamina propria and submucosa and in
draining lymph nodes, with local depletion of CD4+ T-cells (18, 21).
In the absence of virus containment, CD4+ T cell counts decrease below 200
cell/l of blood, resulting in loss of cell-mediated immune responses and allowing
ubiquitous environmental organisms with limited virulence to become life-threatening
pathogens. The average time from infection to progression of AIDS is extremely variable,
but is estimated to be on average 11 years (18). Incidence of AIDS-defining illnesses in
industrialized nations has decreased sharply since 1996 due to highly active antiretroviral
therapy (HAART) and improved access to health care (17).7
Host Immune Responses to HIV infection
HIV infection is characterized by chronic immune activation and progressive
depletion of CD4+ T cells, leading to immune system dysfunction and development of
opportunistic infections and cancers that define AIDS (22). The level of chronic immune
activation correlates with virus load and clinical outcome, with high immune activation
associated with high viral loads and more rapid progression to AIDS and death (23).
HIV infection in humans is closely related to SIV infection in nonhuman
primates. More than 40 species of nonhuman primates are endemically infected with
species-specific SIVs, but unlike HIV, SIVs do not induce immunodeficiencies in their
natural hosts. Differences that have been proposed to contribute to the lack of disease
progression in SIV infection include preservation of healthy levels of peripheral CD4+ T
cells and mucosal immunity, prevention of microbial translocation, maintenance of
normal lymph node architecture and function, preferential sparing of central memory
CD4+ T cells from infection, and lack of chronic immune activation (11).
One of the major challenges associated with HIV infection is that the correlates of
protective immunity are not understood. During acute HIV-1 infection, there is a burst of
inflammatory cytokines promoting cellular activation and potentially inducing
proliferation of CD4+ T cell targets, which would fuel viral replication (24). During the
transition from acute to chronic stages of HIV-1 infection, CD8+ cytotoxic T lymphocyte
(CTL) responses correlate with an initial decline in virus replication. However, despite
this decline in HIV-1 viremia, the majority of HIV-infected individuals are unable to
control virus replication below the level of detection without antiretroviral therapy.
Classic MHC class I-restricted, HIV-specific CTL responses have been demonstrated8
against a variety of HIV proteins, including core proteins, reverse trancriptase (RT), Env,
and regulatory proteins. In particular, a large body of evidence suggests that Gag-directed
responses are immunodominant in chronic HIV infection and are associated with low
viral loads (17, 25). CD4+ T cells, a major target of HIV infection, contribute to
maintenance of host immunity by facilitating CTL and antibody response (26). Natural
killer (NK) cells also contribute to the control of HIV-1 infection through clearance of
infected cells via recognition of virally infected cells by activating and inhibitory killer
immunoglobulin-like receptors (KIRs) and mediating antibody-dependent cellular
cytotoxicity (ADCC) (27-28).
The initial antibody response appears at roughly two weeks post-exposure and is
directed towards nonneutralizing epitopes on the envelope glycoprotein (Env) gp41
subunit. This response is followed within weeks by antibodies directed against the Env
gp120 subunit and capsid (CA, p24) (17, 28-29). Neutralizing antibody (nAb) responses
that block HIV infection of transmitted and early viruses are delayed, rising months after
infection (28). NAbs may be type-specific (i.e. specific for one viral isolate) or broadly
neutralizing (i.e. specific for a broad range of viral isolates), which are rare. NAbs are
detected in circulation within the first year, but in most patients nAb responses lag behind
viral escape and are generally not associated with control of viremia (17, 28, 30).
HIV infection is associated with increased expression of proinflammatory
cytokines (including TNF- IL-1, and IL-6) secreted by PBMCs and macrophages.
These cytokines are found at elevated levels in plasma, cerebral spinal fluid (CSF), and
tissues. Chronically infected T cells and macrophages in lymphoid tissues also produce
IFN- and IL-10. Disease progression is characterized by loss of the ability to produce9
immunoregulatory cytokines such as IL-2 and IL-12, which are critical for effective cell
mediated immune responses and required to stimulate proliferation and lytic activity of
CTLs and NK cells (17).
During late stage infection, a decline in HIV-specific CTL activity correlates with
disease progression. This loss of HIV-specific CTL activity is the result of
downregulation of MHC class I molecules necessary for CTL recognition by viral
proteins Tat, Nef, and Vpu (13, 17, 31) and loss of the IL-2 receptor (CD25) required for
proliferation due to clonal exhaustion from high levels of viral antigens (17, 25). CD4+ T
cells also develop an abnormal phenotype, characterized by loss of the CD25 marker and
resulting in bystander apoptosis and clonal exhaustion or anergy (17, 32). Monocyte and
macrophage dysfunction due to chronic immune activation can contribute to T cell
dysfunction and results in impaired defenses against intracellular parasites (17).
The introduction of antiretroviral therapy (ART) has led to improved outcomes
for individuals with HIV infection. A reduction in HIV viral replication is followed by
recovery of CD4+ T cell lymphocyte numbers, at least partial restoration of overall
immune function, and a reduction in the frequency of opportunistic infection. This
process is known as immune reconstitution. However, some individuals on ART
experience a clinical deterioration, termed immune reconstitution inflammatory
syndrome, despite apparent virological and immunological response to therapy (33).10
HIV Virus
Viral Genome Organization
HIV and SIV are members of the Lentivirus genus of the Retroviridae family,
which are characterized by the ability to reverse transcribe RNA into DNA during viral
replication. The retrovirus genome is composed of two identical copies of a positive-
sense, single-stranded RNA molecule noncovalently linked near the 5’ ends. The
genomic RNA encodes the group-specific antigen (gag), polymerase (pol), and envelope
(env) structural genes, flanked by long terminal repeat (LTR) regions, and a complex
combination of type-specific regulatory and accessory genes. The three primary structural
gene products are initially synthesized as polyprotein precursors, which are subsequently
processed by viral or cellular proteases into viral proteins (Fig. 1.3). Gag is cleaved into
the matrix (MA), capsid (CA), nucleocapsid (NC), and p6 proteins. The Gag-Pol
polyprotein is autocatalyzed into the protease (PR), reverse transcriptase (RT), and
integrase (IN) proteins. Env is cleaved into the gp120 surface and gp41 transmembrane
glycoproteins, which remain associated via noncovalent interactions. The remaining 6
HIV-1 encoded proteins (Vif, Vpr, Tat, Rev, Vpu, and Nef) are primary translation
products of spliced mRNAs. In addition to gene products, the retroviral genome also
contains structural regulatory motifs, such as the trans-active response element (TAR)
and Rev response element (RRE), which are required for transcription and export of non-
spliced and partially spliced viral mRNAs to the cytoplasm (13, 18, 34-35).11
Figure 1.3. HIV-1 genome organization.
The ~9.7 kb HIV-1 genome encodes gag, pol, and env genes flanked by long terminal
repeat (LTR) regions, and a number of accessory genes (vif, vpu, vpr, rev, tat, and nef) in
3 open reading frames. Numbering is relative to reference sequence HXB2. Adapted from
(HIV Sequence Compendium, 2005).
HIV Life Cycle
HIV-1 is an enveloped retrovirus with a distinct
cone-shaped core composed of CA (p24), which
encases the viral genome (Fig. 1.4). Inside the core, the
genome is bound to NC and complexed with IN and
RT. The capsid is surrounded by a layer of MA (p17)
proteins, which are anchored to the outer viral
membrane, a lipid bilayer that includes trimeric Env
spikes formed by the gp120 and gp41 subunits. The
bilayer may also incorporate host cell membrane
proteins during the budding process, including HLA
class I and II proteins and adhesion proteins such as
ICAM-1. Additional viral proteins, including p6, Vpr,
and PR, and numerous cellular proteins, including
cyclophilin A and APOBEC3G, are also incorporated
into the viral particle (13, 18, 34, 36-37).
Figure 1.4. Organization of the HIV-1
virion.
HIV-1 virions consist of a conical core
of capsid containing two copies of the
RNA genome bound to nucleocapsid,
and complexed with integrase and
reverse transcriptase. The core is
surrounded by matrix protein and is
bound by a lipid envelope containing
heterodimeric trimers of the Env
transmembrane subunit (gp41) non-
covalently attached to the surface
subunit (gp120). Adapted from
(http://www.brookscole.com/).12
The HIV life cycle begins when gp120 binds to CD4 on the cell surface,
triggering a cascade of conformational changes that result in fusion between the viral and
host cell membranes (described in more detail later) (Fig.1.5). Following entry, the core
is released into the cytoplasm, where partial uncoating occurs (18, 37-38). RT then
converts the viral RNA into linear double-stranded viral DNA (13). The viral DNA is
assembled along with cellular and viral proteins including MA, IN, and RT into a large
nucleoprotein complex (preintegration complex, or PIC). Following dissolution of the
partial CA core, the PIC is trafficked from the host cell periphery into the nucleus
through the nuclear pore complex. The viral DNA is then integrated into the host cell
genome by IN, which cleaves nucleotides of each of the 3’ ends of the double helix DNA
and transfers the modified provirus DNA into the host genome in a sequence-independent
manner (13, 38-40). Following activation of the host cell, the RNA polymerase II
holoenzyme is recruited to the LTR to transcribe proviral DNA into mRNA, initially
resulting in early synthesis of regulatory proteins Tat, Nef, and Rev. Tat binds to the TAR
site at the 5’ end of the HIV RNA and stimulates transcription and formation of longer
RNA transcripts. Nef activates viral transcription by inducing transcription factors that
transactivate the LTR. Rev binds to the RRE and facilitates transcription of longer RNA
transcripts, expression of structural and enzymatic genes, and inhibits production of
regulatory proteins, thereby promoting formation of mature viral particles. Spliced and
unspliced viral mRNA migrates into the cytoplasm, where structural proteins are
produced (13, 31, 34, 38). The uncleaved Gag polyproteins are the major viral structural
proteins and direct several activities necessary for viral particle formation. MA is
responsible for targeting polyproteins and recruited essential viral components (including13
the RNA genome and Env) to the viral assembly site located at the plasma membrane,
while CA and NC drive multimerization and encapsidation of the viral genome. This
immature particle migrates to the cell surface, where the Gag and Gag-Pol polyproteins
are cleaved by PR, resulting in rearrangement of the virion and creating mature,
infectious virus particles. P6 recruits the ESCRT complex (endosomal sorting complex
required for transport) to mediate scission of the nascent budding virion from the host
cell, where it acquires a lipid envelope containing the Env trimeric spikes (13, 36, 38,
41).
Figure 1.5. The HIV Life Cycle.
Steps in the HIV-1 replication cycle are shown in the context of the host cell and are
described in the text. Adapted from (Engelman & Cherepanov 2012) (38).
During the HIV life cycle, the accessory proteins Vpu, Vif, Vpr, and Nef optimize
viral replication. Vpu counteracts the type II transmembrane protein tethrin (CD317 or
BST2), which inhibits release of budding particles by retaining them at the plasma
membrane. Vif enhances viral infectivity by degrading the cellular antiviral factor14
APOBEC3G. Vpr is part of the PIC and is involved in transport through the nuclear pore
complex. Vpr also enhances replication by arresting infected cells in the G2 phase of the
life cycle, and stimulates replication in MDM. Nef is a multifunctional protein with many
roles during the HIV life cycle, including downregulation of CD4 and MHC class I,
modulation of cellular signaling pathways, and enhancement of viral infectivity and
replication (13, 31, 38, 42).
HIV Envelope Glycoprotein
HIV Env Synthesis and Processing
The HIV envelope glycoprotein (Env) is synthesized from a singly spliced 4.3-kb
Vpu/Env bicistronic mRNA. The 160-kd polyprotein precursor is a type 1 integral
membrane protein, which is anchored to cell membranes by a hydrophobic stop-transfer
signal. The amino-terminal segment of the mRNA contains a short, hydrophobic signal
peptide, which is recognized by the cellular signal recognition particle (SRP) and inserted
into the bilayer of the rough endoplasmic reticulum (rER). Following translocation across
the rER membrane, the signal peptide is cleaved by a cellular protease and gp160 is
glycosylated. Env, particularly gp120, is heavily glycosylated, with half its molecular
weight composed of oligosaccharide side chains. The sites of covalent attachment are
Asn for N-linked sugars, at an Asn-x-Ser/Thr sequence, where x is any amino acid except
Pro. These oligosaccharides are then processed, with the glucose removed to form high-
mannose chains. In addition to the attachment of N-linked glycans, HIV Envs may also
be modified with O-linked (or mucin-type) carbohydrates attached to the hydroxyl group
of Ser and/or Thr (13, 43-44). Following modification, gp160 rapidly associates with host
chaperone BiP/GRP78, forms disulfide bonds, and undergoes oligomerization. The15
predominant oligomeric form is a trimer. As the ribosome approaches the end of the
mRNA, the emergence of a long, hydrophobic amino acid sequence prevents the Env
polyprotein from being released into the rER lumen. The amino acids following this
membrane anchor extend into the cytosolic space and form the gp41 cytoplasmic tail
(CT).
Gp160 is then transported to the Golgi, where it is proteolytically cleaved by furin
or a furin-like protease following the sequence Arg-x-Lys/Arg-Arg to release the mature
gp120 surface and gp41 transmembrane subunits. This cleavage is required for Env-
induced fusion activity and infectivity. Subsequent to cleavage, gp120 and gp41 form a
noncovalent association that is critical for transport of the Env complex from the Golgi to
the cell surface, where it is incorporated into viral particles. Env on the cell surface is
rapidly internalized unless stabilized by Pr
55Gag though a Tyr-x-x-Leu (YXXL) sequence
in the gp41 CT. The YXXL motif interacts with clathrin adapter complexes, and is
important for controlling Env expression levels on the cell surface (13, 44-45).
Sequence and Structure of HIV Env
Figure 1.6. Organization of HIV-1 envelope glycoproteins.
HIV Env is translated as polyprotein precursor gp160 and cleaved by cellular proteases
into surface subunit gp120 and transmembrane subunit gp41. C, conserved region. V,
variable region. HR, heptad repeat region. MSD, membrane-spanning domain.16
HIV Env consists of a surface-
exposed gp120 and a transmembrane
gp41 subunit (Fig. 1.6) (9). The
gp120 subunit is approximately 550
amino acids in length and contains an
average of 25 N-linked glycosylation
motifs. Gp120 sequences are
composed of five alternating
conserved (C1 to C5) and variable
(V1 to V5) regions. The conserved
regions comprise the protein core,
which contains an inner and an outer domain based on their orientation to the trimer axis
(Fig. 1.7). The gp120 core outer domain is heavily glycosylated. This “glycan shield” is
important for maintaining Env structure, providing protection against cellular proteases,
and occluding receptor binding sites and neutralization epitopes (46). Intramolecular
disulfide bonds result in arrangement of the first four variable regions into surface-
exposed loops that extend from the core and partially occlude the coreceptor-binding site
and neutralization epitopes (10, 47-49). The gp41 N-terminus (ectodomain) contains the
fusion peptide, a domain of hydrophobic residues which inserts into the target cell
membrane. There are 2 heptad repeat regions (HR1 and HR2), which are alpha-helical
domains that form stable trimeric coiled-coils during membrane fusion (50-51). The gp41
subunit had a long cytoplasmic tail, which contains intracellular targeting signals and
interacts with MA to allow efficient Env incorporation into virions (50). Residues
Figure 1.7. HIV gp120 core structure.
Structure of HIV gp120 from the HXB2 gp120-
CD4-mAb 17b complex crystal structure (1G9N)
(Wyatt et al., 1998). Inner and outer domains are
based on their relative orientation to the trimer
axis. The orientation of gp120 relative to the viral
membrane is indicated on the left N-linked
glycans are shown on the outer domain. Adapted
from (Wyatt et al 1998) (10).17
identified as important contact points between gp120 and
gp41 are located in the gp120 N-terminus, C2, and C4
regions and the gp41 N-terminus, HR2, membrane-
spanning domain (MSD), and C-terminus (52-59).
HIV Env is organized into trimers on the surface
of virions and infected cells, with the gp120 and gp41
subunits of each monomer remaining associated through
noncovalent interactions (Fig. 1.8). In the CD4-bound
state, two β-hairpins that extend from the inner domain 
(strands β2–β3) and outer domain (β20–β21) come 
together to form a four-stranded “bridging sheet”
minidomain (3, 60). In contrast, a crystal structure of an
unliganded SIV Env showed that in the unliganded core, neither the CD4 nor coreceptor
binding sites were properly formed (Fig. 1.9). In this structure, the CD4-binding loop
projected away from the center of the outer domain, with the 20-21 ribbon tucked
beneath it (3). The -helices of the inner domain, the CD4-binding loop, and the 20-21
ribbon created a long, narrow cavity lined principally with hydrophobic side chains (3). It
was proposed that following CD4-binding to a face of the outer domain partly concealed
within this cavity, the bridging sheet would close up to create the coreceptor binding site,
flanked by the V1/V2 and V3 loops (3).
Figure 1.8. 3D structure of
the HIV Env spike.
Placement of the gp120-CD4-
Fab 17b complex in the
electron density map derived
from cryoelectron tomography
(light gray), with gp120 and
residues involved in gp41
interactions colored in blue
(balls and sticks), and Fab 17b
in light brown. Adapted from
(Pancera et al. 2010) (2).18
Recent mapping of ligand-induced changes in CD4-bound and unliganded HIV
Env crystal structures revealed extensive conformational movement for these β-hairpin 
ribbons of the bridging sheet structure and much less movement for the outer domain.
Quantification of these changes showed that the outer domain moved on average only ~2
Ǻ, the inner domain ~ 4 Ǻ, and the bridging sheet residues ~ 10 Ǻ. These results 
suggested that the unliganded HIV gp120 core more closely resembled the CD4-bound
state than the SIV unliganded Env (60).
Data from thermodynamic studies of gp120 binding to CD4 and to a number of
CD4 binding-site antibodies, and from the SIV unliganded gp120 core structure,
suggested that the structure of unliganded HIV-1 gp120 would be substantially different
from the CD4-bound conformation. However, conformation-dependent ligands, including
Figure 1.9. Crystal structure of liganded HIV and unliganded
SIV gp120.
A) Conformation of the deglycosylated HIV gp120 core, complexed
with CD4 and the Fab fragment of 17b, with the outer domain on the
right and the inner domain on the left. CD4 and Fab have been
omitted for clarity. Twelve disordered V4-loop residues are shown
as a dashed line. Outer domain is in blue; inner domain, colored
according to substructure (N terminus, orange; α1, yellow; three-
strand sheet, cyan; outer/inner domain transition, purple; α5, green; 
bridging sheet, red). B) SIV gp120 core structure, in the same view
and colors as (A). Adapted from (Chen et al. 2005) (3).
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CD4 and monoclonal antibodies (mAb) 17b, b12, b13, F105, and other antibodies that
recognize non–CD4 bound conformations of gp120, recognized the unliganded Env
constructs. These results suggest that ligand binding is not required for Env to obtain the
CD4-bound conformation (60). However, these crystal studies rely on gp120 core
structures that have the first three variable loops and parts of the gp120 core, including
but not limited to the N- and C-termini, removed, possibly resulting in adoption of
conformations that may not exist in the native trimer. Moreover, a number of biochemical
studies have suggested that unliganded Env continuously samples different
conformational states (53, 61-62), suggesting that gp120 core structures used for
crystallization adopt the most energetically favorable of any number of possible
conformations.
Although there are no high resolution structures of gp41, assumptions can be
made based on structural and functional studies. Data support a trimeric model of gp41 in
which the prehairpin intermediate state exists as a parallel trimer of fully-extended
ectodomains between the HIV membrane and the fusion peptide inserted into the target
cell membrane. There is also evidence for the final six-helix bundle (6HB) N-helix-turn-
C-helix hairpin structure (63). Experimental evidence indicates that the membrane
proximal external region (MPER), which is composed of the conserved cysteine-bound
loop between HR1 and HR2 and a conserved region N-terminal to the MSD are surface
exposed, as this region contains epitopes for antibodies directed against HIV (3, 64-66).
Recent cryoelectron tomographic studies of several HIV-1 and SIV strains have
provided insights into the molecular architectures of trimeric Env displayed on native
virions in unliganded, antibody-bound, and CD4-liganded states at resolutions of20
approximately 20 Å (Fig. 1.10). These analyses have
established that trimeric Env from HIV-1 undergoes a
large structural transition from a “closed” unliganded
state to an “open” liganded state when complexed to
CD4 and 17b (Fig. 1.11). This appears to be coupled
with a rearrangement of the gp41 region along the
central axis of the trimer, leading to closer contact
between the viral and target cell membranes. This
quaternary structural change involves rotation of
each gp120 protomer by about 45° around an axis
parallel to the central threefold axis, coupled with an
out-of-plane rotation of about 15°. In some strains,
such as SIV CP-MAC, trimeric Env is already
present in this open conformation even in the absence of soluble CD4 (sCD4), providing
an explanation for CD4-independent viral entry by this strain (9, 67). Interestingly, these
trimeric structures suggest that the gp120 V1/V2 and V3 loops come together to form the
apex of the trimeric structure. This is supported by studies suggesting that V1/V2 and V3
participate in epitope masking in the trimeric structure. However, conflict exists over
whether this epitope masking occurs on the same protomer (cis masking) or
interprotomer (trans masking). The trimeric structures, however, seem to support a model
of trans masking, with V1/V2 loops from one protomer making contacts with the V3
loop on a neighboring protomer within the trimer structure (55, 68-70). This issue
remains to be elucidated by further structural modeling and functional studies.
Figure 1.10. 3D representation of
the HIV Env trimer.
Density map of structure of the
HIV Env glycoprotein trimer
spike. Monomeric CD4-liganded
crystal structure is fit onto the
model, with gp120 shown in red,
and 17b Fab fragment in blue.
Likely locations of V1/V2 loops
and gp41 are indicated by
asterisks. Adapted from (Liu et al.
2008) (9).21
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Figure 1.11. Changes in gp120 in Env trimer induced by CD4-binding.
A) SIV Env trimer modeled in the unliganded conformation (left panel) and CD4-bound
conformation (right panel), viewed along the three-fold axis from outside the virion
towards gp41. The polypeptide chain backbones are in ribbon representation; N-linked
glycans are stick models; deleted V1–V2 and V3 segments are transparent balloons. The
three monomers are in red, green and blue, respectively; the sugars, in grey. gp41 is
shown as a circle in the rear. Adapted from (Chen et al 2005) (3). B) Model for the
conformational change from the unliganded (left panel) to the CD4-bound state (right
panel) shown as top view. The gp120 core, CD4, V1/V2 and V3 stems are shown in
white, yellow, red and green, respectively. Adapted from (Liu et al 2008) (9).
HIV Fusion and Entry
HIV entry into cells is initiated by a high affinity interaction between gp120 and
CD4 (Fig. 1.12). CD4 binding induces conformational changes in gp120 that involve
rearrangements of the hypervariable loops and formation and exposure of the coreceptor
binding site (71-72). In addition to gp120 rearrangements, the gp41 HR1 and HR222
domains are exposed and arrange into the prehairpin conformation. These conformational
rearrangements are detected by exposure of the coreceptor-binding site following CD4-
binding, and by reactivity of the CD4-bound Env with antibodies and synthetic peptides
against the gp41 HR domains (72). CD4-induced conformational changes vary depending
on experimental conditions and HIV isolates. Higher CD4 binding affinity from HIV
strains adapted to grow on immortalized T-cell lines (lab-adapted isolates) results in
greater HR1/HR2 exposure compared to primary isolates, which may require CCR5
binding to fully expose these regions. Pretreatment with high concentrations of sCD4 at
physiological temperatures render virus noninfectious, proceeding through a transient
activation of Env followed by irreversible loss of function. This may be associated with
the observation that CD4 binding in vitro facilitates dissociation of gp120 from gp41, a
phenomenon referred to as soluble gp120 (sgp120) shedding. It remains controversial
whether gp120 needs to be shed from gp41 in order to trigger fusion (72). There are
suggestions that sgp120 shedding may be required to overcome the large activation
energy barrier at the post-coreceptor binding stage, thereby relieving restriction of gp41
refolding (61, 72).
Current models suggest that formation of Env-CD4-coreceptor complexes leads to
exposure of the gp41 fusion peptide, which interacts with the target cell membrane. The
Figure 1.12. HIV Fusion with the Target Cell Membrane.
Steps in the membrane fusion process are shown with the viral membrane on
the bottom and the target cell membrane on the top. Steps are described in
detail in the text. Adapted from (Frey et al 2008) (1).23
pre-hairpin structure has a relatively long half-life and is a target for inhibitory peptides
and neutralizing antibodies directed against HR1 and MPER. The pre-hairpin refolds into
the final 6HB core structure consisting of the trimeric coiled coil. It is this transition that
catalyzes membrane fusion by inserting the fusion peptide into the target cell membrane.
Fusion progresses through a hemifusion intermediate, defined as a merger of contacting
leaflets of 2 bilayers with their distal leaflets by forming a shared bilayer. Hemifusion is
manifested by lipid mixing between virus and target cell membranes. There is conflicting
evidence of whether the prehairpin intermediate or 6HB are implicated in pore formation,
though there is experimental evidence that the energy released during gp41 refolding may
be used to overcome the kinetic barrier, which is underlined by the high thermostability
of the gp41 core structures (65, 72). The fusion pore is then enlarged, allowing the HIV
core to enter the target cell (65, 72).
HIV Cellular Tropism
HIV infects CD4+ T cells and cells of the macrophage lineage through interaction
of Env with CD4 and a chemokine coreceptor, typically CCR5 or CXCR4. CCR5 is
expressed on memory T cells and cells of the macrophage lineage, and CXCR4 is
expressed on naïve T cells [10-13]. Dual-tropic (R5X4) viruses can use either receptor for
entry. The majority of transmitted viruses are CCR5-tropic (R5), and these R5 isolates
remain throughout the course of infection. CXCR4-tropic (X4) isolates emerge during the
late stages of disease in about 50% of individuals, and their emergence is typically
associated with rapid disease progression (73-74). In addition, a variety of other
coreceptors (CCR2, CCR3, CCR8, Apj, STRL33/BONZO/CXCR6, Gpr1, Gpr15/BOB,24
CX
3CR1, ChemR23, RDC-1, and D6 ) may support entry of a subset of HIV isolates in
vitro, but usage of coreceptors other than CCR5 or CXCR4 in vivo is rare (71, 75-77).
Cells of the macrophage lineage are primary infected by R5 HIV, but CCR5 usage
alone is not necessary or sufficient for macrophage tropism (M-tropism) and X4 and
R5X4 M-tropic isolates have been described (78-80) Receptor density also influences
HIV infection of macrophages (81-82). Macrophages and microglia express lower cell
surface levels of CD4 than CD4+ T cells in peripheral blood (83-84). The low levels of
CD4 expressed on macrophages/microglia restrict infection by HIV strains with high
dependence on CD4 for entry (85).
Neuropathogenesis of HIV/AIDS
Epidemiology of CNS Infection
HIV infection of the central nervous system (CNS) can cause neurological
disorders, including HIV-associated dementia (HAD) and other neurological disorders,
collectively termed HIV-associated neurocognitive disorders (HAND) (86). Before the
widespread use of highly active antiretroviral therapy (HAART), the annual incidence of
HAD , the most severe form of HAND, after AIDS diagnosis was 7% and the cumulative
risk over the lifetime of an HIV-infected individual was 5-20%, with some estimates up
to 50% prior to death (15, 87-88). Less severe forms of HAND, including minor
cognitive motor disorder (MCMD) and neuropsychological impairment, were found in
30-60% of people living with HIV/AIDS (15, 89).
HAART reduces HIV RNA levels in plasma and cerebrospinal fluid (CSF) and
improves neurocognitive function, although most antiviral drugs have poor CNS
penetration. Currently, it is thought that patients who initiate HAART and achieve plasma25
and CSF viral suppression and use CSF-penetrating regimens accrue the most benefit
(89). Although the incidence of HAD dropped significantly after the introduction of
HAART, incidence rates began to rise in 2003, suggesting possible viral escape (87). At
the same time, milder forms of HAND continue to persist, and autopsy studies have
shown that over 90% of patients dying with AIDS manifest some type of neurological
disease (15, 88-89). As the number of individuals living with HIV/AIDS on HAART
rises, the prevalence of HAD is actually increasing (87), which may be due in part to the
increased risk of developing HAD as patients age (90-91). Thus, neurocognitive
impairment continues to be a common complication of HIV/AIDS (12).
HAD is most common with infection of HIV clade B viruses, and is therefore a
more common complication in the Western world. While patients infected with clade C
HIV do develop cognitive disorders, the severity may be less, and previous studies have
reported that clade C viruses may exhibit reduced potential for neuroinvasion compared
to clade B viruses, though larger studies are needed to verify these findings (12, 92-93).
Furthermore, reduced diagnosis of HAD with clade C infection in some areas may be
associated with the difficulties of reaching a diagnosis in resource-poor settings, and the
decreased time to the development of complicating opportunistic infections (94).
Regardless of these confounding issues, target cells infected with HIV have been detected
in brain tissue from patients infected with clade C viruses, but without the markers of
neuroinflammation, including multinucleated giant cells, associated with clade B
infection (12, 92-93, 95). The differences in neuropathogenesis of clade B and C HIV
viruses has been partly attributed to the viral protein Tat, with studies reporting that clade
C Tat exhibits reduced ability to recruit macrophages, stimulate production of26
proinflammatory cytokines, and induce neuronal toxicity in vitro compared to clade B
Tat (12, 93, 96-98). Recent work has also demonstrated that the Env gp120 subunit from
clade B HIV may induce production of neurotoxic factors in vitro at a higher level than
gp120 from clade C, suggesting that Env may also play a role in the decreased
neurovirulence associated with clade C HIV infection (97). Thus, genetic variation in
HIV genes between clades may contribute to neurodegeneration.
Neuroinvasion
HIV enters the brain during acute infection or shortly thereafter, most likely
through trafficking of infected lymphocytes and monocytes across the blood brain barrier
(BBB), though it is not clear whether early entry leads to viral persistence (15, 88, 99).
Early colonization of the CNS by HIV is supported by the detection of HIV DNA in pure
populations of perivascular macrophages, parenchymal microglia, and astrocytes from
brain tissue of untreated individuals who died in the presymptomatic stage of infection
from non-HIV causes, as well as high levels of colonization, inflammation, and markers
of BBB disruption in CSF during the early stages of HIV infection (100-101). Several
models of HIV neuroinvasion have been proposed. First, the CNS may suffer from
repeated transitory exposures of HIV via trafficked lymphocytes and monocytes,
followed by immune-mediated virus clearance. Alternatively, the CNS may serve as a
relatively autonomous reservoir of infection, producing virus locally and evolving
independently from other loci of infection within the body (88, 99, 102-103). A third
possibility is that during end-stage infection, as a consequence of immune activation or
other systemic events, there is increased trafficking of blood-born monocytes into the27
brain (99, 102-103), which may increase virus entry into the CNS and/or increase target
cell availability for infection and virus replication within the CNS.
Figure 1.13. HIV Neuroinvasion.
HIV may enter the brain by the “Trojan horse” model pathway, in which
HIV-infected monocytes and lymphocytes carry virus across the blood
brain barrier. Once in the CNS, HIV-infected monocytes differentiate
into perivascular macrophages. HIV released from these infected cells
infects CNS resident cells, including macrophages, microglia, and
astrocytes, leading to CNS viral persistence. Adapted from (Gonzalez-
Scarano & Martin-Garcia 2005) (104).
To penetrate the CNS, HIV or HIV-infected cells must first cross the blood-brain
barrier (BBB). The BBB is a selectively permeable, continuous cellular layer that consists
of brain microvascular endothelial cells (BMVECs) linked to each other by tight
junctions. These cells serve to regulate the traffic of cells and substances from the
bloodstream to the CNS (104-106). Although a number of routes have been proposed for
HIV entry across the BBB, the “Trojan horse” model is the most accepted. This model
posits that infected monocytes transverse the BBB, where they differentiate into
perivascular macrophages. Perivascular macrophages have a short half-life (30% in 90
days) and a high turnover rate, allowing for the potential of continuous delivery of new28
HIV-infected cells to the CNS. This turnover can be greatly increased in inflammatory
conditions, and HIV infected monocytes have been shown to cross the BBB more
efficiently than noninfected monocytes. Studies have conclusively demonstrated that
perivascular macrophages are the cell population most infected by HIV and SIV in the
CNS, lending support to this model (15, 99, 104, 106).
HIV infection of the brain can contribute to further neuroinvasion by a number of
mechanisms. BVMECs exposed to HIV up-regulate intracellular adhesion molecule 1
(ICAM-1) expression, which may facilitate leukocyte migration across the BBB. High
levels of TNF-, a proinflammatory cytokine secreted by HIV-infected macrophages,
increases BBB permeability (107). Matrix metalloproteinases (MMPs), which are
elevated in the CNS of HAD patients, can weaken basal membranes, facilitating
leukocyte transport across the BBB (12). Finally, viral proteins, including HIV Env
gp120 and Tat, have been shown to increase BBB permeability in vitro via a mechanism
that is independent of viral replication (108-109). These mechanisms are especially
important during the late stages of infection, when high peripheral viral loads and overall
immunosuppression contribute to BBB breaches and macrophage trafficking of HIV into
brain (12, 100, 102, 110).
HIV Target Cells in the CNS
Cells of the monocyte/macrophage lineage are the primary cells in the CNS that
express CD4 and CCR5, and are the main target cells for productive HIV infection in
brain. Although perivascular macrophages are the major reservoir of virus, resident
microglia are also infected, particularly within areas of inflammation. Microglia have a29
much lower turnover rate than macrophages (<1% over 90 days), and as terminally
differentiated cells have a high level of CCR5 expression (83, 86, 104). However, M-
tropic HIV Envs capable of using CXCR4 for entry have also been isolated from brain
(78, 80, 111), suggesting that R5-tropism is not necessary for neurotropism.
HIV is occasionally found at low levels in other resident cell types within brain,
including astrocytes and BVMECs, but HIV does not typically infect neurons. While
astrocytes do express early, multiply spliced mRNAs, astrocyte infection is typically
restricted and nonproductive due to defects at several stages of the virus life cycle that
include viral entry, Rev-dependent transport of viral mRNAs into the cytoplasm, and
translation (83). Therefore, while HIV infection of astrocytes is not likely to contribute to
the viral load in the CNS, nonproductive infection impacts astrocyte function, which may
affect neighboring cells or the BBB and contribute to the development of neurological
complications (83, 112-114).
While most viruses isolated from the CNS are M-tropic, a recent study described
a replicating population of R5-tropic T cell-tropic HIV viruses cloned from cerebral
spinal fluid (CSF). While only low levels of HIV-infected CD4+ T cells have been
identified in brain, it has been suggested that the presence of viral antigen during periods
of increased HIV replication in CNS/CSF compartments could drive migration of both
CD8+ and CD4 +T cells into the CNS/CSF. This may lead to persistence of
compartmentalized virus through replication in CD4 T+ cells, resulting in the low
numbers of cells detected in CSF and brain (90). Moreover, during late-stage disease,
especially when complicated with other disease pathologies that could damage blood
vessels or the BBB, viruses may leak at a higher rate from the blood vessels of the30
meninges and accumulate in the tissues surrounding the brain, thereby increasing the
likelihood for the migration of X4 viruses (6).
HIV Compartmentalization and Evolution in the CNS
A number of studies have analyzed paired HIV populations in blood and cerebral
spinal fluid (CSF) during different stages of infection (115-120). CSF is an intermediate
compartment between brain and the periphery, so viral populations in the CSF are
genetically related to those in both compartments. Within 1 month of acute infection,
similar populations were detected in blood and CSF. At later stages of disease, samples
frequently demonstrate unique genetic variants in CSF compared to peripheral blood,
implying the presence of genetic variants that evolved independently within CNS (83,
103). Moreover, CSF viral loads frequently correlate with the severity of HAD
impairment in untreated patients (121). These results suggest that in the absence of
treatment, high levels of viral replication contribute to BBB permeability, thereby
permitting passage of virus between the CSF and brain.
The genetic evolution of HIV variants in brain is distinct from that in lymphoid
tissues and other organs (83, 104, 111, 122-125). Phylogenetic reconstructions have
shown clustering of sequences according to tissue of origin, indicating that CNS viruses
from individuals are more closely related to each other than viruses originating from
peripheral tissues (80, 111, 124, 126-129). Genetic compartmentalization of HIV within
the brain suggests that selection and/or adaptive evolution may occur in the CNS in
response to unique constraints of the brain microenvironment, including different target
cell populations and immune selection pressures. Because many antiretroviral drugs have31
poor CNS penetration, the CNS may serve as a sanctuary for HIV infection, and infected
brain macrophages may comprise an important HIV reservoir during HAART (12).
Furthermore, recent studies have suggested that HIV is capable of migrating out of brain
via the meninges and reseeding the periphery, thereby potentially contributing to HAART
resistance during late-stage AIDS (12, 102).
While macrophages and microglia are the primary target cells for HIV CNS
infection, the ability to infect macrophages is not sufficient for neurovirulence and the
presence of HIV in the CNS is not necessarily sufficient for cognitive impairment (130)
(12, 15). HIV cloned from brain tissue of patients with HAD exhibit increased evidence
of viral evolution and higher recombination rates compared to virus from patients without
HAD (103). Consistent with this observation, certain HIV strains induce multinucleated
giant cells or neuronal apoptosis in vitro in a manner that is independent of their
replication capacities in macrophages and microglia (111, 123, 131-132). However, viral
phenotypes that distinguish neurotropic and neurovirulent strains and increase risk of
neurological disease are poorly understood.
Specific Env sequences, particularly in the gp120 V3 region, have been associated
with brain compartmentalization (122-124, 132). Env sequences from AIDS patients with
HAD are genetically and biologically distinct than those from patients without HAD
(122-123, 125, 132-134), suggesting that particular Env variants may play an important
role in CNS infections and the development of HAD. However, little is known about
specific Env determinants that underlie that neurotropism and neurovirulence of HIV.32
Mechanisms of HIV Neuropathogenesis
Although HIV infects the CNS during acute primary infection, the brain typically
remains asymptomatic until after the development of immunosuppression and
progression to AIDS (83, 104). HIV infection of the CNS is not sufficient for the
development of neurological disorders. Factors that are thought to contribute to HIV
neuropathogenesis include loss of immune control associated with disease progression,
chronic immune activation, BBB abnormalities that allow increased trafficking of
infected monocytes and T cells, and late emergence of viral variants that impact CNS
disease progression (83, 122, 135-136).
Although the mechanisms by which HIV induces neurological damage are not
well understood, several models have been proposed to explain how HIV infection
contributes to neuronal injury. One model suggests that the release of soluble neurotoxic
factors, including cytokines, chemokines, and small molecules such as nitric oxide, are
produced by activated or infected macrophages and microglia as a consequence of HIV
infection and may induce neurological damage (104, 137-140). Alternatively, HIV
infection can cause direct injury to the CNS by the production of viral proteins, including
the Env gp120 subunit, Vpr, and Tat, which have been shown to be neurotoxic in vitro
(104, 132).33
Figure 1.14. Model for macrophage-induced CNS pathology.
Once in brain, HIV-1 infection is perpetrated in both lymphocytes and macrophages
where it can be latent or productive. Ultimately, persistently infected macrophages can
cause tissue damage and disease in brain, where HIV-infected macrophages often
become immune activated and develop a neurotoxic phenotype. Macrophage activation
can lead to tissue damage and the development of neurological complications including
HAD. Adapted from (Ciborowski et al 2006) (141).
The development of HAD, the most severe form of HAND, does not correlate
with HIV viral infection in brain, leukoencephalopathy, axonal damage, or number of
apoptotic neurons or neuronal cell loss. Indeed, the most important predictor of HAD
seems to extensive macrophage and microglia infiltration (12, 86, 99). In HAD patients,
levels of production of proinflammatory cytokines, including IL-1, IFN-, TNF-,
TGF-, and IL-6, correlate roughly with HAD. These cytokines may be secreted by
macrophages, astrocytes, neurons, and endothelial cells when infected by HIV or
stimulated by activated macrophages Neurotoxins produced by activated microglia
include nitric oxide, superoxide anions, -chemokines, MMPs, glutamate receptor
agonists, proinflammatory cytokines, and growth factors, and have been linked to a
number of chronic, progressive neurological disorders in addition to HAD (107, 142).
Once initiated, chronic activation could be self-perpetuating, maintained in an autocrine
or paracrine fashion by continued presence of macrophage-derived molecules, HIV34
proteins, or downstream products from astrocytes or other cells expressed as consequence
of microglial activation (99). Indeed, HIV infection may induce persistent inflammation
in the CNS mediated by chronically activated microglia and other immune cells even
after apparently successful antiretroviral therapy (ART) (86, 107, 143). Consistent with
this, persistent neuroinflammation is observed at autopsy in brains of ART treated
patients, with microglia and macrophages expressing high levels of CD14, CD16, CD68,
and MHC class II molecules. HAD may therefore represent a condition in which
microglial cell-driven inflammation is the primary cause of neurodegenerative disease
(86, 107).
In addition to neurotoxins produced by activated cells, a number of viral products
have been implicated in the development of HAD and milder forms of neurocognitive
impairment, including the Env gp120 subunit, Tat, Nef, and Vpr. Gp120 neurotoxicity is
indirect and relies on the production of toxic intermediate such as proinflammatory
cytokines, arachidonic acid metabolites, and nitric oxide by activated cells, including
macrophages, microglia, and astrocytes (12, 107, 144). Tat is secreted by infected cells
and may induce neuronal apoptosis directly, via increases in intracellular calcium,
thereby stimulating production of reactive oxygen intermediates and caspase activation,
or indirectly, by stimulating macrophages to produce MMPs that induce neuronal
apoptosis. Tat has also been associated with microglial migration, prolonged cytokine
production, and induction of neuronal nitric oxide synthase (nNOS) via the NF-B and
C/EBP pathways. Furthermore, Tat has been implicated in formation of a
macromolecular complex of low-density lipoprotein receptor-related protein (LRP),
postsynaptic density protein-95 (PSD-95), N-methyl-D-aspartic acid (NMDA) receptors,35
and nNOS at the neuronal plasma membrane, which is believed to trigger apoptosis (145-
146). Both Tat and Nef increase production of neurotoxic quantities of quinolinic acid, a
glutamate receptor agonist that induces apoptosis of neurons and astrocytes in vitro (107,
138, 147). Nef has also been shown to induce apoptosis of HBMECs in vitro (145),
while Vpr may induce neuronal apoptosis in vitro and has been associated with neuronal
cell loss in brain regions including the hippocampus and cortex (107, 145). Thus, HIV
infection in the CNS likely contributes to neurocognitive disorders directly though viral
infection of macrophages and microglia, and indirectly due to activation of infected and
uninfected cells, resulting in the production of neurotoxic factors and neuronal cell loss.
Fig. 1.15. Mechanisms by which gp120 may contribute to neuropathogenesis.
Shedding of sgp120 from the surface of virions and infected cells in the CNS binds to and
activates uninfected macrophages, microglia and astrocytes, leading to increased
production of proinflammatory cytokines and neurotoxic factors, which may in turn
promote neuronal injury and cell death, thereby contributing to processes involved in
development of HAND. Adapted from (Kaul et al 2001) (137).36
Scope of this Dissertation
HIV infection of macrophages in brain and other tissues plays an important role in
the development of HIV-associated neurological disorders (HAND) and other aspects of
disease pathogenesis. Infected macrophages show no obvious cytopathic effects of HIV
infection and continue to shed virus for the duration of their normal lifespan, representing
a long-lived reservoir for viral persistence (136). The major viral determinant of M-
tropism is Env. Macrophages express lower levels of CD4 than CD4+ T cells in
peripheral blood and are preferentially infected by viruses that can utilize low levels of
CD4 for entry (84-85, 148-153).
Mechanisms that enhance Env interactions with CD4 include increased affinity
for CD4 and increased exposure of the CD4-binding site (148, 152, 154-157). Another
mechanism by which HIV Envs may overcome the restriction imposed by reduced CD4
on macrophages is through enhanced Env interactions with CCR5. Although several
studies described M-tropic Envs with reduced CCR5 dependence, the genetic
determinants in M-tropic Envs that contribute to this phenotype are poorly understood
(124, 128, 158-159)
A second mechanism that influences this phenotype is increased exposure of the
CD4 or CCR5 binding sites, which may also increase dissociation of soluble gp120
(sgp120) from the Env trimer based on structural models. While a large number of in
vitro studies suggest a potential role for sgp120 in chronic activation and immune system
dysfunction (108, 137-138, 160-176) (24-26), no studies have conclusively demonstrated
that sgp120 contributes to HIV pathogenesis in vivo. Furthermore, little is known about
spontaneous sgp120 shedding from primary HIV Envs or its biological significance.37
In Chapter 2, we sought to identify determinants in M-tropic brain-derived Envs
that contribute to reduced CD4-dependence by enhancing gp120 interactions with CCR5.
To accomplish this goal, we examined brain and lymphoid gp120 sequences from the
CCR5 binding site bridging sheet region from AIDS patients with or without HIV-
associated dementia (HAD). Two determinants in the surface exposed 3 strand of the
bridging sheet were identified. D197, which results in the elimination of an N-linked
glycosylation site, was associated with brain infection and dementia. Position 200 was
under positive selection in HAD patients. D197 and T/V200 enhanced fusion and entry
with macrophages and other cells expressing low CD4 by enhancing gp120 binding to
CCR5. The influence of T/V200 on fusion and entry was additive when combined with
D197, suggesting that variants in 3 might enhance M-tropism cooperatively.
In Chapter 3 we analyzed spontaneous sgp120 shedding from a panel of 65
primary brain and lymphoid Envs from 12 AIDS patients. Sgp120 shedding from primary
brain and lymphoid Envs was highly variable within and between patients, representing a
spectrum rather than a categorical phenotype, and reached levels overlapping those
shown to induce biological effects in vivo. Brain Envs with high sgp120 shedding
mediated enhanced fusion and infection with cells expressing low CD4. Furthermore,
viruses expressing brain Envs with high sgp120 shedding demonstrated an increased
capacity to induce lymphocyte activation during infection of PBMC, despite similar
levels of viral replication. Genetic analysis demonstrated greater entropy and positive
selection in Envs with high versus low levels of sgp120 shedding, suggesting that
diversifying evolution influences gp120-gp41 association.38
In Chapter 4, we sequenced the gp120 coding region of nine full-length dual-
tropic (R5X4) env genes cloned directly from autopsy brain and spleen tissue from an
AIDS patient with severe HAD. We then compiled a dataset of 30 unique clade B R5X4
Env V3 sequences from this subject and 16 additional patients (n=4 brain and 26
lymphoid/blood Envs) and used it to compare the ability of six bioinformatic algorithms
to correctly predict CXCR4 usage in R5X4 Envs. The results demonstrated that most
predictive algorithms underestimated the frequency of R5X4 HIV-1 in brain and other
tissues. SVMgeno2pheno was the most accurate predictor of CXCR4 usage by R5X4 HIV-1.
In summary, we demonstrated that genetic determinants in the gp120 bridging
sheet influence M-tropism by enhancing gp120 binding to CCR5. Furthermore, we
demonstrated that a significant proportion of brain and lymphoid Envs readily shed
sgp120 and present evidence that this phenotype is associated with enhanced interactions
between gp120 from brain-derived Envs and CD4 and/or CCR5 and possibly with
lymphocyte activation during PBMC infection. Our work provides a better understanding
of the mechanisms by which gp120 determinants in brain Envs influence M-tropism. In
addition, our findings demonstrate that spontaneous sgp120 shedding from primary brain
and lymphoid Envs represents a phenotypic spectrum that may influence HIV
pathogenesis by contributing to immune activation and bystander cell apoptosis.39
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ABSTRACT
Macrophages and microglia are the main target cells for HIV infection of the
central nervous system (CNS). Macrophages/microglia express lower levels of CD4
compared to CD4+ T cells, and macrophage-tropic (M-tropic) HIV strains express
envelope glycoproteins (Envs) that have adapted to overcome this restriction to viral
entry by mechanisms that are poorly characterized. One mechanism that influences this
phenotype is enhanced binding of the HIV Env gp120 subunit to CCR5, but viral
determinants of this phenotype in M-tropic strains have not been characterized. Here, we
identified two genetic determinants in the HIV gp120 3 strand of the bridging sheet in
the CCR5 binding site that enhance M-tropism of primary brain-derived Envs. D197,
which results in the loss of an N-linked glycosylation site, was associated with brain
infection and HIV-associated dementia (HAD), while position 200 was identified as a
codon under positive selection in HAD patients. Mutagenesis studies showed that D197
and T/V200 enhance fusion and infection of macrophages and other cells expressing low
CD4 in a strain-dependent manner by enhancing gp120 binding to CCR5. This phenotype
was not associated with increased neutralization sensitivity to monoclonal antibodies 17b
and 412d, which recognize epitopes overlapping the CCR5-binding site. However,
exposure to low levels of sCD4 increased neutralization sensitivity of some viruses
expressing D197 and T/V200 to 17b. These findings suggest that genetic determinants in
the 3 strand of the bridging sheet of HIV gp120 overcome the restriction to macrophage
infection imposed by low CD4 by enhancing Env interactions with CCR5, thereby
contributing to infection of the CNS and other macrophage-rich tissues.56
INTRODUCTION
Human immunodeficiency virus type I (HIV) infects CD4+ T cells and cells of
the macrophage lineage. Tissues harboring persistently infected macrophages include
brain, lung, liver, spleen, small bowel, colon, and bone marrow (1-3). In these tissues,
infected macrophages show no obvious cytopathic effects of HIV infection and continue
to shed virus for the duration of their normal lifespan, representing a long-lived reservoir
for viral persistence (1). Infected macrophages also contribute to disease pathogenesis in
brain and other tissues by producing proinflammatory cytokines and other soluble factors,
which in turn can induce bystander cell activation and apoptosis (1). Furthermore,
macrophage reservoirs the brain represent a barrier to virus eradication due to limited
penetration by antiretroviral therapy (1, 4-9).
The major determinant of M-tropism is the viral envelope glycoprotein (Env). The
HIV Env, which consists of a surface-exposed gp120 and a transmembrane gp41 subunit,
is organized into trimers on the surface of virions and infected cells (10). The gp120
subunit core is composed of an inner domain, a heavily glycosylated outer domain, and 4
surface exposed variable loops that extend from the core and partially occlude the
coreceptor binding site and neutralization epitopes (11-12). HIV entry into cells is
initiated by a high affinity interaction between gp120 and CD4, which induces
conformational changes in gp120 resulting in formation of the coreceptor binding site
(13). CCR5 is the primary coreceptor for virus entry into macrophages/microglia;
however, CCR5 usage alone is neither necessary nor sufficient for M-tropism (14-15).
Moreover, HIV M-tropism of CCR5-using (R5) isolates represents a spectrum rather than
a categorical phenotype, with up to a 1000-fold variation in replication capacity in
primary monocyte-derived macrophages (MDM) (8, 14, 16-18). One factor that57
contributes to this spectrum of M-tropism is receptor density (19-20). Macrophages
express lower levels of CD4 than CD4+ T cells in peripheral blood and are preferentially
infected by viruses that can utilize low levels of CD4 for entry (18, 21-27). Determinants
of reduced CD4-dependence or CD4-independence have been mapped to the HIV and
SIV gp120 V1/V2, V3, and V4 variable loops, C2 and C3 regions, and regions of gp41
(21, 23, 28-34).
Mechanisms that enhance Env interactions with CD4 include increased affinity
for CD4 and increased exposure of the CD4-binding site (21, 26, 28, 35-37). Another
mechanism by which HIV Envs may overcome the restriction imposed by reduced CD4
on macrophages is through enhanced Env interactions with CCR5. Although several
studies described M-tropic Envs with reduced CCR5 dependence, the genetic
determinants in M-tropic Envs that contribute to this phenotype are poorly understood
(16, 38-40). Genetic determinants that enhance gp120-CCR5 interactions in a strain-
dependent manner have been mapped to the CCR5-binding site, which includes residues
in the gp120 V3 loop, inner domain, and bridging sheet (11, 41-43). The bridging sheet is
a 4-strand -sheet formed by the 20/21 strands, located between the inner and outer
domains, and surface-exposed 2/3 strands, which serve as the conserved stem of the
V1/V2 loop (11, 37, 41-44). Genetic determinants in the 20/21 strands that disrupt the
hairpin structure have been shown to eliminate gp120 binding to CCR5 (45). Genetic
determinants in the 3 strand have been shown to reduce Env binding to CCR5 and
decrease membrane fusion efficiency in a strain-dependent manner (44). Moreover,
amino acid variants in 3 may compromise interactions between the V1/V2 variable
loops, which occlude the CCR5-binding site, and the V3 loop (46-47), possibly58
disrupting the inter-protomer interactions that stabilize the unliganded Env trimer (47-
48). Because the bridging sheet region undergoes structural rearrangements following
CD4 binding, determinants in this region are likely to influence receptor-induced
conformational changes that affect the viral entry process.
In this study, we identified viral determinants in the 3 strand of the HIV gp120
bridging sheet region that contribute to enhanced macrophage entry of brain-derived
Envs. D197, which eliminates an N-linked glycosylation site, was associated with brain
infection, and position 200 was a positively selected codon in patients with HIV-
associated dementia (HAD). Mutagenesis studies showed that D197 and T/V200
enhanced macrophage entry in a strain-dependent manner, a phenotype that was
associated with enhanced fusion and infection of cells expressing low CD4 due to
enhanced gp120 binding to CCR5. These findings suggest that the 3 strand of the HIV
gp120 bridging sheet in M-tropic Envs contains determinants that can overcome the
restriction imposed by low CD4 for entry by enhancing Env interactions with CCR5.59
MATERIALS AND METHODS
Sequence Analysis. Nucleotide sequences from published studies and Genbank were
aligned using ClustalX2. Gp120 V1-V5 region sequences were examined using three
different approaches to identify codons under positive selection: single likelihood
ancestor counting (SLAC), fixed-effects likelihood (FEL), and internal fixed effects
likelihood (IFEL) (HyPhy software, datamonkey web server). SLAC and FEL detect sites
under selection at external branches of the phylogenetic tree, while IFEL identifies sites
along internal branches (49-51). Sites were classified as positively selected when a
significant p-value (p<0.05) was estimated by a minimum of 2 methods. To identify
determinants associated with brain compartmentalization or dementia, gp120 2 and 3
strand amino acid sequences were aligned using ClustalX2. Stratified 2x2 contingency
tables were used to account for sequence correlations within each patient. P values were
assigned using Fisher’s exact test with p<0.05 considered significant.
Cells. 293T and TZM-bl cells, a HeLa cell clone engineered to express CD4 and CCR5
that contains integrated reporter genes for firefly luciferase and E. coli -galactosidase
under control of HIV-1 LTR, were cultured in DMEM media supplemented with 10%
(vol/vol) fetal bovine serum (FBS) and 100 g/ml penicillin and streptomycin. CF2-Luc
cells, which are derived from canine thymocyte cell line CF2th and stably express firefly
luciferase under control of HIV-1 LTR (52), and CF2th-synCCR5 cells, which express a
codon-optimized version of human CCR5 containing a C-terminal nonapeptide
(TETSQVAPA) tag derived from bovine rhodopsin (38), were cultured in medium
supplemented with 0.7 mg/ml G418 (Mediatech, Herndon, VA). Affinofile cells were60
cultured in DMEM supplemented with 10% dialyzed FBS (Gibco, Grand Island, NY),
100 g/ml penicillin and streptomycin, and 50 g/ml blasticidin S HCl (Invitrogen,
Grand Island, NY) (53). Monocyte-derived macrophages (MDM) were derived from
peripheral blood mononuclear cells (PBMC) isolated from healthy HIV-negative donors.
As previously described, MDM were isolated from PBMC by plastic adherence and
cultured in RPMI 1640 medium supplemented with 10% FBS, 100 g/ml penicillin and
streptomycin, and 10 ng/ml macrophage colony stimulating factor (M-CSF, R&D
Systems, Minneapolis, MN) (38). TZM-bl cells were provided by Norm Letvin.
Affinofile cells were provided by Benhur Lee.
Viruses and Mutagenesis. Primary clade B env genes from AIDS patients with HIV-
associated dementia were cloned into pCR3.1 as previously described (16, 38). Env
expression and processing was verified by Western blotting with goat anti-gp120 (AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, Bethesda,
MD) (21, 28). Mutant Env plasmids with changes at positions 197 and 200 (HXB2
numbering) were created by PCR-based mutagenesis and verified by DNA sequencing.
Entry Assays. HIV luciferase reporter viruses were generated by cotransfection of 293T
cells with pNL4-3env-luc, an HIV provirus with env deleted and nef replaced with
luciferase, and an Env-expressing plasmid as described (38). TZM-bl cells were seeded
into 96-well plates in media supplemented with 15 g/ml DEAE-dextran and infected
with 10
4 3H cpm reverse transcriptase (RT) units of virus stock. Cells were lysed 48 hours
post-infection and assayed for luciferase activity. MDM were prepared in 48-well plates61
and infected overnight with 2 x 10
4 RT units of virus stock in media supplemented with 2
g/ml polybrene. Cells were lysed 6 days post-infection and assayed for luciferase
activity. Affinofile cells were seeded into 96-well plates and treated for 20 hours with
serial dilutions of 0-3 ng/ml doxycycline (Clontech, Mountain View, CA) to induce CD4
expression and 0-2 M Ponasterone A (Invitrogen) to induce CCR5 expression (53).
Cells were then infected with 10
4 RT units of virus stock, lysed 2 days post-infection, and
assayed for luciferase activity. Mock infected cells were used as negative controls.
Background luciferase levels were subtracted from all results.
Fusion Assays. 293T cells were cotransfected with 2 g pCR3.1 Env-expressing plasmid
and 0.2 g pLTR-Tat using calcium phosphate. Cf2-Luc cells were cotransfected with 0.1
(low), 1 (medium), or 10 g (high) amounts of pcDNA3-CD4 and 10 g (high) pcDNA3-
CCR5 using Lipofectamine 2000 (Invitrogen). 2.5 x 10
4 293T cells and 2.5 x 10
5 CF2-
Luc cells were mixed in 48-well plates and incubated for 5-8 hours. Cells were then lysed
and analyzed for luciferase activity. 293T cells cotransfected with a nonfunctional Env
(pSVIII-KSenv) and pLTR-Tat were used to determine background levels of luciferase.
Flow Cytometry. Cell surface expression of CD4 and CCR5 on induced Affinofile and
transfected CF2-Luc cells was analyzed by collecting cells with 5 mM EDTA in PBS and
staining with anti-CD4-PE (BD Biosciences, San Jose, CA) and anti-CCR5-PE (BD
Pharmingen, San Diego, CA). Cell surface staining was analyzed using a FACSCantoII
flow cytometer (BD Biosciences). The approximate number of CD4 and CCR5 molecules62
per cell was calculated using FACS analysis of Quantibrite beads according to
manufacturer’s instructions (BD Biosciences).
ELISA. ELISAs were based on previously described methods (54-56) with several
modifications. Briefly, 96-well microplates were coated overnight with sheep antibody
D7324 at 5 g/ml in PBS (AALTO Bioproducts, Ltd., Ireland). Wells were washed 3
times with PBS supplemented with 2.5% Tween-20 (PBS-T) and blocked for 1 hour at
room temperature with PBS-T supplemented with 3% BSA. Supernatants were incubated
in the wells for 3 hours, followed by 10 washes with PBS-T and 1 hour incubation with
polyclonal rabbit anti-gp120 (American Biotechnologies Inc.). After 10 additional
washes with PBS-T, wells were incubated with anti-rabbit-HRP (GE Healthcare). The
reaction was developed using BM chemiluminescence ELISA substrate (Roche)
according to the manufacturer’s instructions. The reaction was read on a luminometer
(Viktor2, Perkin Elmer, Waltham, MA). Calculations of sgp120 concentrations were
based on a standard curve of purified gp120 (21). Supernatant from cells transfected with
empty pcDNA3 vector was used to determine background.
CCR5-Binding Assays. Plasmids expressing soluble gp120 (sgp120) glycoproteins were
constructed by introducing a frameshift in gp120 that resulted in a truncation at position
518 (HXB2 numbering). Supernatants from 293T cells transfected with the Env-
expressing plasmids were collected 48 hours post-transfection and cleared by
centrifugation at 2000 rpm for 5 minutes. Supernatants were stored at -80ºC until used.
Supernatants were concentrated by centrifugation using Amicon Ultra columns with a 30-63
kD cutoff (Millipore, Billerica, MA). Sgp120 concentrations in concentrated supernatants
were determined by ELISA. Equal concentrations of sgp120 were incubated with or
without 1 g/ml soluble CD4 (sCD4, Immunodiagnostics, Woburn, MA) for 30 minutes
at 37ºC prior to incubation with CF2-synCCR5 cells. Binding of sgp120 to cells was
detected by staining with mAb C11, followed by anti-human-PE (Bio-Rad, Hercules,
CA), and was analyzed by flow cytometry. Specificity of gp120 interaction with CCR5
was verified by pre-incubating CF2-synCCR5 cells with 100 nM TAK-779 (obtained
through the AIDS Research and Reference Reagents Program, Division of AIDS, NIAID,
NIH, Bethesda, MD) (57) for 1 hour at 37ºC prior to incubation with sgp120.
Neutralization Assays. HIV luciferase reporter viruses were incubated with a range of
concentrations of sCD4, monoclonal antibody (mAb) 17b (obtained from the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, from Dr.
James E. Robinson), or 0.1 g/ml sCD4 and a range of concentrations of 17b in
combination for 1 hour at 37ºC prior to infection of TZM-BL cells. Cells were harvested
48 hours post-infection and assayed for luciferase activity (58).64
RESULTS
Identification of determinants in the gp120 bridging sheet associated with brain
infection and HAD. The genetic evolution of HIV variants in brain is distinct from that
in lymphoid tissues and other organs (3, 16, 59-63). Furthermore, diversifying evolution
associated with CNS infection can result in nonsynonymous substitutions that affect
protein structure and function (51, 64-67). The gp120 CCR5-binding site includes
residues in the V3 loop, the inner domain, and the bridging sheet. The bridging sheet is
formed following gp120 binding to CD4, and residues in this region have been shown to
impact gp120 interactions with CCR5 in a strain-specific manner by influencing gp120
binding to CCR5 and positioning of the V1/V2 loops, thereby increasing exposure of the
CCR5 binding site (29, 45-47). Therefore, to investigate whether M-tropic HIV brain-
derived Envs contain genetic determinants in the gp120 bridging sheet that enhance
gp120 interactions with CCR5, analyzed viral sequences in this region.
To identify potential sites of positive selection in the gp120 bridging sheet, brain-
derived gp120 V1-V5 region sequences from patients diagnosed with or without clinical
dementia were analyzed (n=336 unique sequences from 19 HAD subjects and 119 from
11 non-HAD subjects) (16, 18, 26, 61, 63, 68-72). The SLAC, FEL, and IFEL methods
(datamonkey web server) were used to calculate the probability that codon variation was
due to positive selection (Fig. 2.1) (49-50, 73). A total of 29 and 14 sites were estimated
to be under positive selection in brain sequences from patients with or without HAD,
respectively (p<0.05 in a minimum of 2 methods) (Table S2.1). In the bridging sheet
region, only position 200, located in the surface-exposed 3 strand, was estimated to be
under positive selection in brain sequences from HAD patients (p=0.02) (Table 2.1).65
When the dataset was expanded to
include blood and lymphoid-derived Env
sequences matched to the brain
sequences, the prediction of positive
selection at position 200 in HAD
patients was strengthened (p=0.005)
(Fig. S2.1). However, position 200 was
not estimated to be under positive
selection in either brain or brain and
blood/lymphoid sequences in non-HAD
patients. Thus, position 200 in the 3
strand is a positively selected codon in
brain and blood/lymphoid-derived
sequences in HAD patients
Figure 2.1. Predicted sites of positive selection
in brain Envs from subjects with or without
HAD. Brain-derived Env sequences from AIDS
patients with or without HAD (n=336 and 119
sequences from patients with or without HAD,
respectively) were aligned using ClustalX2. dN-
dS values were estimated by SLAC, FEL, and
IFEL and normalized by total codon tree length
using the datamonkey web server. dN-dS values
shown are averages calculated for any codon
with p<0.05 by a minimum of 2 methods. Sites
from HAD subjects are shown in red and from
non-HAD subjects in blue. Codons were
numbered according to codon env position of
HIV-1 HXB2 reference strain. *indicates
position 200 in the 3 strand of the gp120
bridging sheet.66
Table 2.1. Position 200 in the gp120 3 strand is estimated to be under positive
selection in HAD patients.
Alignment Codon Region Average
dN-dS
Average p-value
a
HAD brain
b 200 3 0.8 0.021 (FEL, IFEL)
HAD lymphoid
c 200 3 2.6 0.005 (all 3)
Non-HAD brain
d NS S NS NS
Non-HAD lymphoid
e NS S NS NS
a SLAC, FEL, and IFEL analyses (HyPhy software package) were used to
reconstruct ancestral sequences at each node of a phylogenetic tree (data not shown).
Substitutions are calculated at each branch and terminal node. P-values are averaged
for methods in parentheses.
b n=336 unique brain-derived gp120 V1-V5 region sequences from 19 HAD subjects
cn=171 unique blood/lymphoid-derived gp120 V1-V5 region sequences from 15
HAD subjects
dn=119 unique brain-derived gp120 V1-V5 region sequences from 11 non-HAD
subjects
en=66 unique blood/lymphoid-derived gp120 V1-V5 region sequences from 7 non-
HAD subjects
Position 200 is located in the surface-exposed 3 strand of the gp120 bridging
sheet. The 2/3 hairpin structure forms the conserved stem of the V1/V2 loops. Genetic
determinants in the V1/V2 stem region can increase Env interactions with CCR5 by
influencing the position of the V1/V2 loops, which occlude the coreceptor binding site in
unliganded gp120 (20, 33, 47). Thus, determinants in the2/3 strands may enhance
reduced CD4 dependence by increasing gp120 affinity for CCR5 or increasing exposure
of the CCR5-binding site. To determine whether determinants at position 200 or other
positions in the 2/3 hairpin were associated with brain infection, we examined 796
matched brain- and blood/lymphoid-derived 2 and 3 strand sequences from 26 patients
(n=498 brain sequences, range 3-89 sequences/patient; median=8 sequences/patient; and
298 blood/lymphoid sequences, range 2-57 sequences/patient; median 5
sequences/patient) (16, 18, 26, 36, 61, 63, 68, 71-72, 74-76). While more common in67
brain-derived sequences, the most common variant at position 200 (Thr) was not
associated with brain infection, appearing in 15% of brain and 10% of blood/lymphoid
sequences (Table 2.2). However, elimination of the N-linked glycosylation site (PNGS)
at position 197 was associated with brain infection, appearing in 8% of brain sequences
and 1% of blood/lymphoid sequences (p=0.03, Fisher’s exact test). No other determinants
associated with brain infection were identified in the 2 or 3 strands (Table 2.2 and data
not shown). Because position 200 was under positive selection in sequences from HAD
patients, the dataset of brain-derived sequences from patients with or without HAD was
expanded to include patients without matched lymphoid sequences (n=419 sequences
from HAD patients, range 1-89 sequences/patient; median=5 sequences/patient; and 163
sequences from non-HAD patients, range 1-81 sequences/patient; median 4
sequences/patient) (16, 61, 63, 68-71, 75, 77). This dataset was then used to determine
association with dementia. In this dataset, elimination of the PNGS at 197 appeared in
10% of brain sequences from HAD patients and 0% of brain sequences from non-HAD
patients (p=0.001). T200 appeared in 10% of sequences from HAD patients and 17% of
sequences from non-HAD patients. Thus, the elimination of the PNGS at position 197 in
3, while rare, is associated with brain compartmentalization and dementia.68
Table 2.2. Loss of N-linked glycosylation site at position 197 in gp120 3 strand is
associated with brain infection and dementia.
Variant Amino Acid Frequency
a
197
b A198
c T199
c T200
c V201
c A202
c
By Tissue (n=26 subjects)
Brain (n=498) 8%* (3) 4% (1) 0.2% (1) 15% (4) 8% (2) 0.5% (1)
Blood/Lymphoid (n=298) 1% (2) 4% (1) 0% (0) 10% (3) 7% (2) 0.8% (1)
Brain, by disease
d
Dementia (n=419) 10%** (5) 4% (1) 0% (0) 10% (2) 4% (1) 0.5% (0)
No dementia (n=163) 0% (0) 0% (0) 0% (0) 17% (2) 5% (1) 0% (0)
a Variant amino acid frequency calculated as number of sequences containing most common
variant/number of sequences containing any other amino acid (including clade B
consensus) for each position. Sequences are correlated within each patient. The number in
parentheses indicates the number of patients who have sequences containing the most
common variant.
b  indicates the presence of any amino acid that results in elimination of the N-linked
glycosylation site
c Amino acid designation reflects the most common variant at each position.
d n=419 brain-derived sequences from 27 subjects with HAD and 163 brain-derived
sequences from 18 non-HAD subjects
*p=0.03; ** p=0.001, Fisher’s Exact Test
Determinants at 197 and 200 enhance macrophage entry by increasing fusion and
infection of cells expressing low CD4. Many N-linked glycans that compose the
“glycan shield” of the gp120 outer domain are highly conserved and essential for proper
protein folding, stability, and interactions between gp120, CD4, and CCR5 (12, 64, 78).
Moreover, studies in rhesus macaques infected with SIV and SHIV suggest that loss of
specific PNGS sites in the V1/V2 loop region may affect viral replication, sensitivity to
antibody neutralization, and M-tropism, possibly by increasing exposure of the CCR5-
binding site (32, 79). Therefore, determinants at position 197 may influence macrophage69
infection by enhancing Env interactions with CD4 and CCR5. To investigate this
question, we used mutagenesis to introduce N197D (the most common variant) and
V200T into a brain-derived Env cloned from a weakly M-tropic isolate (MACS2br13,
hereafter referred to as M2br) and reciprocal changes to clade B consensus amino acids
(D197N and T200V) into a highly M-tropic brain-derived Env cloned from autopsy brain
tissue (UK1br2-14, hereafter referred to as UK1br) (Fig. 2.2A) (16, 21, 38). In addition, a
double mutant (N197D/V200T) expressing both determinants was introduced into M2br.
The parental and mutant Envs were processed to gp120 and gp41 and expressed on the
cell surface at similar levels (Fig. 2.2B). Viruses expressing the parental and mutant Envs
mediated similar levels of virus entry into control TZM-BL cells expressing high CD4
and CCR5, with viruses expressing UK1br Envs mediating high levels of entry,
comparable to virus expressing the control ADA Env (Fig. 2.2C). M2br N197D and
N197D/V200T exhibited significantly increased entry into monocyte-derived
macrophages (MDM) compared to the parental Env (p<0.01, student’s t test), while M2br
V200T, which contains the PNGS at position 197, mediated entry at levels similar to the
parental M2br Env (Fig. 2.2D). UK1br T200V exhibited increased macrophage entry
compared to the parental Env (p=0.05), while similar levels of entry were observed for
viruses expressing parental UK1br and UK1br D197N Envs (Fig. 2.2D). These results
suggest either a Val or Thr at position 200 contributes to enhanced macrophage entry in a
strain-dependent manner when combined with Asp at position 197.70
Figure 2.2. Determinants at positions 197 and 200 enhance macrophage entry in a
strain-dependent manner. A) HIV UK1br and M2br gp120 3 sequences were
previously published (16, 38) and were aligned against the clade B consensus sequence.
Dots represent residues identical to the Clade B consensus sequence. Positions 197 and
200 are shown in red. B) 293T cells transfected with pCR3.1 Env expression plasmids
were analyzed by Western blotting with polyclonal rabbit anti-gp120. ADA and YU2
Envs were used as assay controls. C) TZM-bl cells expressing high levels of CD4 and
CCR5 were infected with HIV luciferase reporter viruses expressing UK1br and M2br
parental and mutant Envs, lysed 48 hours after infection, and analyzed for luciferase
activity. D) Monocyte-derived macrophages (MDM) were infected with reporter viruses
expressing the parental and mutant Envs, lysed 6 days after infection, and analyzed for
luciferase activity. For data in C and D, relative luciferase units (RLU) with background
subtracted are shown for viruses expressing no Env (mock), ADA, UK1br, and M2br
Envs on the left. Data on the right are presented as percentage of wild-type entry and
represent duplicate wells of a single experiment. Error bars represent standard deviations.
The experiment was repeated a minimum of 3 times for each Env set. *p<0.05, student’s
T test.71
Fig. 2.2, Continued72
Macrophages express low CD4 compared to CD4+ T cells, so M-tropic Envs
must overcome this restriction for virus entry. Therefore, we tested the capacity of the
parental and mutant Envs to initiate fusion with cells expressing low levels of CD4 (Fig.
2.3A) (38). M2br N197D and N197D/V200T enhanced the overall efficiency of fusion
compared to parental M2br (p=0.14, 0.03, and 0.06 for N197D and 0.03, 0.05, and 0.02
for N197D/V200T, for cells expressing low, medium, and high CD4, respectively,
student’s t test), but M2br V200T, which contained the PNGS at 197, did not enhance
fusion compared to the wild-type M2br Env (Fig. 2.3C, left panel). M2br N197D/V200T
mediated fusion with cells expressing very low CD4 levels, but was not CD4-
independent (data not shown). UK1br T200V enhanced fusion with cells expressing low
and medium levels of CD4 compared to the parental Env (p=0.2 and 0.05, respectively).
UK1br D197N exhibited decreased fusion with cells expressing reduced CD4 compared
to the parental Env (p=0.08, medium CD4) (Fig. 2.3C, right panel).73
Figure 2.3. D197 and T/V200 enhance capacity of Envs to use low CD4 and CCR5
for fusion and entry. A) Env cell surface expression of CD4 on transfected CF2-Luc
cells (left panel) or CD4 and CCR5 on induced Affinofile cells (middle and right panels)
determined by flow cytometry. Estimated CD4 and CCR5 antibody binding sites (ABS)
on Affinofile cells are calculated using QuantiBrite beads (Invitrogen). (B) 293T cells
expressing control ADA Env, M2br parental and mutant Envs (left panel), and UK1br
parental and mutant Envs (right panel) were mixed with CF2luc cells expressing low,
medium, or high levels of CD4 as indicated. Fusion was measured by analyzing
luciferase activity at 5 (UK1br) or 8 hours (M2br) depending on the kinetics of fusion.
Background luciferase activity, measured as luciferase activity for 293T cells expressing
the nonfunctional KS Env, was subtracted from each time point. Results are expressed
as mean percentages of fusion of the parental Env with cells expressing high CD4 and
CCR5 and represent duplicate wells of a single experiment. Error bars represent standard
deviations. The experiment was repeated a minimum of 3 times for each Env set. C)
Affinofile cells were induced with doxycycline and Ponasterone A for 20 hours, then
infected with HIV luciferase reporter viruses pseudotyped with UK1br and M2br wild-
type and mutant Envs. Infection was quantified after 48 hours by analyzing luciferase
activity. Background luciferase activity, measured as luc activity for Affinofile cells
infected with env- virus, was subtracted. Results are presented as percentage of infection
of cells expressing high CD4 and CCR5 for virus expressing the parental Env. *p<0.05,
student’s T test.74
Figure 2.3, Continued
0
1000
2000
3000
4000
5000
6000
7000
Low Medium High
CD4 Expression
M
e
a
n
F
l
u
o
r
e
s
c
e
n
c
e
Fusion: CD4 Expression
0
50000
100000
150000
200000
250000
300000
0 ng 0.375 ng 3 ng
Doxycycline (ng/ml)
A
B
S
/
C
e
l
l
Affinofile: CD4 Expression
0
20000
40000
60000
80000
100000
120000
140000
0 uM 0.5 uM 2 uM
Ponasterone A (uM)
A
B
S
/
C
e
l
l
Affinofile: CCR5 Expression
0
20
40
60
80
100
120
Low CD4 Medium CD4 High CD4
%
f
u
s
i
o
n
R
e
l
a
t
i
v
e
t
o
H
i
g
h
C
D
4
/
H
i
g
h
C
C
R
5
ADA
UK1br
M2br
Fusion
A
B
0
10
20
30
40
50
60
70
80
90
Low CD4/High CCR5 High CD4/Medium CCR5 Low CD4/ Low CCR5
%
I
n
f
e
c
t
i
v
i
t
y
ADA
UK1br
M2br
Affinofile Infection
0
1000
2000
3000
4000
5000
6000
7000
Low Medium High
CD4 Expression
M
e
a
n
F
l
u
o
r
e
s
c
e
n
c
e
Fusion: CD4 Expression
0
50000
100000
150000
200000
250000
300000
0 ng 0.375 ng 3 ng
Doxycycline (ng/ml)
A
B
S
/
C
e
l
l
Affinofile: CD4 Expression
0
20000
40000
60000
80000
100000
120000
140000
0 uM 0.5 uM 2 uM
Ponasterone A (uM)
A
B
S
/
C
e
l
l
Affinofile: CCR5 Expression
0
20
40
60
80
100
120
Low CD4 Medium CD4 High CD4
%
f
u
s
i
o
n
R
e
l
a
t
i
v
e
t
o
H
i
g
h
C
D
4
/
H
i
g
h
C
C
R
5
ADA
UK1br
M2br
Fusion
A
B
0
10
20
30
40
50
60
70
80
90
Low CD4/High CCR5 High CD4/Medium CCR5 Low CD4/ Low CCR5
%
I
n
f
e
c
t
i
v
i
t
y
ADA
UK1br
M2br
Affinofile Infection
0
10
20
30
40
50
60
70
80
90
Low CD4/High CCR5 High CD4/Medium CCR5 Low CD4/Low CCR5
%
I
n
f
e
c
t
i
v
i
t
y
R
e
l
a
t
i
v
e
t
o
H
i
g
h
C
D
4
/
C
C
R
5
M2br
N197D
V200T
N197D/V200T
UK1br Envs
0
5
10
15
20
25
30
35
40
Low CD4/High CCR5 High CD4/Medium CCR5 Low CD4/Low CCR5
%
M
a
x
I
n
f
e
c
t
i
o
n
H
i
g
h
C
D
4
/
C
C
R
5
UK1br
D197N
T200V
Affinofile: UK1br Envs Affinofile: M2br Envs
\ *
\ *
\*
\*
\ *
*
M2br Envs
0
20
40
60
80
100
120
140
160
180
Low CD4 Medium CD4 High CD4
%
w
i
l
d
-
t
y
p
e
f
u
s
i
o
n
H
i
g
h
C
D
4
/
C
C
R
5
M2br
N197D
V200T
N197D/V200T
Fusion: M2br Envs
*
*
\ *
\*
0
20
40
60
80
100
120
140
160
180
low cd4 medium cd4 high cd4
%
F
u
s
i
o
n
R
e
l
a
t
i
v
e
t
o
w
t
H
i
g
h
C
D
4
/
C
C
R
5
wt
D197N
T200V
Fusion: UK1br Envs
*
D
C
0
10
20
30
40
50
60
70
80
90
Low CD4/High CCR5 High CD4/Medium CCR5 Low CD4/Low CCR5
%
I
n
f
e
c
t
i
v
i
t
y
R
e
l
a
t
i
v
e
t
o
H
i
g
h
C
D
4
/
C
C
R
5
M2br
N197D
V200T
N197D/V200T
UK1br Envs
0
5
10
15
20
25
30
35
40
Low CD4/High CCR5 High CD4/Medium CCR5 Low CD4/Low CCR5
%
M
a
x
I
n
f
e
c
t
i
o
n
H
i
g
h
C
D
4
/
C
C
R
5
UK1br
D197N
T200V
Affinofile: UK1br Envs Affinofile: M2br Envs
\ *
\ *
\*
\*
\ *
*
M2br Envs
0
20
40
60
80
100
120
140
160
180
Low CD4 Medium CD4 High CD4
%
w
i
l
d
-
t
y
p
e
f
u
s
i
o
n
H
i
g
h
C
D
4
/
C
C
R
5
M2br
N197D
V200T
N197D/V200T
Fusion: M2br Envs
*
*
\ *
\*
0
20
40
60
80
100
120
140
160
180
low cd4 medium cd4 high cd4
%
F
u
s
i
o
n
R
e
l
a
t
i
v
e
t
o
w
t
H
i
g
h
C
D
4
/
C
C
R
5
wt
D197N
T200V
Fusion: UK1br Envs
*
D
C75
We next investigated whether Envs with enhanced capacity to fuse with cells
expressing low CD4 also mediated enhanced entry into cells expressing low CD4 using
the Affinofile cell line (53). Affinofile cells are a dually inducible cell line with
independent regulation of CD4 and CCR5 expression. The use of 3 serial dilutions each
of doxycyline and Ponasterone A to regulate CD4 and CCR5 expression, respectively,
created a matrix of 9 conditions to analyze CD4 and CCR5 usage (Fig. 2.3A). Consistent
with the fusion assay, viruses expressing M2br N197D, M2br N197D/V200T, and UK1br
T200V mediated enhanced entry into Affinofile cells expressing low CD4 and high
CCR5 compared to viruses expressing the parental Envs (p<0.05, student’s t test) (Fig.
2.3D). Furthermore, UK1br T200V and M2br N197D/V200T mediated enhanced entry
into Affinofile cells expressing lower CCR5 in combination with high CD4 compared to
the parental Envs, and M2br N197D and N197D/V200T had the capacity to infect cells
expressing low CD4 and CCR5 (p<0.05). Interestingly, M2br V200T, which contains the
PNGS at 197, exhibited reduced entry into cells expressing low CD4 and CCR5
compared to the parental Envs. Furthermore, the ability to use low CD4 and CCR5 for
fusion and entry was associated with enhanced macrophage entry (Fig. S2.2). Thus, D197
and T/V200 increased infection of cells expressing low CD4 and CCR5, suggesting that
these determinants enable Envs to overcome restrictions imposed by low CD4 by
enhancing interactions with CCR5.
Determinants at 197 and 200 increase Env interactions with CCR5. To investigate
the mechanism by which D197 and T/V200 contribute to reduced CD4-dependence, we
investigated binding of the parental and mutant Envs to cell-surface CCR5. UK1br76
T200V bound to CF2 cells expressing high
CCR5 with a 3-fold increase in the presence
of sCD4 and a 10-fold increase in the absence
of sCD4 compared to the parental Env (Fig.
2.4). These results suggest that enhanced
fusion and infection of cells expressing low
CD4 is due to enhanced gp120 affinity for
CCR5.
N-linked glycosylation is integral to
maintaining Env structure and occluding
conserved structural epitopes, including the
CCR5-binding site, from neutralizing antibodies
(80-83). Loss of the PNGS at 197 in Envs
adapted to grow on immortalized T cell lines
(lab-adapted Envs) influences sensitivity to neutralizing antibodies in a strain-specific
manner (45, 80, 84-85). Therefore, we measured neutralization sensitivity of the parental
and mutant Envs to soluble CD4 (sCD4) and monoclonal antibodies (mAb) 17b and 412.
17b has been used as a surrogate for CCR5-binding to probe conformational changes in
gp120 (86), and 412d recognizes a CD4-induced (CD4i) epitope. Viruses expressing the
M2br parental and mutant Envs were resistant to neutralization by sCD4 at
concentrations up to 50 g/ml, consistent with published results (Table 2.3 and Fig. S2.3)
(45, 84). UK1br Envs containing the loss of the PNGS at position 197 (UK1br and
UK1br T200V) were sensitive to sCD4 neutralization, with IC50 values of 1.3 and 0.4
Figure 2.4 V200 enhances macrophage
entry mediated by UK1br by increasing
gp120 binding to CCR5. Soluble gp120
(sgp120) from the wild-type and mutant
Envs was produced by transfected 293T
cells with Env plasmids containing a stop
codon at position 518. Concentrations of
sgp120 in the supernatant were determined
using ELISA and verified by Western
blotting. Concentrated sgp120s were
incubated with CF2th-synCCR5 cells with
or without preincubation with sCD4.
Binding of sgp120 to CCR5 on the cell
surface was determined by flow cytometry.
Results are representative of 3 independent
experiments.77
g/ml, respectively. As previously reported, the change to Asn at position 197 in the
UK1br Env resulted in increased resistance to sCD4 neutralization, with a 12-fold
increase in the IC50 compared to the parental UK1br (IC50=16.0 g/ml) (78, 80, 84-85,
87). Despite previous reports that the loss of the PNGS at position 197 resulted in
increased sensitivity to 17b neutralization (45, 84-85), only virus expressing the control
ADA Env was neutralized by 17b. Viruses expressing the UK1br and M2br parental and
mutant Envs were resistant to neutralization by 17b at concentrations up to 40 g/ml or
412d at concentrations up to 10 g/ml (Table 2.3, Fig. S2.3, and data not shown).
Preincubation of the viruses with a combination of sCD4 and 17b increased neutralization
sensitivity of M2br N197D and N197D/V200T, with IC50 values of 26 and 0.22 g/ml,
respectively. However, the M2br Envs containing N197 and all UK1br Envs remained
resistant at concentrations of 17b up to 25 g/ml. Together, these results suggest that
changes in amino acid sequence in 3 that include D197 in combination with T/V200
may affect stability and exposure of the CCR5-binding site following interactions with
CD4.
Table 2.3. Neutralization of parental and mutant Envs by sCD4
and 17b.
a
Virus sCD4 17b sCD4 + 17b
ADA 1.7 4.4 ND
M2br >50 >40 >25
N197D >50 >40 26.0
V200T >50 >40 >25
N197D/V200T >50 >40 0.22
UK1br 1.3 >40 >25
D197N 16.0 >40 >25
T200V 0.4 >40 >25
aValues (g/ml) represent IC50 values calculated from neutralization curves.78
DISCUSSION
In this study, we identified viral determinants in the HIV gp120 3 strand of the
bridging sheet that were associated with brain infection and dementia. D197, which
results in the loss of a PNGS, is associated with brain infection and dementia, and
T/V200 is under positive selection in HAD patients. D197 and T/V200 enhanced fusion
and infection of cells expressing low CD4, including macrophages. Viruses expressing
Envs containing D197 and T/V200 also mediated enhanced entry into Affinofile cells
expressing low CD4 and CCR5 (Fig. 2.3). UK1br T200V exhibited increased gp120
binding to CCR5, reaching levels 10-fold those of the parental Env, suggesting that D197
and T/V200 contribute to high-affinity interactions between M-tropic brain-derived Envs
and CCR5.
The PNGS at 197 is highly conserved among clade B Envs. Determinants that
eliminate this PNGS were found in only 8% of brain-derived and 1% of blood/lymphoid-
derived Envs from our dataset (Table 2.2). Based on previous studies (80, 84-85, 88), we
expected to find that the loss of the PNGS at 197 would increase exposure of the CCR5-
binding site and corresponding neutralization epitopes. Unexpectedly, viruses expressing
both the UK1br and M2br Envs containing D197 were not neutralization sensitive to
mAb 17b at concentrations up to 40 g/ml (Table 2.2 and Fig. S2.3). However,
incubation with both sCD4 and 17b increased neutralization sensitivity of viruses
expressing M2br N197D and N197D/V200T (IC50=26.0 and 0.2 g/ml, respectively),
but not the UK1br Envs. These results suggest that in M2br, D197 and T200 may
enhance gp120 interactions with CCR5 by stabilizing the region of the 17b epitope
following interactions with low concentrations of sCD4. Viruses expressing the UK1br79
Envs were sensitive to neutralization by sCD4, with a 12-fold increase in neutralization
resistance associated with the addition of the PNGS at position 197 (IC50=16.0 and 1.3
g/ml for UK1br D197N and UK1br, respectively). Haim et al demonstrated that Envs
have different susceptibilities to inactivation by sCD4, which may be linked to reactivity
and a propensity to sample different conformations, resulting in increased sCD4-induced
sgp120 shedding and virus inactivation (89-90). Thus, these results suggest that D197 and
T/V200 enhance gp120-CCR5 affinity by context-specific mechanisms.
Previous mutagenesis studies investigated the effects of eliminating the PNGS at
197 in both primary and lab-adapted HIV Envs (38, 45, 78, 80, 84, 87-88, 91-92). These
studies reported strain-dependent sensitivity to entry inhibitor BMS-806, sCD4, and a
number of monoclonal antibodies, including 17b, b3, b12, F105, 2G12, and patient sera,
and binding to sCD4 and CCR5. These results may reflect context-specific differences in
the position of the V1/V2 loops, resulting in exposure of the CCR5-binding site or
disrupting interactions between the V1/V2 and V3 loops, which may result from
enhanced Env affinity for CCR5. Our data show that the effect of T/V200 on fusion and
entry into cells expressing low CD4 is additive when combined with D197. Therefore,
determinants in the 3 strand may act cooperatively to enhance gp120 interactions with
CCR5.
Genetic evolution of HIV Env occurs in response to selection pressures, which
include adaptation to target cell populations and immune evasion. However, the selection
pressures in vivo that drive changes in M-tropism of R5 Envs are poorly understood (17).
Analysis of diversifying selection in the bridging sheet region of the CCR5-binding site
identified position 200 under positive selection in both brain and blood/lymphoid80
sequences from patients with HAD. Position 200 is located in several overlapping
immunodominant cytotoxic T lymphocyte (CTL) epitopes (LANL CTL/CD8+ T Cell
Database); diversifying selection at this position may therefore be a consequence of
immune evasion. The association between positive selection at position 200 and HAD
patients may reflect the greater genetic diversity of the env gene that is associated with
HAD (93-94).
In summary, this study identified determinants in the gp120 3 strand from M-
tropic brain-derived HIV Envs that increase gp120 binding to CCR5, thereby enhancing
macrophage entry. T/V200 enhanced fusion and entry when combined with D197,
suggesting that the sequence context of the 3 strand in M-tropic Envs is important for
influencing gp120 interactions with CCR5. These findings suggest that genetic
determinants in the 3 strand of the bridging sheet of HIV gp120 overcome the restriction
to macrophage infection imposed by low CD4 by enhancing Env interactions with CCR5,
thereby contributing to infection of the CNS and other macrophage-rich tissues.81
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ABSTRACT
The HIV envelope glycoprotein (Env) soluble gp120 (sgp120) subunit induces biological
effects in vitro, that include activation of signaling pathways and proinflammatory cytokine
production in bystander T cells and macrophages and altered T cell migration. Sgp120 shedding
from HIV virions and infected cells can occur spontaneously due to weak noncovalent
interactions with gp41 or be induced following Env binding to CD4. Although sgp120 has been
detected in plasma and tissues from HIV-infected individuals by ELISA, the range and
variability of sgp120 shedding from primary Envs in patients is unknown. Here, we analyzed
spontaneous sgp120 shedding from primary env clones and explored the biological significance
of these findings. Full-length env genes (n = 65 Envs)were amplified from brain and lymphoid
tissue from 12 AIDS patients and spontaneous sgp120 shedding was quantified by Western
blotting and ELISA. Relationships between shedding and biological data were examined.
Sgp120 shedding from primary brain and lymphoid Envs was highly variable within and
between patients, representing a spectrum rather than a categorical phenotype, with
concentrations overlapping those shown to induce biological effects in vitro. Brain Envs with
high sgp120 shedding exhibited enhanced fusion and infection with cells expressing low CD4
and an increased capacity to induce T cell activation during infection of PBMC, despite similar
levels of viral replication. Genetic analysis demonstrated greater entropy and positive selection
in Envs with high versus low levels of sgp120 shedding, suggesting that diversifying evolution
influences gp120-gp41 association. These findings suggest that increased spontaneous shedding
of sgp120 may be a viral phenotype that contributes to HIV pathogenesis by enhancing bystander
T cell activation.93
INTRODUCTION
The HIV envelope glycoproteins (Env) bind to CD4 and CCR5 or CXCR4 on target cells,
resulting in fusion and viral entry. The multimeric Env complex, which consists of surface-
exposed gp120 subunits held together by noncovalent interactions with transmembrane gp41
subunits, is organized into trimeric spikes on the surface of virions and infected cells (4-5). HIV
entry is mediated by high affinity interactions between gp120 and CD4, triggering a cascade of
conformational changes that include formation and exposure of the coreceptor binding site and
the gp41 prehairpin conformation. Subsequent binding of CD4-bound gp120 to CCR5 or
CXCR4 triggers formation of the gp41 6-helix bundle and initiates membrane fusion (6). The
relatively weak interactions mediating gp120 association with gp41 allow the soluble gp120
(sgp120) subunit to be readily shed from Env trimers, either spontaneously or following receptor
binding. Spontaneous dissociation of sgp120 occurs in a subset of Envs and is influenced by viral
determinants in regions important for gp120-gp41 association (7-10). Sgp120 shedding can also
be induced in a strain-dependent manner following binding of gp120 to the soluble subunit form
of CD4 (sCD4) in vitro (11-18).
Many studies have demonstrated that sgp120 can induce biological effects in vitro (19-
29), but the relevance of these results to pathogenesis in vivo is unknown. Sgp120 has been
detected by ELISA in plasma and tissues from a subset of AIDS patients and SHIV-infected
macaques. Sgp120 concentrations detected in plasma range from less than 20 to 800 pM,
depending on the ELISA protocol and stage of HIV infection, and in excess of 4 nM in lymph
nodes and spleen (21, 30-34). Purified sgp120 at concentrations overlapping those detected in
vivo has been shown to induce many biological effects in vitro. Sgp120 binds to CD4 on
uninfected T cells and macrophages, resulting in cellular activation and production of94
proinflammatory cytokines (21-23, 35-40). In one study, sgp120 concentrations measured by
ELISA in plasma from patients in the early stages of HIV infection correlated with higher levels
of plasma IL-6, IL-10, and TNF- compared to subjects without detectable sgp120 in plasma
(21). Sgp120-induced activation of T cells and macrophages can induce apoptosis of uninfected
T cells and neurons, (19-20, 24-26, 35, 39, 41-45), a mechanism proposed to contribute to T-cell
depletion and the development of HIV-associated neurological disorders (HAND) (19-20, 46).
Furthermore, incubation of T cells and dendritic cells with purified sgp120 alters cell chemotaxis
and migration (27-29). While these studies suggest a potential role for sgp120 in chronic
activation and immune system dysfunction, no studies have conclusively demonstrated that
sgp120 contributes to HIV pathogenesis in vivo.
The majority of in vitro studies investigating sgp120-induced biological effects used
sgp120 purified from lab-adapted HIV isolates that were adapted to grow on immortalized T-cell
lines (23-26, 35, 38, 42, 47-48). However, Envs from primary HIV isolates differ markedly from
lab-adapted Envs. For example, lab-adapted isolates are more sensitive to neutralization by
polyclonal sera from HIV-infected individuals, monoclonal antibodies, and recombinant sCD4
(11, 49), suggesting they adopt conformations in which gp120 neutralization epitopes that are
normally concealed on primary Envs are exposed. Therefore, biological effects induced by
sgp120 from lab-adapted strains may not be indicative of the ability of primary Envs to
contribute to HIV pathogenesis. Furthermore, in vitro studies often use sgp120 derived from a
single HIV isolate to analyze biological effects (23-26, 35-36, 38, 43-45, 47-48). While some
studies utilized purified sgp120 from 2-5 isolates (27-28, 39, 47, 50-52), the range and variability
of spontaneous sgp120 shedding from primary Envs is unknown.95
Here, we investigated spontaneous shedding of sgp120 from 65 primary HIV Envs
cloned from brain and lymphoid tissues from 12 AIDS patients. We demonstrate that
spontaneous shedding of sgp120 from primary brain and lymphoid Envs is highly variable within
and between patients, representing a spectrum rather than a categorical phenotype. Sgp120
concentrations shed by a subset of brain and lymphoid Envs overlapped concentrations
previously shown to induce biological effects in vitro. Brain Envs with high sgp120 shedding
mediated enhanced fusion and infection with cells expressing low CD4, and viruses expressing
these Envs demonstrated an increased capacity to induce lymphocyte activation during infection
of PBMC despite similar levels of viral replication. Genetic analysis demonstrated greater
entropy and positive selection in Envs with high versus low levels of shedding, suggesting that
diversifying evolution influences gp120-gp41 association. These findings suggest that increased
spontaneous shedding of sgp120 may be a viral phenotype that contributes to pathogenesis by
enhancing T cell activation.96
MATERIALS AND METHODS
Cells and HIV Env clones. 293T and TZM-bl cells were cultured in DMEM media
supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 100 g/ml penicillin and
streptomycin. CF2-Luc cells, which are derived from canine thymocyte cell line CF2th and
stably express firefly luciferase under control of HIV-1 LTR, were cultured in medium
supplemented with 0.7 mg/ml G418 (Mediatech, Herndon, VA) (53-54). Affinofile cells were
cultured in DMEM supplemented with 10% dialyzed FBS (Gibco), 100 g/ml penicillin and
streptomycin, and 50 g/ml blasticidin S HCl (Invitrogen) (55). All primary clade B env genes
were amplified directly from brain and lymphoid tissue as previously described. Briefly, primary
env genes from AIDS patients UK1, UK7, MACS2 (M2), MACS3 (M3), and MACS1 (M1) were
cloned into pCR3.1 (1-2, 56). Primary env genes from AIDS patients A, B, C, and D were
subcloned into pSVIIIenv using the KpnI to BamHI fragment (57). Primary env genes from
AIDS patients NA118, NA20, and NA420 were cloned into pSVIIIenv using the KpnI to KpnI
fragment (3). Reference Envs, including primary Envs ADA, YU2, JRFL, and JRCSF, and lab-
adapted Env HXB2, were cloned into pcDNA3.1 (Invitrogen, Grand Island, NY). TZM-bl cells
were provided by Norm Letvin. Affinofile cells were provided by Benhur Lee. NA118, NA20,
and NA420 Env expression plasmids were provided by Paul Clapham.
Detection of sgp120 shedding by Western blotting. 293T cells were transfected with
pCR3.1Env or pSVIIIEnv plus pLTR-Tat at a 1:10 ratio using calcium phosphate transfection (1,
53, 58-59). Cells were washed after 18 hours and incubated in media containing 0.3 g/ml
sodium butyrate. Cell lysates and supernatant were collected after 48 hours, centrifuged for 5
minutes at 2000 rpm to remove cell debris, and stored at -80ºC prior to analysis. Gp120 in cell97
lysates and supernatants was detected by Western blotting with polyclonal rabbit anti-gp120
(American Biotechnologies Inc.), a pool of 2 patient sera and monoclonal human anti-gp120
(Immunodiagnostics, Woburn, MA), or a pool of monoclonal antibodies 2G12 (NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, from Dr. Hermann
Katinger), b12 (NIH AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, from Dr. Dennis Burton and Carlos Barbas), and human anti-gp120 (60). Bands
were visualized using Pierce ECL Western Blotting Substrate (Thermo Scientific, Billerica,
MA). Blots were scanned into Photoshop to analyze mean band intensity. Results are presented
as % sgp120 shedding, calculated as [sgp120 (supernatant)/gp120 (lysate)] x 100. All results are
representative of at least 3 independent experiments.
ELISA. The ELISA assay was based on previously described methods (59, 61-62) with several
modifications. Briefly, 96-well microplates were coated overnight with sheep antibody D7324 at
5 g/ml in PBS (AALTO Bioproducts, Ltd., Ireland). Wells were washed 3 times with PBS
supplemented with 2.5% Tween-20 (PBS-T) and blocked for 1 hour at room temperature with
PBS-T supplemented with 3% BSA. Supernatants were incubated in the wells for 3 hours,
followed by 10 washes with PBS-T and 1 hour incubation with polyclonal rabbit anti-gp120
(American Biotechnologies Inc.). After 10 more washes with PBS-T, wells were incubated with
anti-rabbit-HRP (GE Healthcare). The reaction was developed using BM chemiluminescence
ELISA substrate (Roche) according to the manufacturer’s instructions. The reaction was read on
a luminometer (Viktor2, Perkin Elmer, Waltham, MA). Calculations of sgp120 concentrations
were based on a standard curve of purified HIVIIIB (Immunodiagnostics). Background calculated
from 293T cells transfected with empty pcDNA3.1 was subtracted from each well.98
Entry Assays. HIV luciferase reporter viruses were generated by cotransfection of
293T cells with pNL4-3envLuc, an HIV provirus with env deleted and nef replaced
with luciferase, and an Env-expression plasmid as described (53). To investigate sgp120
shedding following incubation at 37ºC, 10
4 3H cpm reverse transcriptase (RT) units of
virus stock were incubated at 37ºC for 0, 2, or 6 hours prior to infection of TZM-BL
cells seeded into 96-well plates. Cells were lysed with passive lysis buffer (Promega)
after 48 hours of incubation and virus infection was quantified by luciferase activity
(Promega). Affinofile cells were seeded into 96-well plates and treated for 20 hours
with serial dilutions of 0-3 ng/ml doxycycline (Clontech, Mountain View, CA) to
induce CD4 expression and 0-2 M Ponasterone A (Invitrogen) to induce CCR5
expression (55). Cells were then infected with 10
4 RT units of virus stock, lysed 2 days
post-infection, and assayed for luciferase activity. Cell surface CD4 and CCR5 levels
were analyzed by collecting cells with 5 mM EDTA in PBS and staining with anti-CD4-
PE (BD Biosciences, San Jose, CA) and anti-CCR5-PE (BD Pharmingen, San Diego,
CA). Cell surface staining was analyzed using a FACSCantoII flow cytometer (BD
Biosciences). The approximate number of CD4 and CCR5 molecules per cell was
calculated using FACS analysis of Quantibrite beads according to manufacturer’s
instructions (BD Biosciences). Mock infected cells were used as negative controls.
Single-round infection of CF2th CD4+/CCR5+ cells, HeLa hiCD4/hiCCR5 cells, and
monocyte-derived macrophages (MDM) were previously described (1, 3).99
Fusion Assays. 293T cells were cotransfected with 2 g Env-expression plasmid and 0.2 g
pLTR-Tat using calcium phosphate. Cf2-Luc cells were cotransfected with 0.1 (low) or 10 g
(high) amounts of pcDNA3-CD4 and 10 g (high) pcDNA3-CCR5 using Lipofectamine 2000
(Invitrogen). Cell surface expression levels of CD4 and CCR5 were verified by flow cytometry
as described for Affinofile cells. 2.5 x 10
4 293T cells and 2.5 x 10
5 CF2-Luc cells were mixed in
48-well plates and incubated for 8 hours. Cells were then lysed and analyzed for luciferase
activity. 293T cells cotransfected with a nonfunctional Env (pSVIII-KSenv) and pLTR-Tat
were used to determine background levels of luciferase.
PBMC Activation Assays. Healthy HIV-/HCV- donor blood provided by Research Blood
Components (Boston, MA) was collected into EDTA vacutainer tubes. The protocol for
obtaining blood was approved by the Dana-Farber Cancer Institute IRB. After collection, 10 ml
of fresh blood were diluted 1:1 with PBS and layered over 15 ml Ficoll Histopaque 1077 (Sigma)
and spun at 2000 × g for 20 min at room temperature. 5 ml of PBMC containing serum were
collected at the interface and diluted with 20 ml of PBS. The diluted cells were pelleted at 1000
× g for 10 min at 4°C, resuspended in 10 ml of PBS, and pelleted again at 1000 × g for 10 min.
The cell pellet was resuspended in 10 mls of RPMI-1640 (Invitrogen) and pelleted at 1000 × g
for 10 min. Cells were counted and resuspended at 2 × 10
6/ml in RPMI-1640 with 10% FBS and
100 g/ml penicillin/streptomycin. PBMC were incubated with a low concentration of PHA (1
ug/ml) for 2 days, followed by a 24 hour incubation with a low concentration of human IL-2 (10
U/ml). 250,000 cells were incubated in round-bottom 96-well plates with 10,000
3H cpm RT
units of virus stock for 3 h at 37
oC. Fifty percent medium changes were performed every 3 to 4
days for 14 days and replication was monitored by p24 antigen ELISA (Perkin Elmer, Boston,100
MA). Cells were collected for FACS analysis at days 3, 6, 10, and 14 post-infection and stained
with combinations of anti-CD3-PE-Cy5, anti-CD4-FITC, anti-CD8-PE, anti-CD25-APC-Cy7,
anti-HLA-DR-PE, anti-CD69-PE-Cy5, anti-TNF--APC, anti-IL-1-PE, and anti-IL-6-V450
(BD Biosciences) to monitor cell activation. Alternatively, cells were stained with a combination
of anti-CD4-FITC or anti-CD8-FITC, Annexin V V450, and 7-AAD (BD Biosciences) to
monitor apoptosis. Fluorescent cells were detected using a FACSCantoII flow cytometer (BD
Biosciences). Data were analyzed using FACSDiva software (BD Biosciences).
Sequence Analysis. Primary brain and blood/lymphoid-derived Envs were characterized as high
shedding (% sgp120 shedding >20%) or low shedding (% sgp120 shedding <20%) based on
Western blotting. Gp160 nucleotide and protein sequences for both groups were aligned using
ClustalX2. The entropy at each position in the protein alignment was measured with Shannon’s
entropy using EntropyOne (LANL). Detection of N-linked glycosylation sites was performed
with Glycosite (LANL). Selection pressures over gp160 for each group were examined with
methods available on the datamonkey web server. Three different approaches were used to
identify codons under positive selection: single likelihood ancestor counting (SLAC), fixed-
effects likelihood (FEL), and internal fixed effects likelihood (IFEL). SLAC and FEL detect sites
under selection at the external branches of the phylogenetic tree, while IFEL identifies sites
along the internal branches (63-65). Sites were classified as positively selected with p<0.1 at
least 2 methods. Bootstrapped phylogenetic trees for each group were created by the neighbor-
joining method using ClustalX2 and visualized using Treeview.101
Statistical Analysis. Data were analyzed using analysis of variance (ANOVA), Mann Whitney
test, unpaired t test with Welch’s correction, and Spearman correlation using GraphPad Prism
software. Differences were considered significant at p≤0.05. 102
RESULTS
Characteristics of Study Subjects and Envelope Clones. Low concentrations (<100 ng/ml) of
purified HIV sgp120 can induce apoptosis of uninfected neurons in vitro (19, 41-45), a
mechanism proposed to contribute to the development of HIV-associated neurological disorders
(HAND) (19, 46). However, sgp120 shedding from HIV in the brain has not been examined.
Given that, HIV adaptation to macrophages, which express low levels of CD4 and are the main
target cells for infection in the brain, can result in adoption of more “open” Env conformations
(1, 3, 53, 58, 66-69) that enhance gp120-receptor interactions, but may also may increase
spontaneous shedding of sgp120 (5, 7-8). We predicted that HIV Envs in the brain would shed
sgp120 at higher levels than Envs in blood/lymphoid tissues. To address this question, we
compiled a panel of 65 primary Envs cloned from brain and blood or lymphoid tissue (hereafter
referred to as lymphoid) from 12 AIDS patients that were previously characterized for biological
functions including cell tropism and neutralization sensitivity (1, 3, 56-57). Viral loads from
these tissues ranged from 301 to 100,841 HIV copies per million cells (Table S3.1). As detailed
in Table 3.1, 7 patients were diagnosed with HAD and 8 patients showed evidence of HIV
encephalitis (1, 3, 56-57, 70). All samples were collected prior to the advent of the HAART era;
the patients received limited or no antiretroviral therapy. There were an average of 4 brain and 4
lymphoid Envs per patient (range 1-5 Envs from brain and lymphoid tissue per patient). Mean
pairwise genetic distance of env clones from each tissue within each patient ranged from 0.002 to
0.057 and was independent of tissue viral load (Table S3.1 and data not shown). There was
evidence of genetic compartmentalization between Envs from brain and lymphoid tissues (p<0.1,
Slatkin-Maddison) for 5 patients (Table S3.1). As reference controls we used a panel of 5 well-103
characterized Envs (primary Envs ADA, YU2, JRFL and JRCSF, and lab-adapted Env HXB2)
for which spontaneous levels of sgp120 shedding were previously reported (9, 18, 71-72).Table 3.1. Clinical Characteristics of 12 AIDS Patients
# SGA Clones
Patient
a Risk Factor
b Clinical Dementia HIV Encephalitis Coreceptor Usage
c Brain LN/SP/BL
d Source
M2
e MSM Severe Moderate R5 4 3 Thomas 2007
M3
e MDM Severe Moderate R5 3 3 Thomas 2007
UK1 IVDU Severe Moderate R5 5 3 Thomas 2007
UK7 IVDU Severe Severe R5 5 1 Thomas 2007
M1
e MSM Yes Severe R5X4 3 1 Mefford 2008
NA118 IVDU Yes Severe R5 1 2 Peters 2004
NA20 Hemophilia Mild Mild R5 3 5 Peters 2004
NA420 IVDU No Mild R5 3 2 Peters 2004
A MSM No No R5, X4 2 2 Ohagen 2003
B MSM No No R5 2 2 Ohagen 2003
C MSM No No R5 2 2 Ohagen 2003
D MSM No No R5X4 1 5 Ohagen 2003
aAll samples were taken in the pre-HAART era and patients received either no ART or single drug regimens (1-2, 70)
b MSM, men who have sex with men; IVDU, intravenous drug user
c R5, CCR5; X4, CXCR4; R5X4, dual tropic (CCR5 and CXCR4)
d LN, lymph node; SP, spleen; BL, blood
e M2, MACS2; M3, MACS3; M1, MACS1
1
0
4105
Spontaneous shedding of sgp120 from primary brain and lymphoid Envs is highly variable
within and between patients. To investigate levels of spontaneous sgp120 shedding from
primary Envs, sgp120 levels in supernatants and cell lysates from 293T cells transfected with
Env-expression plasmids were analyzed by Western blotting (Fig. 3.1A). Median levels of
spontaneous sgp120 shedding were highly variable between patients (Fig. 3.1B; p<0.0001,
ANOVA). Percent sgp120 shedding relative to gp120 levels in cell lysates ranged from 24.4% to
97.8% for the reference control Envs and 0% to 84.6% for the panel of primary Envs. At least 1
Env from 10 of the subjects had high levels of spontaneous sgp120 shedding, while Envs from
the remaining 2 subjects exhibited little to no sgp120 shedding. Further analysis demonstrated a
range of sgp120 shedding levels for the primary and control Envs, independent of patient or
tissue of origin (Fig. 3.1C, Table S3.2). Additionally, mean sgp120 shedding calculated for brain
and lymphoid tissues within each patient did not correlate with tissue viral load or mean pairwise
genetic distance of the env clones (Fig. S3.1, p=0.4, r=0.3 and p=0.2,r=0.3, respectively,
Spearman correlation) (1). Sgp120 shedding into supernatants was not associated with levels of
gp120 in cell lysates (Fig. S3.2B; p=0.9, r=-0.01). These results suggest sgp120 from primary
Envs is highly variable both within and between patients, and represents a spectrum rather than a
categorical phenotype.106
Fig. 3.1. Detection of sgp120 spontaneously shed from primary brain and
lymphoid Envs by Western blotting.
293T cells were transfected with Env-expression plasmids. Gp120 was detected in cell
lysates and supernatants by Western blotting or ELISA following 48 hours of
incubation. A) Representative Western blots depicting gp160 and gp120 bands in cell
lysates (top gel) and supernatants (bottom gel) from 293T cells expressing brain and
lymphoid Envs from 7 patients. Reference Envs depicted include ADA, YU2, and
JRFL. B) Sgp120 shedding from 65 Envs from 12 AIDS patients and 5 reference Envs
(ADA, YU2, JRFL, JRCSF, HXB2) detected by Western blotting were compared.
Mean band intensity was determined using Photoshop. Percent sgp120 shedding was
calculated as [sgp120 (supernatant)/gp120 (cell lysate)] x 100, with a range of 0% (no
sgp120 detected in supernatant) to nearly 100% (equal amounts of sgp120 detected in
supernatant and cell lysate). Scatter plots showing average % sgp120 shedding values
from a minimum of 3 independent experiments were created using Graphpad Prism
software. Brain Envs are depicted with red circles, lymphoid Envs with blue circles,
and control Envs with black circles Median levels of sgp120 shedding (black lines)
from combined brain and lymphoid Envs within each patient differed significantly
(p>0.0001, ANOVA). C) Range of sgp120 shedding detected by Western blotting.
Error bars represent standard deviations from at least 3 independent experiments. D)
Median levels of sgp120 shedding were compared for brain and lymphoid Envs from
patients diagnosed with or without clinical dementia. Median levels of shedding for
each group are depicted with a line.107
Fig. 3.1, Continued108
We also compared sgp120 shedding from brain-derived Envs from HAD compared to
non-HAD patients. Overall, there was a trend towards higher levels of sgp120 shedding from
brain compared to lymphoid Envs, although these differences did not reach statistical
significance (Fig. 3.1D; p=0.5 and 0.09 for HAD and non-HAD patients, respectively, Mann
Whitney). Furthermore, median levels of sgp120 shedding were similar for brain-derived Envs
from patients with and without HAD (Fig. 3.1D). These results suggest that for patients with
late-stage AIDS, Envs with high levels of sgp120 shedding are not significantly associated with
brain infection or dementia.
Previous studies have used ELISAs to measure the concentration of sgp120 shed from
viruses and cells (11, 60, 73-75). ELISA is a more sensitive method than Western blotting, but
does not allow quantitation of gp120 levels in cell lysates to normalize results for differences in
cell surface expression. To validate the results obtained by Western blotting, we compared
detection of sgp120 in transfected 293T cell supernatants by Western blot and gp120 sandwich
ELISA. Sgp120 concentrations in the cell supernatants detected by ELISA ranged from below
the threshold of detection (1 ng/ml) to in excess of 1.5 ug/ml (Fig. 3.2A, Table S3.2) and median
levels of sgp120 detected in supernatants were highly variable between patients (p<0.0001,
ANOVA). The levels of sgp120 shedding detected in supernatants of transfected 293T cells by
ELISA were consistent with those detected by Western blotting (Fig. 3.2B, p<0.0001, r=0.6,
Spearman correlation). For 66.1% of the primary Envs, levels of sgp120 measured in supernatant
exceeded concentrations shown to induce biological effects in vitro (27, 36, 41, 43-45, 50).109
combined brain and lymphoid Envs within each patient differed significantly (p>0.0001,
ANOVA). B) Comparison of methods of detection of sgp120 in supernatants of
transfected 293T cells in a single representative experiment. P and R values were
calculated using Spearman correlation on GraphPad Prism software.
High levels of sgp120 shedding are not associated with reduced infectivity. High levels of
sgp120 shedding from primary Envs on virions can be detrimental to infectivity. Indeed, this was
clearly seen for a series of mutants constructed in the YU2 Env in a study by Finzi et al, where
Envs with the highest levels of sgp120 shedding had the lowest infectivity (Fig. S3.3) (7).
However, when we compared sgp120 shedding from a subset of primary Envs to viral infectivity
measured during single-round infection of CF2 CD4+/CCR5+ cells, we found no relationship.
Incubation of virus at 37ºC has been shown to increase sgp120 dissociation of sgp120 from a
subset of Envs (11, 60). Therefore, we examined the relationship between virus inactivation due
Fig. 3.2. Detection of sgp120 shed
into 293T cell supernatants by
ELISA.
A) Concentrations of sgp120 shed
from 293T cells transfected with 65
Env plasmids from 12 AIDS
patients and a panel of 5 reference
Envs was determined using ELISA.
Concentrations were determined by
comparison to a standard curve
generated using 2-fold dilutions of
HIVIIIB. Median levels of sgp120
shedding (black lines) from110
to increased sgp120 shedding at
37C and viral infectivity by
analyzing infectivity of TZM-bl
cells for HIV reporter viruses
expressing a subset of the
primary R5-tropic Envs (n=16
Envs from 7 patients; 8 Envs
each from brain and lymphoid
tissues) following incubation at
37ºC for 0, 2, or 6 hours. As
previously reported, a wide
range of infectivity was observed
following 2 hours incubation at
37ºC (Fig. 3.3A). When Envs were
divided into 2 groups based on
tissue of origin, mean infectivity at
both 2 and 6 hours was higher for
viruses expressing brain compared
to lymphoid Envs (Fig. 3.3B,
p=0.01 and 0.02, respectively, unpaired t test with Welch’s correction). These results suggest that
high levels of sgp120 shedding from brain Envs are not necessarily detrimental to viral
infectivity.
Fig. 3.3. Decreased infectivity following incubation at
37ºC is associated with tissue of origin but not levels of
sgp120 shedding.
A) HIV luciferase reporter viruses pseudotyped with
primary brain and lymphoid Envs from 7 patients were
incubated at 0, 2, and 6 hours at 37ºC prior to infection of
TZM-BL cells. Cells were lysed 48 hours after infection
and assayed for luciferase activity. Envs with high levels
of shedding (>20%) are shown in red and Envs with low
levels of shedding (<20%) are shown in blue. B)
Comparison of infectivity following 2 and 6 hours
incubation at 37ºC for brain and lymphoid Envs. Lines
depict mean % infectivity compared to viruses with no
incubation at 37C for each group. P-values were calculated
using unpaired t test with Welch’s correction.111
Brain Envs with high levels of spontaneous sgp120 shedding exhibit enhanced fusion and
infection with cells expressing low CD4. Brain Envs have adapted to infect target cells
expressing low levels of CD4 (50, 54, 58). One mechanism that influences this phenotype is
increased exposure of the CD4 or CCR5 binding sites, a phenotype that may also increase
sgp120 shedding (8, 66-69). To determine whether brain Envs with high levels of sgp120
shedding are associated with enhanced infection of cells expressing low CD4, we analyzed
infection of Affinofile cells expressing low CD4 and CCR5 for viruses expressing a subset of
matched brain and lymphoid primary Envs from 6 patients (n=14 Envs; 8 from brain and 6 from
lymphoid tissues). Viruses expressing brain Envs mediated enhanced infection of cells
expressing low CD4 and high CCR5 compared to lymphoid Envs (Fig. 3.4A, p=0.05). Viruses
expressing lymphoid Envs mediated higher infection with cells expressing high CD4 and
medium CCR5 compared to brain Envs, as previously reported (data not shown) (76). Further
analysis revealed that Envs with high sgp120 shedding exhibited enhanced infection of cells
expressing low CD4 compared to those with low sgp120 shedding (Fig. 3.4B, p=0.02). In this
dataset, the majority of the brain Envs fell into the high shedding category. These results suggest
that mechanisms used by brain Envs to utilize reduced CD4 for entry may decrease gp120-gp41
association.112
Next, we examined the association between sgp120 shedding from brain and lymphoid
Envs and interaction with cells expressing low CD4 using a larger dataset. Cell-cell fusion assays
were performed with CF2Luc cells expressing low or high levels of CD4 (MFI low CD4 ≤15% 
MFI high CD4) and high CCR5 for Envs from 8 patients (n=44 Envs from 7 patients
with HAD and 1 patient with no HAD). Results are presented as fusion with cells expressing low
CD4/fusion with cells expressing high CD4 (Fig. 3.5A/B). There was an association between
high levels of sgp120 shedding from CCR5-tropic brain but not lymphoid Envs and relative
enhancement of fusion with cells expressing low CD4 compared to high CD4 (p= 0.02 and 0.47,
respectively, Spearman correlation) (1). We then compared the relationship between sgp120
shedding from brain Envs and enhanced infection of cells expressing low CD4 using Envs from
7 patients (n=34 Envs from 6 patients with HAD and 1 patient with no HAD) (1, 3). Results are
presented as infection of cells expressing low CD4/high CD4 (Fig. 3.5 C/D). There was a
Fig. 3.4. Primary Envs from brain with high levels
of sgp120 shedding are associated with enhanced
infection of Affinofile cells expressing low CD4.
Affinofile cells expressing low CD4 and high CCR5
were infected with HIV luciferase reporter viruses
pseudotyped with primary brain and lymphoid Envs
from 6 patients. Cells were lysed 48 hours after
infection and assayed for luciferase activity. Brain
Envs are shown in red and lymphoid Envs are shown
in blue. A) Comparison of infectivity for brain and
lymphoid Envs. Lines depict mean % infectivity of
cells expressing high CD4 and CCR5. B)
Comparison of infectivity for Envs grouped
according to % sgp120 shedding (high shedding >
20%; low shedding < 20%). P-values were calculated
using unpaired t test with Welch’s correction.113
correlation between brain Envs with high levels of shedding and enhanced infection of cells
expressing low CD4 (p=0.01). Furthermore, an inverse correlation was observed between
lymphoid Envs with high levels of shedding and infection of cells expressing low CD4 (p=0.01).
Thus, the association between reduced CD4-dependence and high levels of sgp120 shedding may
reflect CNS-specific adaptations.114
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Fig. 3.5. Association between brain Envs with high levels of sgp120 shedding and
enhanced fusion and infection of cells expressing low CD4.
Percent sgp120 shedding from 293T cells transfected with primary brain and lymphoid
CCR5-tropic Envs from a subset of 7 AIDS patients was compared to relative fusion (A,
B) and infectivity (C, D) of cells expressing low CD4/high CD4 (1, 3, 56). P and R
values were calculated using Spearman correlation on GraphPad Prism software.
Macrophages and microglia, the target cells of HIV in brain, express low levels of CD4.
Therefore, HIV viruses from brain express Envs adapted to overcome this restriction on infection
(3, 58, 68, 77-81). Because brain Envs with high levels of sgp120 shedding mediated enhanced
infection into cells expressing low CD4, we investigated whether these Envs also mediated
enhanced entry into monocyte-derived macrophages (MDM). However, we found no relationship
between brain Envs with high levels of sgp120 shedding and MDM entry (p=0.48, r=-0.18) (Fig.
3.6A). This may reflect the different mechanisms used by HIV Envs to mediate efficient entry115
into MDMs. Interestingly, there was a stronger association between the Envs that mediated high
infectivity in TZM-bl cells (infectivity >0.05) following 2 hours of incubation at 37ºC and
enhanced MDM entry (n=8 Envs, 7 brain and 1 lymphoid from 5 patients; p=0.06, r=0.68) (Fig.
3.6B). TZM-bl cells express high levels of CD4 and CCR5, and the subset of Envs was mixed
between high and low levels of sgp120 shedding (n=4 Envs with % sgp120 shedding >20% and
4 Envs with %sgp120 shedding <20%). These results suggest that understanding the relationship
between Envs with high levels of sgp120 shedding and the mechanisms by which brain and
lymphoid Envs contribute to M-tropism requires further investigation.
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One mechanism proposed to reduce CD4-dependence of brain-derived Envs is increased
exposure of the CD4 or CCR5 binding sites, which can be probed using sCD4 and monoclonal
antibodies directed against CD4-induced epitopes. To address this question, we compared
sgp120 shedding with inhibition of single-round infection by neutralizing antibodies and entry
Figure 3.6. Brain Envs with high levels
of sgp120 shedding are not associated
with enhanced entry into primary
macrophages.
A) Relative entry into macrophages of
viruses expressing brain-derived Envs from
7 AIDS patients was compared to sgp120
shedding. % Max MDM ratio is calculated
as [(MDM entry/entry into cells)/maximum
MDM ratio for each study]*100 (thomas,
peters) to control for inter-study variations..
P values were calculated using Spearman
correlation on Graphpad Prism software. P
values <0.05 were considered significant.
B) Relative entry into macrophages was
compared with % sgp120 shedding by
brain and lymphoid Envs (n=8 Envs, 7
brain and 1 lymphoid, from 5 patients) that
mediated high levels of infectivity in TZM-
bl cells following 2 hours of incubation at
37ºC.116
inhibitors (54, 68, 80). Sgp120 shedding from 7 patients (n=33 Envs from 6 patients with HAD
and 1 patient with no HAD) did not correlate with sensitivity to sCD4, monoclonal CD4-binding
site antibody b12, or patient sera (data not shown). Shedding from these Envs also did not
correlate with inhibition by entry inhibitors, including Tak779, AD101, or T20, although there
was a trend toward correlation between Envs with high levels of sgp120 shedding and T20
sensitivity (p=0.07, r=0.31) (data not shown).
Envs with high levels of shedding induce activation of bystander cells during PBMC
infection. To examine whether Envs with high levels of sgp120 shedding are associated with
phenotypes that may contribute to HIV pathogenesis in vivo, we performed a pilot study to
analyze activation of lymphocytes during virus replication in vitro. PBMCs were infected with
replication competent viruses expressing Envs with high (ADA), medium-high (UK1br), or low
(UK7br) levels of sgp120 shedding as measured by Western blotting. Envs with high levels of
shedding induced upregulation of cell surface CD25 on both CD4+ and CD8+ lymphocytes at
day 6 post-infection (Fig. 3.7A, Fig. S3.4). On day 10 post-infection, there was a corresponding
decrease in this cell population, possibly reflecting the preferential loss of the activated cells due
to bystander apoptosis (Fig. 3.7B). Upregulation of IL-1 was observed at day 3 post-infection
(Fig. 3.7C). Although the sample size is small, upregulation of both CD25 and IL-1 is
consistent with the increased levels of sgp120 shed by the same Envs from transfected 293T
cells. Importantly, the viruses replicated to similar levels, suggesting that the T cell activation
was independent of an effect on levels of viral replication (Fig. 3.7D).117
Fig. 3.7. Induction of lymphocyte activation markers is associated with Envs with high
levels of sgp120 shedding. PBMC were stimulated for 24 hours with PHA-P (1 g/ml), then the
stimulation media was removed and replaced with IL-2 (10 U/ml) for 2 days. PBMCs were
infected with an equivalent MOI of replication competent virus. Cells were collected on days 3
(C), 6 (A), and 10 (B) post-infection, stained for cell surface markers and cytokine production,
and analyzed by flow cytometry. A/B) CD25 expression is presented as percentage of CD4+ or
CD8+ T cells. C) Percent IL-1+ cells from the activated lymphocyte population. D)
Supernatants were collected every 3–4 days, and replication was monitored by p24 ELISA.
Results shown are from duplicate samples. Error bars represent standard deviations.
Genetic analysis of Envs with high versus low levels of shedding. Diversifying evolution of
the Env gene is important for immune evasion and adaptation to target cells. To examine the
molecular and evolutionary features of Envs with high and low sgp120 shedding, Envs were
divided into 2 groups based on levels of sgp120 shedding detected by Western blotting. Envs
with high levels of sgp120 shedding (% sgp120 shedding >20% compared to gp120 in cell118
lysate; n=38 Envs from 13 patients; 22 brain and 16 lymphoid Envs; median=2 Envs/patient)
were compared to Envs with low levels of sgp120 shedding (% sgp120 shedding < 20%
compared to cell lysate; n=29 Envs from 9 patients; 13 brain and 16 lymphoid Envs; median=2
Envs/patient). Amino acid diversity in Envs between the 2 groups was compared by calculating
Shannon’s entropy (Fig. 3.8 A/C, Table S3.4). Median entropy values averaged across gp160
were significantly higher for Envs with high versus low levels of sgp120 shedding (p<0.0001,
Mann Whitney). Mean entropy values across gp120 and gp41 were also higher for Envs with
high versus low levels of sgp120 shedding (0.554 versus 0.359 and 0.511 versus 0.214,
respectively). These results were confirmed by constructing neighbor joining phylogenetic trees
for both groups (Fig. S3.4). Tight within-patient clustering was observed for Envs from
individual patients in the low sgp120 shedding, while higher in-patient diversity was apparent in
the high sgp120 shedding group.119
Fig. 3.8. Diversity and positive selection in sequence alignments from Envs with high and
low levels of sgp120 shedding.
Primary brain and lymphoid Envs were characterized as high shedding (% sgp120 shedding
>20%; n=38 Envs from 13 patients) or low shedding (% sgp120 shedding <20%, n=29 Envs
from 9 patients). Nucleotide sequences for each group were aligned using Clustal X2. A/C)
Shannon’s entropy values were calculated from aligned sequences using Entropy One (LANL)
and plotted against codon number (HXB2 numbering). (B/D) dN-dS values were estimated by
SLAC, FEL, and IFEL analysis (datamonkey.org) from aligned sequences and scaled by total
codon tree length. X-axis values represent codon positions (HXB2 numbering). Bars represent
sites with p<0.1 in at least 2 analyses. Box represents area of gp41 with high number of sites
predicted to be under positive selection in Envs with high levels of shedding.
To examine whether the higher env diversity observed in the high sgp120 shedding group
is a result of increased positive selection, synonymous (dS) and nonsynonymous (dN)
substitution rates were analyzed for each codon in both groups using three models of molecular
evolution (63-65, 82-83). Ratios of non-synonymous and synonymous substitution rates were
estimated for each codon in the Env alignments using SLAC, FEL, and IFEL analysis. Sites were
considered to be under significant levels of positive selection if p-values <1.0 were estimated by120
at least 2 methods. Site by site analysis revealed different patterns of positive selection between
the 2 groups (Fig. 3.8 B/D and Table S3.3). An increased number of sites predicted to be under
positive selection were identified in the high shedding group in regions previously demonstrated
to be important for gp120-gp41 association, including the gp120 N-terminus, C2, and C4 regions
and the gp41 N-terminus, HR2, MSD, and C-terminus (7-9, 17, 84-87).
To determine whether the association between Envs with high levels of sgp120 shedding
and enhanced infection of cells expressing low CD4 may be due to a decrease in the number of
N-linked glycosylation sites, a mechanism proposed to influence interactions between gp120 and
CD4 and CCR5, the number of predicted N-glycosylation sites was compared between the 2
groups. The distribution of predicted N-glycans was similar between the 2 groups, although there
was a higher number of N-glycans predicted in >90% of sequences in the low compared to high
sgp120 shedding group (17 versus 12) (Table S3.3). Therefore, high sgp120 shedding was not
associated with a significant decrease in N-linked glycosylation sites.121
DISCUSSION
In this study, we demonstrated that sgp120 is spontaneously shed from a significant
proportion of primary brain and lymphoid HIV Envs, but the phenotype is highly variable
between and within patients (p<0.0001), representing a spectrum rather than a categorical
phenotype. Levels of sgp120 shed by a subset of primary Envs overlapped with concentrations
previously shown to induce biological effects in vitro. Moreover, viruses expressing Envs that
spontaneously shed sgp120 at high levels induced higher levels of bystander T cell activation
during infection of PBMC compared to those that shed sgp120 at low levels, despite similar
levels of viral replication. Genetic analysis demonstrated greater median entropy (p<0.0001) and
more codons under position selection in env sequences from patients with high versus low levels
of sgp120 shedding (45 versus 29 positively selected codons, respectively; Fig. 3.8, Table S3.3).
Thus, diversifying evolution may select for Env determinants that decrease gp120-gp41
association.
The main target cells of HIV in the CNS are macrophages and microglia, which express
low levels of CD4. These cell types are preferentially infected by viruses that can utilize low
levels of CD4 for entry (3, 58, 68-69, 77-81). Here, we found an association between enhanced
fusion and infection with cells expressing low CD4 and brain Envs with high levels of sgp120
shedding (p=0.06, r=0.4 and p=0.01, r=0.6, respectively; Fig. 3.5). Because brain-derived Envs
are generally M-tropic, we expected to find an association between levels of macrophage
infection and sgp120 shedding by Envs from brain. However, we did not find this association
(Fig. 3.6). The lack of correlation was unexpected, and may reflect different mechanisms of M-
tropism. While brain Envs exhibited an association between reduced CD4 dependence and high
levels of sgp120 shedding, not all M-tropic Envs preferentially infect cells expressing low CD4.122
Other mechanisms that may contribute to M-tropism include enhanced Env affinity for CCR5
(53, 77, 88-89) (see Chapter 2) or increased interactions with high mannose oligosaccharides
expressed on the macrophage cell surface (90-91). Enhanced Env-CD4 interactions can result
from increased exposure of the CD4 binding site through shifting of the V1/V2 and V3 loops,
thereby leading to increased spontaneous sgp120 shedding (5, 8). Future work is needed to
determine if specific mechanisms contributing to M-tropism are associated with high levels of
sgp120 shedding.
Purified HIV sgp120 induces biological effects in vitro that include cellular activation
and bystander cell apoptosis, raising the possibility that sgp120 may contribute to the immune
activation and immune dysregulation characteristic of HIV infection. However, a link between
sgp120 and HIV pathogenesis in vivo has not been demonstrated. We found that viruses
expressing brain Envs with high levels of sgp120 shedding had an increased capacity to induce
lymphocyte activation, resulting in increased cell surface expression levels of CD25 and IL-1
(Fig. 3.6). Furthermore, CD4+ and CD8+ cells expressing high CD25 were lost over the course
of PBMC infection despite similar levels of viral replication. Although this study was small (n=3
viruses), these results raise the possibility that sgp120 shed from virions and infected cells may
contribute to bystander T cells activation during HIV infection.
Low concentrations (<100 ng/ml) of purified HIV sgp120 are required to induce
apoptosis of uninfected neurons in vitro (19, 41, 43-45), a mechanism proposed to contribute to
the development of HIV-associated neurological disorders (HAND) (19, 46). The low levels of
antibodies in the CNS (19, 92) combined with adaptation to target cells expressing low CD4, can
result in adoption of more open Env conformations with increased exposure of the CD4 and
CCR5-binding sites and neutralization epitopes (1, 3, 53, 58, 66-69). Structural and functional123
studies raise the possibility a consequence of these conformations may be increased spontaneous
shedding of sgp120 (5, 7-8). Therefore, we expected to find that brain Envs shed sgp120 at
higher levels than lymphoid Envs. However, although there was a trend towards higher median
levels of sgp120 shedding from brain Envs compared to lymphoid Envs, these differences did
not reach statistical significance (Fig. 3.1D). Furthermore, brain-derived Envs from patients with
or without HAD had similar median levels of sgp120 shedding. The lack of correlation between
sgp120 shedding and tissue of origin or disease status may be due to sample collection during
late-stage AIDS.
One caveat of this study is that we measured spontaneous sgp120 shedding from a large
panel of primary brain and lymphoid Envs from transfected 293T cells, which results in
overexpression of Env trimer spikes on the cell surface, thereby facilitating detection of shed
sgp120. These results may therefore exaggerate levels of sgp120 shedding compared to
physiological conditions. We calculated our results as % sgp120 shedding, which takes into
account differences in cell-associated gp120 production. As such, we expect that our results are
indicative of relative levels of sgp120 shedding during physiological conditions.
In summary, this study demonstrated a wide range of sgp120 shedding from primary HIV
Envs in brain and lymphoid tissues from AIDS patients with advanced disease. Sgp120 shedding
from primary Envs represents a spectrum rather than a categorical phenotype. Envs with high
levels of sgp120 shedding were associated with enhanced infection of cells expressing low CD4
and bystander T cell activation during PBMC infection. Thus, increased sgp120 shedding may be
a viral phenotype that contributes to HIV pathogenesis.124
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ABSTRACT
Human immunodeficiency virus (HIV-1) variants in brain primarily use CCR5 for
entry into macrophages and microglia, but dual-tropic (R5X4) HIV-1 has been detected
in brain and cerebral spinal fluid (CSF) of some patients with HIV-associated dementia
(HAD). Here, we sequenced the gp120 coding region of 9 full-length dual-tropic (R5X4)
env genes cloned directly from autopsy brain and spleen tissue from an AIDS patient with
severe HAD. We then compiled a dataset of 30 unique clade B R5X4 Env V3 sequences
from this subject and 16 additional patients (n=4 brain and 26 lymphoid/blood) and used
it to compare the ability of 6 bioinformatic algorithms to correctly predict CXCR4-usage
in R5X4 Envs. Only one program (SVMgeno2pheno) correctly predicted the ability of R5X4
Envs in this dataset to use CXCR4 with 90% accuracy (n=27/30 predicted to use
CXCR4). The PSSMSINSI, Random Forest, and SVMgenomiacprograms and the commonly
used charge rule correctly predicted CXCR4-usage with >50% accuracy (22/30, 16/30,
19/30, and 25/30, respectively), while the PSSMX4R5 matrix and “11/25” rule correctly
predicted CXCR4-usage in <50% of the R5X4 Envs (10/30 and 13/30, respectively).
Two positions in the V3 loop (19 and 32) influenced coreceptor usage predictions of 9
R5X4 Envs from patient MACS1 and a total of 12 Envs from the dataset (40% of unique
V3 sequences). These results demonstrate that most predictive algorithms underestimate
the frequency of R5X4 HIV-1 in brain and other tissues. SVMgeno2pheno is the most
accurate predictor of CXCR4-usage by R5X4 HIV-1.135
INTRODUCTION
Human immunodeficiency virus type I (HIV-1) infects macrophages and
microglia in the central nervous system (CNS) and causes HIV-associated dementia
(HAD) or mild neurocognitive impairment in 10-20% of AIDS patients. HIV-1 variants
in brain are genetically distinct from those in lymphoid tissues and other organs, and
specific sequences in the envelope glycoprotein (Env) coding region of gp160 have been
associated with brain compartmentalization (1). HIV-1 tropism is influenced by the
interaction of Env with CD4 and a coreceptor, typically CCR5 or CXCR4. CCR5 (R5) is
the primary coreceptor for HIV-1 infection of macrophages and microglia. Several
studies identified HIV-1 brain or CSF isolates capable of mediating entry using CXCR4
(X4 isolates) or both CCR5 and CXCR4 (R5X4 or dual-tropic isolates) (1-4). However,
the frequency of X4 or R5X4 strains in the brain of AIDS patients is unknown.
The third hypervariable loop of Env gp120 (V3), a disulfide-linked loop of
approximately 35 amino acids, makes direct contact with the coreceptor and is the
primary determinant for R5- or X4-tropism (5). Bioinformatic algorithms that use V3
sequence to predict HIV-1 coreceptor usage have been developed as a timely and cost-
effective alternative to traditional phenotypic assays (6-10). However, database sequence
sets are heavily dependent on R5 sequences and may underestimate X4-usage and dual-
tropism. Furthermore, the ability of bioinformatic algorithms to reliably predict X4-usage
by R5X4 isolates has not been addressed. Here, we cloned and sequenced 9 full-length
R5X4 HIV-1 Envs from autopsy brain and spleen tissues from an AIDS patient with
severe HAD. We then added these sequences to a larger dataset of unique clade B R5X4136
V3 sequences and compared the ability of freely available bioinformatic algorithms to
accurately predict X4-usage.
RESULTS
MACS1, a male homosexual patient in the Chicago component of the Multicenter
AIDS Cohort Study with no history of antiretroviral therapy, had severe HAD and a
CD4+ T-cell count of 2 cells/l at the time of death (3-4). Analysis of CCR5 alleles by
PCR demonstrated that the patient was homozygous wild type for CCR5. At autopsy,
sections through the frontal and parietal cortex showed pathology consistent with HIV
encephalitis (i.e. multiple microscopic foci of necrosis and focal perivascular lesions
throughout the white matter occasionally associated with multinucleated giant cells). HIV
vacuolar myelopathy and leukoencephalopathy was unusually advanced within the brain
stem and cerebellum. We previously isolated four R5X4 HIV-1 viruses from brain (br)
and spleen (spln) tissue from this patient [MACS1-br (pbmc), MACS1-br (mdm),
MACS1-spln (pbmc), and MACS1-spln (mdm)]. These viruses were isolated from
cultures with CD8-depleted peripheral blood mononuclear cells (PBMC) or monocyte-
derived macrophages (MDM) as indicated. These R5X4 isolates replicated efficiently in
MDM and microglia and induced syncytia formation in >90% of cells by day 10 post-
infection. The brain- and spleen-derived isolates entered macrophages and microglia
primarily via CXCR4 and induced neuronal apoptosis in primary brain cultures,
suggesting that R5X4 variants may be pathogenic in the CNS (3-4).
To investigate the frequency of R5X4 variants in tissues from patient MACS1,
env genes were amplified from genomic DNA isolated from autopsy brain and spleen137
tissues and cloned into the pCR3.1 expression plasmid as described (4, 11). A single-
round infection assay screen yielded 28 clones that encoded functional Envs (n=10 brain
and 18 spleen clones). Ten Envs from this set (n=5 brain and 5 spleen) were selected for
sequencing and further analysis. Expression and processing of 9/10 Envs on 293T cells
was verified via Western blotting with antibodies directed against gp120 (goat anti-gp120
from the National Institutes of Health AIDS Research and Reference Reagent Program)
(data not shown) (2, 4, 11). Coreceptor usage was investigated using a cell-cell fusion
assay as previously described (Table 4.1) (4, 11). We previously showed that CCR5 and
CXCR4 usage determined in this cell-cell fusion assay correlates well with coreceptor
usage determined in viral infection assays (2-3, 12-13). The well characterized ADA
(R5), 89.6 (R5X4), and HxB2 (X4) Envs were used as controls. Nine of ten MACS1
Envs tested (n=5/5 brain and 4/5 spleen) were equally capable of using CCR5 and
CXCR4 for fusion in CD4-expressing cells (Table 4.1). None of the Envs showed a
reduced dependence on CD4 levels in the cell-cell fusion assay (data not shown). One
Env (spleen-derived clone sp7a-14) was non-functional based on cell-cell fusion assays
using either CCR5 or CXCR4; this Env contains an amino acid variant (R507) at the
gp120/gp41 interface, disrupting the REKR motif required for furin cleavage which is
critical for HIV fusion (14). Thus, Env sp7a-14 is probably non-functional due to loss of
gp160 cleavage.138
Table 4.1. MACS1 Envs use both CCR5 and
CXCR4 to mediate fusion
a
Envelope CCR5 CXCR4
ADA ++++ -
89.6 +++ ++++
HXB2 - ++++
MACS1br6b-8
1 ++ ++
MACS1br6b-9
1 ++ ++
MACS1br6b-3 +++ +++
MACS1br6b-13
2 ++++ +++
MACS1br6a-9 ++++ ++++
MACS1sp7b-11 +++ ++++
MACS1sp8a-2 +++ ++++
MACS1sp7a-14
2 - -
MACS1sp7a-13 +++ ++++
MACS1sp7b-9 +++ ++++
a293T cells cotransfected with pCR3.1Env and
pLTR-Tat were mixed with Cf2-Luc cells
cotransfected with pcDNA3-CD4 and either
pcDNA3-CCR5 or pcDNA3-CXCR4. Cells were
harvested following an 8-hour incubation. The
levels of fusion in cells expressing CD4 and CCR5
or CXCR4 as measured by luciferase activity are
indicated as follows: -, +, ++, +++, and ++++
representing levels that were at background, 1-25%,
25-50%, 50-75%, and 75-100% of control Envs,
respectively. Unless otherwise indicated, results are
representative of 5 independent assays.
1Results
from 1 fusion assay.
2Results from 2 fusion assays.
Analysis of amino acid sequences revealed that 9 envs (4 brain and 5 spleen)
encode a full-length gp120 protein. One brain-derived env clone (br6b-9) has a short N-
terminal truncation with sequence initiating at the second methionine (position 26) due to
a frameshift at position 15 in the N-terminus; this truncation did not affect Env function
in the cell-cell fusion assay. Phylogenetic analysis of gp120 nucleotide sequences
confirmed distinct compartmentalization of brain- and spleen-derived Env clones (Fig.
4.1). Phylogenetic analysis of V1V2 amino acid sequences showed tight clustering of139
brain V1V2 sequences and separation of brain- and spleen-derived Env V1V2 sequences
(Fig. 4.1). MACS1 brain-derived Env clone br6b-8 was more closely related to V1V2
sequences derived from spleen than from brain.
Figure 4.1. Phylogenetic analysis of HIV-1 gp120 and V1V2 sequences.
Sequences from brain and spleen tissues are color-coded black and gray, respectively.
Numbers associated with each branch are bootstrap values, which represent the number
of trees, out of 1000 replicates performed, in which the same branching order was found.
Only values above 800 for the major branches are shown. Branch lengths are proportional
to the amount of sequence divergence. Scale bars indicate 1% sequence divergence. The
left panel depicts the phylogenetic relationship among gp120 nucleotide sequences
amplified directly from brain and spleen tissues from patient MACS1. The right panel
depicts V1V2 amino acid sequences derived from patient MACS1. MACS1 brain and
spleen viral isolates obtained by PBMC coculture are shown in italics.(3-4)
The gp120 V3 loop contains important determinants of coreceptor usage and
syncytium-induction in MT-2 cells (5). Consequently, patterns of V3 amino acid
variation are frequently used to predict coreceptor usage of primary HIV strains (6-10,
15-16). To determine the ability of freely available bioinformatic algorithms to predict
X4-usage in R5X4 Envs, we compiled a dataset containing 30 unique clade B R5X4 V3140
sequences (27 unique V3 sequences from 16 patients in 9 published studies and 3 unique
V3 sequences from patient MACS1; n=4 brain- and 26 lymphoid/blood-derived
sequences) (Fig. 4.2) (2, 12-13, 17-22). Envs in this dataset were cloned and sequenced
directly from tissue or from low passage isolates, and coreceptor usage of the clones was
experimentally determined using viral infection assays (12-13, 17, 20-22), or a
combination of viral infection assays and cell-cell fusion assays (2, 13). We then used
this dataset to determine the ability of 6 bioinformatic algorithms to accurately predict
X4-usage by R5X4 Envs (Fig. 4.2).141
Figure 4.2. Prediction of coreceptor usage by R5X4 V3 sequences using
bioinformatic prediction algorithms.
A. Unique R5X4 V3 amino acid sequences (n=30) from 17 patients were aligned using
ClustalX. The sequences are shown aligned to the CCR5-tropic Clade B consensus
sequence. Sequences are grouped by patient. Sequences derived from brain (n=4) are
underlined. Positions 11 and 25 in the V3 loop are highlighted in the sequence
alignments. Algorithms that correctly predict the ability to use CXCR4 are indicated
following each sequence. 1= 11/24/25 rule; 2=Charge rule; 3= PSSM (X4R5); 4= PSSM
(SINSI);5= Random Forest; 6= SVMgenomiac; 7= SVMgeno2pheno. B. Summary of
total number of correct predictions for each bioinformatic algorithm and the program’s
specificity for the 30 R5X4 V3 sequences.142
Figure 4.2, Continued
A
Clade B CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC
MACS1br6b-8 ...........MSL...K......Q......K...(2,7)
MACS1br6b-9 .I.........MSL...KV.....Q......K...(2,4,6,7)
MACS1br&sp ...........MSL...KV.....Q......K...(2,4,6,7)
aBR01 .........R.VTM..........D..........
aBL01 ........KR..TR....VY....D.V........(2,3,4,6,7)
dBR02/07 .........RKGSM......LAREQ...N......(1,2,3,4,5,6,7)
15888 .........RG.Y......I...DK.V....K.Y.(1,2,3,4,5,6,7)
C2-3/16 ............TM....VY...............(7)
C2-22 ............TM....VY...I...........(4,7)
C2-24 ............TM....VD...............(7)
DR-1 .I.........MTL...KV.....-VT.S..K...(2,4,5,6,7)
DR-8/17 .I.........MTL...KV.....-VT....K...(2,4,6,7)
DR-19 .I.........MTL...KV.....-VT....KE..(2,4,6,7)
89.6 .........RRLS........ARRN..........(1,2,3,4,5,6,7)
DH12 ..........G.TL....V.......V....K...(2,4,7)
T5-R5X4-1/2 ..........R.TM....VY...........K...(1,2,3,4,5,6,7)
3921F12+3 ..........R.SLS...V............K...(1,2,3,4,5,6,7)
20813B1 .........RR.Y..Q...V...RQ......K.Y.(1,2,3,4,5,6,7)
92HT594 ..........R.S......S....Q......K...(1,2,3,4,5,6,7)
17141raf5 ....G....RR.S..........EQ...N......(1,2,3,4,5,6,7)
17136roe11 ....G.....R.S..........EQ...N......(1,2,3,4,5,6,7)
17131rog6 ....G.....R............EQ...N......(1,2,4,5,6,7)
17129roa10 ....G.....R............RQ...N......(1,2,4,5,6,7)
17136rod11 ....G.....R.S..........EQ..........(1,2,4,5,6,7)
QH1520c.2 ............RM.IR.....RE-..........(2,5,7)
QH1549c.13 ........I...RM.IR.....RE-..........(2,4,5,7)
96USHIPS9 ..........G.N.....TV.A..K..........(1,2,4,5,7)
49030rog6 ..........G..L.....L.A..G.V........(2)
409028rod7 .............L..........G...N......(2)
QH1521c.34 ..........H..L.A.K....GE-..........(6,7)
B
Predictive Correct Predictions/ Accuracy
Algorithm Total # R5X4 Envs
11/24/25 Rule 13/30 43.3%
Charge Rule 25/30 83.3%
PSSMX4R5 10/30 33.3%
PSSMSINSI 22/30 73.3%
Random Forest 16/30 53.3%
SVMgenomiac 19/30 63.3%
SVMgeno2pheno 27/30 90.0%143
Two simple and commonly used prediction methods are the “11/25” rule and the
charge rule. In the “11/25” rule, the presence of a positively-charged amino acid at either
position 11 or 25 of the V3 loop predicts that the virus can use X4 to mediate entry (6-9,
15-16). This prediction method is significantly less accurate for X4 than for strictly R5-
tropic viruses, with <50% and >90% accuracy, respectively (6, 9, 16). The charge rule
states that an increase in the net charge of the V3 loop (>3) is strongly associated with
CXCR4-usage (10). The Position-Specific Scoring Matrix (PSSM) detects nonrandom
distributions of V3 amino acids at adjacent sites associated with an empirically
determined group of sequences (8, 15). Two separate matrices are available for clade B
Envs at: http://ubik.microslu.washington.edu/computing/pssm. PSSMX4R5 bases
predictions on sequences of known coreceptor-usage phenotype. PSSMSINSI bases
predictions on known syncytium-inducing phenotypes on the MT-2 cell line (8). Random
forest (http://yjxy.ujs.edu.cn/R5-X4 pred.rar) evaluates the relative importance of 37
features of the V3 loop including amino acid variation at each position, net charge, and
polarity (10). Finally, two versions of the Support Vector Machine (SVM) algorithm can
be used for coreceptor phenotype predictions (9). SVMgenomiac
(http://genomiac2.ucsd.edu:8080/wetcat/v3.html) outputs a categorical score (CCR5 or
CXCR4) using a dataset aligned to a standard amino acid sequence. SVMgeno2pheno
(http://coreceptor.bioinf.mpi-sb.mpg.de/cgi-bin/coreceptor.pl) similarly outputs a144
categorical score based on alignment of V3 nucleotide sequences. The accuracy of these
methods in predicting coreceptor usage of R5X4 Envs has not been reported.
Coreceptor usage predictions for the R5X4 V3 sequence dataset using the “11/25”
rule were comparable to those reported for X4-tropic V3 sequences, with an accuracy of
43.3% (13/30 Envs). Including position 24 in this rule (“11/24/25” rule) is reported to
increase accuracy of prediction of X4-tropic sequences (6). However, including position
24 did not affect the prediction accuracy of this R5X4 dataset. The Cardozo et al model
was constructed using strictly R5- or X4-tropic Envs. However, R5X4 Envs contain V3
loops that can adopt conformations capable of interacting with either CCR5 and CXCR4,
and may therefore contain surface patches that do not conform to the static models of V3
structure in this proposed model (6). A second commonly used coreceptor-prediction
method, the charge rule, predicted that 83.3% of the V3 data set could use CXCR4 for
entry (25/30 Envs). Of the two PSSM matrices, PSSMX4R5 matrix correctly predicted X4
usage for 10/30 V3 sequences (33.3% accuracy). PSSMX4R5 predicted that 3/3 MACS1
unique V3 sequences would be strictly R5-tropic (0% accuracy). The PSSMSINSI matrix
correctly predicted X4-usage in 22/30 V3 sequences, thereby increasing the accuracy of
prediction for our dataset of R5X4 Envs from 33.3% to 73.3%. X4-usage was correctly
predicted for 2/3 unique MACS1 V3 sequences (66.6% accuracy). The random forest
program predicted X4-usage for 16/30 Envs, with an accuracy of 53.3%, and predicted
that 3/3 unique MACS1 Envs were strictly R5-tropic (0% accuracy). SVMgenomiac
correctly predicted 19/30 Envs could use CXCR4 to mediate entry, with an accuracy of
63.3%. As with PSSMSINSI, X4-usage was correctly predicted for 2/3 unique MACS1 V3
sequences (66.6% accuracy). Finally, SVMgeno2pheno predicted that 27/30 R5X4 Envs145
could use X4 for entry, with an accuracy of 90.0% (specificity, defined here as rate of
false positives, set at 10%). Prediction of X4-usage for the unique MACS1 Envs was 3/3
(100%). X4-usage predictions were most accurate when specificity levels were at 5-10%.
Increasing the stringency of predictions through decreasing the specificity rate to <5%
resulted in a concurrent decrease in prediction accuracy, but could be overcome by
inputting clinical data (CCR5-genotype and CD4+ counts).
SUMMARY AND DISCUSSION
While no single variant appears to affect the accuracy of coreceptor prediction in
every genetic background, changing the Env V3 sequence entered into bioinformatic
programs to assess the effects of specific amino acids on prediction accuracy in our R5X4
dataset identified several positions that may contribute to the accuracy of coreceptor
prediction using bioinformatic approaches. Both the X4R5 and SINSI PSSM matrices
incorrectly predict that MACS1 brain Env clone br6b-8 is R5-tropic. Env br6b-8 contains
the consensus alanine at position 19 in the V3 loop, while the other eight MACS1 Env
clones contain a valine at this position. Changing the amino acid sequence from our
dataset of 30 unique V3 sequences from valine to alanine at position 19 also changes the
PSSM prediction from X4- to R5-tropic in 9 additional Envs. These results suggest that
an alanine-to-valine change at position 19 may be associated with a change from R5- to
X4-tropism in sequences from the training sets of both matrices. Another interesting
finding from the PSSM matrix predictions is that a glutamine to lysine variant at position
32 in the V3 loop changed the prediction for our set of MACS-1 Env clones from R5-
tropic to X4-tropic. This trend is applicable to additional V3 sequences from our dataset146
that contain the lysine variant at position 32. These results suggest that inclusion of V3
amino acid sequences from more X4 or R5X4 Envs to algorithm training sets will further
increase the prediction accuracy of these matrices.
In summary, we identified R5X4 HIV-1 in brain from a patient with severe HAD.
Comparison of the ability of bioinformatic algorithms to correctly predict X4-usage by
R5X4 Envs in our dataset showed that the frequency of R5X4 HIV-1 is underestimated
by most commonly used predictive algorithms. SVMgeno2pheno is the most accurate
predictor of CXCR4-usage by R5X4 HIV-1 in brain and other tissues. Bioinformatic
prediction tools provide a convenient method to screen for coreceptor usage, an issue of
increasing importance for clinicians considering the use of CCR5 antagonists in HIV-
infected patients. It will therefore be important for future studies to increase X4 and
R5X4 sequences associated with bioinformatic algorithm training set sequences in the
development of prediction tools in order to better define the patterns of amino acid
variation that contribute to inaccurate predictions.
SEQUENCE DATA
Sequences reported here were assigned Genbank accession numbers EU401895-
EU401904.147
ACKNOWLEDGEMENTS
We thank Mark Jensen for helpful discussions. This work was supported by NIH grants
NS37277 and MH83588. M.M. was supported in part by NIH fellowship
1F31NS060611-01. P.R.G. is the recipient of an Australian National Health and Medical
Research Council (NHMRC) R. Douglas Wright Biomedical Career Development Award
and was supported, in part, by a grant from the Australian NHMRC (433915). Core
facilities were supported by Harvard Medical School Center for AIDS Research (CFAR)
and DFCI/Harvard Cancer Center grants.148
REFERENCES
1. Dunfee R, Thomas ER, Gorry PR, Wang J, Ancuta P, Gabuzda D. Mechanisms of
HIV-1 neurotropism. Curr HIV Res. 2006;4(3):267-78.
2. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, et al. Genetic
and functional analysis of full-length human immunodeficiency virus type 1 env genes
derived from brain and blood of patients with AIDS. J Virol. 2003;77(22):12336-45.
3. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, et al.
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and
lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol.
2001;75(21):10073-89.
4. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, et al. Increased
CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human
immunodeficiency virus type 1 isolate. J Virol. 2002;76(12):6277-92.
5. LaBranche CC, Hoffman TL, Romano J, Haggarty BS, Edwards TG, Matthews
TJ, et al. Determinants of CD4 independence for a human immunodeficiency virus type 1
variant map outside regions required for coreceptor specificity. J Virol.
1999;73(12):10310-9.
6. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. Structural
basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses.
2007;23(3):415-26.
7. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction
of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence
using neural networks. Virology. 2001;288(1):51-62.
8. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, et al.
Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition
by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J
Virol. 2003;77(24):13376-88.
9. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, et al. Current V3
genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical
isolates. Aids. 2007;21(14):F17-24.
10. Xu S, Huang X, Xu H, Zhang C. Improved prediction of coreceptor usage and
phenotype of HIV-1 based on combined features of V3 loop sequence using random
forest. J Microbiol. 2007;45(5):441-6.
11. Thomas ER, Dunfee RL, Stanton J, Bogdan D, Taylor J, Kunstman K, et al.
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined149
by the capacity to use low CD4 levels and overall efficiency of fusion. Virology.
2007;360(1):105-19.
12. Gray L, Churchill MJ, Keane N, Sterjovski J, Ellett AM, Purcell DF, et al.
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope
glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J
Virol. 2006;80(7):3684-91.
13. Gorry PR, Dunfee RL, Mefford ME, Kunstman K, Morgan T, Moore JP, et al.
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an
HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology. 2007;362(1):163-78.
14. Bosh VMP. Mutational analysis of the human immunodeficiency virus type I env
gene product proteolytic cleavage site. J Virol. 1990;64:2337-44.
15. Shah M, Smit TK, Morgello S, Tourtellotte W, Gelman B, Brew BJ, et al. Env
gp120 sequence analysis of HIV type 1 strains from diverse areas of the brain shows
preponderance of CCR5 usage. AIDS Res Hum Retroviruses. 2006;22(2):177-81.
16. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R.
Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to
phenotype-associated changes in the V3 loop. J Virol. 2002;76(8):3852-64.
17. Yi Y, Shaheen F, Collman RG. Preferential use of CXCR4 by R5X4 human
immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J Virol.
2005;79(3):1480-6.
18. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, et al.
Molecular cloning and analysis of functional envelope genes from human
immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID
Networks for HIV Isolation and Characterization. J Virol. 1996;70(3):1651-67.
19. Sullivan PS, Schable C, Koch W, Do AN, Spira T, Lansky A, et al. Persistently
negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1
infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical
Study Group. Aids. 1999;13(1):89-96.
20. Skrabal K, Saragosti S, Labernardiere JL, Barin F, Clavel F, Mammano F. Human
immunodeficiency virus type 1 variants isolated from single plasma samples display a
wide spectrum of neutralization sensitivity. J Virol. 2005;79(18):11848-57.
21. van Rij RP, Blaak H, Visser JA, Brouwer M, Rientsma R, Broersen S, et al.
Differential coreceptor expression allows for independent evolution of non-syncytium-
inducing and syncytium-inducing HIV-1. J Clin Invest. 2000;106(12):1569.
22. Hu QX, Barry AP, Wang ZX, Connolly SM, Peiper SC, Greenberg ML.
Evolution of the human immunodeficiency virus type 1 envelope during infection reveals150
molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J
Virol. 2000;74(24):11858-72.CHAPTER 5: DISCUSSION152
Summary
HIV infection of macrophages in brain and other tissues plays an important role in the
development of HIV-associated neurological disorders (HAND) and other aspects of disease
pathogenesis. Macrophages express low levels of CD4, and envelope glycoproteins (Envs) from
macrophage-tropic (M-tropic) HIV strains adapt to overcome this restriction to virus entry by
mechanisms that are not well characterized. One mechanism that influences this phenotype is
increased exposure of the CD4 or CCR5 binding sites, which may also increase dissociation of
soluble gp120 (sgp120) from the Env trimer based on structural models. Little is known about
spontaneous sgp120 shedding from primary HIV Envs or its biological significance.
In Chapter 2, we sought to identify determinants in M-tropic brain-derived Envs that
contribute to reduced CD4-dependence by enhancing gp120 interactions with CCR5. To
accomplish this goal, we examined brain and lymphoid gp120 sequences from the bridging sheet
region of the CCR5 binding site from AIDS patients with or without HIV-associated dementia
(HAD). Two determinants in the surface exposed 3 strand of the bridging sheet were
identified. D197, which results in the elimination of an N-linked glycosylation site, was
associated with brain infection and dementia. Position 200 was under positive selection in HAD
patients. D197 and T/V200 enhanced fusion and entry with macrophages and other cells
expressing low CD4 by enhancing gp120 binding to CCR5. The influence of T/V200 on fusion
and entry was additive when combined with D197, suggesting that variants in the 3 strand
might act cooperatively enhance M-tropism. In Chapter 3, we analyzed spontaneous sgp120
shedding from a panel of 65 primary brain and lymphoid Envs from 12 AIDS patients. Sgp120
shedding from primary brain and lymphoid Envs was highly variable within and between
patients, representing a spectrum rather than a categorical phenotype, and for 66% of Envs153
reached levels overlapping those shown to induce biological effects in vivo. Brain Envs with
high sgp120 shedding mediated enhanced fusion and infection with cells expressing low CD4.
Furthermore, viruses expressing brain Envs with high sgp120 shedding demonstrated an
increased capacity to induce lymphocyte activation during infection of PBMC, despite similar
levels of viral replication. Genetic analysis demonstrated greater entropy and positive selection
in Envs with high versus low levels of sgp120 shedding, suggesting that diversifying evolution
influences gp120-gp41 association. Finally, in Chapter 4 we sequenced the gp120 coding region
of nine full-length dual-tropic (R5X4) env genes cloned directly from autopsy brain and spleen
tissue from an AIDS patient with severe HAD. We then compiled a dataset of 30 unique clade B
R5X4 Env V3 sequences from this subject and 16 additional patients (n=4 brain and 26
lymphoid/blood Envs) and used it to compare the ability of six bioinformatic algorithms to
correctly predict CXCR4 usage in R5X4 Envs. The results demonstrated that most predictive
algorithms underestimated the frequency of R5X4 HIV-1 in brain and other tissues.
SVMgeno2pheno was the most accurate predictor of CXCR4 usage by R5X4 HIV-1.
Together, our work provides a better understanding of the mechanisms by which gp120
determinants in brain Envs influence M-tropism. In addition, our findings demonstrate that
spontaneous sgp120 shedding from primary brain and lymphoid Envs represents a phenotypic
spectrum that may influence HIV pathogenesis by contributing to immune activation and
bystander cell apoptosis. The following sections will discuss these phenotypes in greater detail.154
Mechanisms of HIV-1 Macrophage Tropism
Macrophages express lower levels of CD4 than CD4+ T cells in peripheral blood, and are
preferentially infected by viruses that can utilize low levels of CD4 for entry (1-9). The major
viral determinant of M-tropism is Env. Mechanisms that enhance Env interactions with CD4
have been elucidated in a number of studies, and include increased binding affinity for CD4 and
increased exposure of the CD4-binding site (1, 6, 9-12). One mechanism by which HIV Envs
may overcome the restriction imposed by reduced CD4 on macrophages is through enhanced
Env interactions with CCR5. Although several studies described M-tropic Envs with reduced
CCR5 dependence, the determinants in M-tropic Envs that contribute to this phenotype are
poorly understood (13-15). Gorry et al (14) characterized brain-derived Env clones with
increased affinity for CCR5. These Envs mediated cell-cell fusion with target cells expressing
low CD4 or CCR5, and were sensitive to CCR5-targeted small molecule inhibitors, suggesting
that high-affinity Env-CCR5 interactions might contribute to infection of target cells expressing
low CD4. Other studies have also identified M-tropic R5 viruses that can use low levels of CD4
and CCR5 for entry (2, 15-17), raising the possibility that enhanced gp120-CCR5 interactions
may be a mechanism that contributes to M-tropism in brain-derived Envs. Possible mechanisms
that may contribute to these interactions include increased exposure of the CCR5 binding site,
increased affinity of Env for CCR5, adoption of conformations that facilitate the rearrangements
that occur following CD4 and/or coreceptor binding, and sampling of the CD4-bound
conformation of gp120.
In Chapter 2, we investigated whether D197 and T/V200 in the HIV gp120 3 strand of
the bridging sheet enhanced gp120-CCR5 interactions of M-tropic Envs. Viruses expressing
Envs containing D197 and T/V200 mediated enhanced entry into Affinofile cells expressing low155
CD4 and CCR5 (Fig. 2.3). The UK1br T200V Env exhibited increased gp120 binding to CCR5
at levels 10-fold those of the parental Env (Fig. 2.4), suggesting that D197 and T/V200
contribute to high-affinity interactions between M-tropic brain-derived Envs and CCR5.
The increased interactions between gp120 and CCR5 were not due to increased exposure
of the CCR5 binding site, as was previously reported for mutagenesis studies in which the N-
linked glycosylation site (PNGS) at position 197 was eliminated (14, 18-20). Differences in
neutralization sensitivity were detected between the UK1br and M2br Envs, indicating that the
mechanism by which D197 and T/V200 contribute to M-tropism is context-specific. None of the
parental or mutant Envs exhibited neutralization sensitivity to monoclonal antibodies 17b or
412d (Table 2.3, Fig. S2.2, data not shown). However, although the M2br Envs were resistant to
neutralization by sCD4, viruses expressing M2br N197D and N197D/V200T were sensitive to
neutralization by 17b following preincubation with sCD4. This suggests that D197 and T200 in
this context may influence the formation or stability of the 17b epitope following binding to low
levels of sCD4, or influence the kinetics of post-CD4 binding conformational rearrangements. In
contrast, the UK1br Envs remained neutralization resistant to 17b following incubation with
sCD4, but were neutralization sensitive to sCD4 alone. There was a 12-fold increase in resistance
to sCD4 neutralization for UK1br D197N compared to the parental Env, as was previously
reported (18-19, 21-22). Haim et al demonstrated that Envs have different susceptibilities to
inactivation by sCD4, which may be linked to reactivity and a propensity to sample different
conformations, resulting in increased sCD4-induced sgp120 shedding and virus inactivation (23-
24). Thus, D197 and T/V200 seem to enhance gp120-CCR5 affinity by distinct mechanisms that
may include sampling conformations that enhance gp120 binding to CCR5 and stabilizing the
CCR5-binding site region following interactions with low levels of CD4.156
Gp120 interactions with CCR5 are dependent on the tyrosine-rich and highly acidic
CCR5 amino terminus and the second extracellular loop (ECL2). In particular, sulfation of the
tyrosines at positions 10, 14, and 15 appears to be the most critical (25-27). Recent studies have
suggested that brain Envs with increased affinity for the CCR5 ECL-2 region demonstrate
increased efficiency of CCR5 usage (15, 28-29). This model has been predicted to contribute to
M-tropism through alterations in the gp120 V3 loop, CD4-binding site, and gp41 interaction sites
in the N- and C-termini (15). To examine whether D197 and T/V200 influenced interactions with
CCR5, we analyzed cell-cell fusion with cells expressing CD4 and CCR5 coreceptors containing
amino acid alterations in the N-terminus and ECL-2 regions (provided by D. Kabat) (25).
However, there were only minor differences in the ability of the parental and mutant Envs to
mediate fusion with cells expressing these attenuated CCR5s (data not shown). These results
indicate that enhancement of M-tropism observed for these Envs was not due to increased
dependence on the CCR5 ECL-2 region.
Model for Enhanced Infection of Target Cells Expressing Low CD4 by Envs with High
Levels of sgp120 Shedding
HIV entry into cells is initiated by a high affinity interaction between gp120 and CD4.
CD4 binding induces conformational changes in gp120 that involve rearrangements of the
V1/V2 and V3 variable loops and formation and exposure of the CCR5 binding site (30-31). The
V1/V2 and V3 loops in the unliganded Env trimer are thought to both protect the CD4 and CCR5
binding sites and neutralization epitopes and provide contact points at the apex of the trimer (32-
33). The interactions between the variable loops in the context of the trimer are supported by157
functional studies, which suggest that the V1/V2 loops on one protomer may mask neutralization
epitopes by interacting with the V3 loop of an adjacent protomer (33-37). Adaptations to target
cells expressing low CD4 may result in increased exposure of the CD4-binding site or CD4-
induced epitopes, or adoption of an “open” conformation with partial formation of the CCR5
binding site and exposure of the gp41 prehairpin intermediate (8, 10-11, 33, 38-39), possibly due
to repositioning of the variable loops. This is turn may destabilize the unliganded Env trimer,
resulting in spontaneous sgp120 shedding.
In Chapter 3, we demonstrated that brain-derived Envs with high levels of sgp120
shedding mediated enhanced fusion and entry into cells expressing low levels of CD4 (Fig. 3.5).
However, we did not find any correlations between Envs with high levels of sgp120 shedding
and neutralization sensitivity to sCD4, monoclonal antibody b12, or patient sera (data not
shown), which may reflect context-specific differences in adaptation to target cells expressing
low CD4. In support of this idea, we found associations between neutralization sensitivity to b12
and high levels of shedding for Envs from three patients, although the sample size was too small
to be considered significant (n=11 Envs, p=0.03, r=-0.68, Spearman correlation) (data not
shown). Because enhanced affinity of Env for CCR5 may also contribute to reduced CD4-
dependence, we analyzed correlations between Envs with high levels of sgp120 shedding and
sensitivity to entry inhibitors targeting CCR5 (TAK779 and AD101, data not shown), but found
no associations. Published results showed that a subset of the Envs used in our study mediate
fusion and infection of cells expressing low CCR5 (7, 13), but the sample size was too small to
analyze correlations between Envs with enhanced interactions with CCR5 and TAK-779
sensitivity. There was a trend towards an association between sensitivity to the entry inhibitor
T20 and Envs with high levels of shedding (p=0.07, r=0.31, data not shown). T20 is an antiviral158
C-peptide which targets gp41 HR1 and blocks gp41 conformational changes, including
formation of the six-helix bundle (40). The gp41 HR1 and HR2 regions are exposed following
gp120 binding to CD4 (31); therefore, sensitivity of Envs with high levels of sgp120 shedding to
T20 suggests that some of these Envs may sample a CD4-bound conformation. Thus, Envs that
mediate enhanced fusion and entry with cells expressing low levels of CD4 may increase sgp120
shedding in a context-dependent manner by influencing positioning of the variable loops or
adopting an “open” conformation.
Possible Contributions of sgp120 to HIV Pathogenesis
The HIV Env sgp120 subunit induces biological effects in vitro at concentrations ranging
from <800 pM to in excess of 40 nM. In contrast, concentrations of sgp120 detected by ELISA
in vivo range from less than 20 to 800 pM in plasma and in excess of 4 nM in lymph nodes and
spleen (41-45). These concentrations overlap the lower range of concentrations used in vitro, and
bring into question the physiological relevance of some of the in vitro data. Moreover, questions
have been raised concerning the validity of detection of sgp120 in plasma and tissues by ELISA
(46). Sgp120 in excess of that associated with virions is detected in only a subset of patients (42-
45), and the presence of plasma antibodies is proposed to interfere with accurate detection of free
sgp120 (46). Therefore, the most accurate assessment of the technique may be from the studies
that measured sgp120 in plasma and tissues during the acute and early stages of infection (41-43)
when nonneutralizing anti-gp41 antibodies predominate (47). However, a recent study by Liu et
al showed that during chronic infection in a subset of patients, levels of HIV in plasma
complexed to gp120-specific IgG antibodies only approached 50% of free virus, suggesting that
even during the later stages of HIV/AIDS free sgp120 in plasma may be available to activate159
bystander cells (47). Indeed, sgp120 levels measured in plasma in one study remained constant
before and after seroconversion, suggesting that plasma antibodies may not invariably impede
detection (42). Therefore, sgp120 concentrations measured in vivo, especially during the early
stages of infection, may be a fairly accurate measure of free sgp120.
The question remains whether sgp120 in plasma and tissues can reach the concentrations
detected in vivo. Env trimers are expressed on the surface of virions and infected cells. Limited
numbers of Env trimer spikes are found on virions, with an average of 14 spikes on HIV-1 (48).
However, while the concentration of Env on the surface of infected cells in vivo is not known
(46), higher concentrations of Env are found on the surface of infected cells compared to virions
in vitro. These results suggest that to reach high concentrations locally, sgp120 must be shed
from the surface of infected cells. Therefore, during periods of viral replication, sgp120 shed
from virions and infected cells in tissue compartments with high local cell density and low
extracellular space, including lymph node and spleen, has the potential to reach concentrations
shown to induce biological effects in vitro (41, 46). This is especially true in brain, where low
levels of neutralizing antibodies provide a milieu conducive to sgp120-induced activation of
macrophages and potential involvement in development of HAND (46).
In Chapter 3, we present evidence that brain-derived virions with high levels of sgp120
shedding upregulated CD25 expression and induced IL-1 production from bystander CD4+ and
CD8+ T cells during viral replication in vitro (Fig. 3.7). The observed lymphocyte activation was
independent of levels of viral replication, but instead was associated with levels of sgp120
shedding detected by Western blotting in vitro. However, the question remains whether sgp120
induces biological effects relevant for disease pathogenesis in vivo. Purified sgp120 at
concentrations overlapping those detected in vivo has been shown to induce many biological160
effects in vitro. A large number of studies have demonstrated that sgp120 binds to CD4 on
uninfected T cells and macrophages, resulting in cellular activation and production of
proinflammatory cytokines, including IL-1, IL-1, IL-6, IL-8, TNF-, IFN-/, and IFN- (42,
49-56). A recent study showed that sgp120 concentrations measured by ELISA in plasma from
patients in the early stages of HIV infection correlated with higher levels of plasma IL-6, IL-10,
and TNF- compared to subjects without detectable sgp120 in plasma, suggesting that Envs that
readily shed sgp120 in vivo may also induce cytokine production (42). Activation of both HIV-
infected and bystander T cells and macrophages can induce apoptosis of uninfected T cells and
neurons, (49, 55, 57-66), which may contribute to T-cell depletion and development of HIV-
associated neurological disorders (HAND) (58, 62, 67). Interestingly, low dose exposures of
sgp120 are associated with upregulation of lymphocyte activation markers including HLA-DR,
CD25, and CD69 (41, 49, 53), while high dose exposures (>1 mg) induced T cell anergy and
inhibited proliferation to mitogens including tetanus toxin (68-72). These results are in
agreement with a study investigating proliferation of lymphocytes isolated from lymph node and
plasma from SHIV-KB9-infected rhesus macaques (41). In this study, CD4+ and CD8+ T cells
from plasma responded to a KB9 Env peptide pool in vitro, while responses from lymphocytes
isolated from lymph nodes were suppressed. When plasma lymphocytes were incubated with
concentrations of SHIV-KB9 Env overnight at concentrations equivalent to those detected in
macaque lymph nodes, responses from CD4+ and CD8+ T cells were suppressed similarly to
those isolated from lymph nodes. Therefore, long-term exposure to high doses of sgp120 may
induce anergy and contribute to lack of immune-mediated clearance of HIV from reservoirs such
as lymph node.161
Sgp120 has been shown to be capable of disrupting epithelial barriers in vitro, including
models of both mucosal epithelia and the blood brain barrier (BBB) (52, 73). Furthermore,
results from in vitro assays showed that sgp120 independent from viral replication increased
monocyte adhesion and migration across BBB models, providing a possible mechanism for
enhanced virus penetration into the central nervous system (CNS) (52). Incubation with sgp120
has also been shown to impair the barrier function of primary epithelial cells in vitro, allowing
translocation of virus and bacteria across a model of the mucosal epithelium (73). This
translocation promotes systemic immune activation (74), suggesting that sgp120 shed from cells
in the brain and gut-associated lymphoid tissues (GALT) might contribute to HIV pathogenesis.
While the amounts of sgp120 needed to induce cytopathic effects in some model systems
may exceed physiologically relevant concentrations, concentrations of sgp120 required to induce
neuronal apoptosis (<100 ng/ml) in vitro are significantly lower than amounts of sgp120 detected
in tissues such as lymph node and spleen (41, 43, 57, 64-66). Because antibodies are present at
low levels in the CNS (62, 75), there is a lower probability of antibody-mediated clearance of
sgp120 from brain tissue. In addition to inducing neuronal apoptosis, sgp120 induces the
production of toxic intermediates such as proinflammatory cytokines and arachidonic acid
metabolites from activated cells, including macrophages/microglia (76-78). Sgp120 has been
implicated in inducing nitric oxide synthase from astrocytes in vitro through binding to CXCR4
(77), which may impair their ability to protect neurons from damage. Thus, sgp120 at low
concentrations may contribute to HIV neurological complications by increasing trafficking of
infected lymphocytes and monocytes across the BBB and inducing production of neurotoxic
factors from activated macrophages, microglia, astrocytes, and BMVECs.162
Identification of Viral Determinants Associated with Brain Compartmentalization and
Dementia
The genetic evolution of HIV variants in brain is distinct from that in lymphoid tissues
and other organs (13, 79-83). Genetic compartmentalization of HIV within the brain suggests
that selection and/or adaptive evolution may occur in the CNS in response to unique constraints
of the brain microenvironment, including different target cell populations and immune selection
pressures. However, the selection pressures in vivo that drive changes in M-tropism of R5 Envs
are poorly understood (84).
Three main approaches are used to identify genetic determinants associated with brain
infection. The first approach uses mutagenesis to identify determinants that contribute to the
phenotype of a specific brain-derived Env (7, 9, 28, 34, 85-86). The second approach identifies
determinants or signature sequences associated with brain using sequence analysis and
bioinformatic tools (80, 87-89). The third approach uses a combination of molecular and
bioinformatic approaches to identify variants associated with brain in a large dataset and
determine whether the determinant contributes to a phenotype associated with brain infection (1,
11). The third approach is the one we chose for our studies.
In Chapter 2, we analyzed brain- and lymphoid-derived Env sequences from a large
dataset of Envs from published studies and identified the loss an N-linked glycosylation site
(PNGS) at position 197 as being associated with brain infection (Table 2.2). Further analysis of
brain-derived sequences from patients with or without HAD determined that the loss of the
PNGS was also associated with dementia. Functional studies confirmed that D197 influenced
macrophage entry (Fig. 2.2). Thus, the combination of bioinformatic and molecular approaches163
identified a viral determinant that, while rare, is associated with brain infection in a large dataset
of primary Envs and contributes to HIV infection.
We analyzed diversifying selection in the bridging sheet region of the CCR5-binding site
in Env sequences from patients with or without HAD. By this approach, we identified one codon
(position 200 in the 3 strand of the gp120 bridging sheet) under positive selection in HAD
patients (Fig. 2.1, Table 2.1). Position 200 was under positive selection in both brain and
blood/lymphoid sequences from patients with HAD, and evolution was therefore not due to
CNS-specific selection pressures. Position 200 is located in several overlapping
immunodominant CTL epitopes (LANL CTL/CD8+ T Cell Database); diversifying selection at
this position may therefore be a consequence of immune escape. T200 is found in matched brain
and lymphoid sequences from 4 patients. In these patients, T200 was present in 100% of brain-
derived sequences, and 60-100% of lymphoid sequences. This suggests that Thr could be the
result of a founder effect in these patients, or the result of immune escape from CTL responses.
In summary, the combination of sequence analysis approaches described above allowed
us to identify two genetic determinants that contribute to reduced CD4-dependence in brain-
derived Env clones in an additive manner. The combination of approaches therefore identified
variants that would have not been identified by either approach alone. Thus, studies that
investigate both the genetic and molecular contributions of viral determinants of brain infection
may provide a better understanding of mechanisms by which viral evolution and selection in the
CNS contribute to HIV-associated neurological diseases.164
Conclusions
Over the 28 years since its discovery, HIV infection has resulted in over 25 million
deaths worldwide, and an estimated 35 million people are currently living with HIV infection
(UNAIDS 2011). However, the use of HAART has resulted in a decline in incidence in 33
countries, and advances continue to be made. One of the main barriers to eradication of HIV
infection is the seclusion of virus in reservoirs in the infected host. Cells of the macrophage
lineage are reservoirs for HIV, contributing to virus persistence and disease pathogenesis (90-
91). Persistently infected macrophages are less susceptible to the cytopathic effects of HIV
infection than activated T cells and continue to shed virus for the duration of their normal
lifespan (91). Furthermore, HIV-infected macrophages in tissues with low antiretroviral
penetration, such as perivascular macrophages in brain, create sanctuaries of HIV infection that
may persist for years (77). Env is the main determinant of M-tropism. Molecular and
bioinformatic approaches provide a way to identify determinants in brain-derived Envs that
contribute to M-tropism. A better understanding of the mechanisms by which brain-derived M-
tropic Envs enhance interactions with CD4 and CCR5 will facilitate the development of
therapeutics aimed at blocking these interactions.
In summary, we demonstrated that genetic determinants in the gp120 bridging sheet
influence M-tropism by enhancing gp120 binding to CCR5. Furthermore, we demonstrated that a
significant proportion of brain and lymphoid Envs readily shed sgp120 and present evidence that
this phenotype is associated with enhanced interactions between gp120 from brain-derived Envs
and CD4 and/or CCR5 and possibly with lymphocyte activation during PBMC infection. Our
finding that spontaneous sgp120 shedding represents a spectrum rather than a categorical165
phenotype has implications for HIV pathogenesis and optimization of therapeutics, including
native Env mimetics and vaccines.166
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Figure S2.1. Predicted sites of positive selection in
brain and lymphoid Envs from patients with HAD.
Brain and lymphoid Env sequences from patients with
HAD were aligned using ClustalX2 (n=336 brain
sequences from 19 HAD patients and 171
blood/lymphoid sequences from 15 HAD patients). dN-
dS values were estimated by SLAC, FEL, and IFEL and
normalized by total codon tree length using HyPhy
software. dN-dS values shown are averages calculated
for any codon with p<0.05 by at least 2 of the
programs. Sites from brain sequences are shown in red,
sites from lymphoid sequences are shown in blue, and
sites predicted from both brain and lymphoid sequences
are shown in black. Codons were numbered according
to codon env position of HIV-1 HXB2 reference strain.
* indicates position 200 in the 3 strand of the bridging
sheet.177
Table S2.1. Codons under positive selection detected by SLAC, FEL, and IFEL
in brain and lymphoid sequences from patients with and without HAD.
HAD Brain
Region Codon
a SLAC
b FEL
b IFEL
b
135 6.96 (0.014) 1.69 (0.005) 3.14 (0.0002)
137 7.24 (0.003) 1.81 (0.002) 2.83 (0.0001)
138 4.93 (0.008) 0.70 (0.027) 0.58 (0.07)
140 8.69 (0.0003) 1.06 (0.003) 1.24 (0.002)
145 6.92 (0.066) 1.47 (0.011) 2.04 (0.004)
151 4.55 (0.059) 1.03 (0.045) 1.74 (0.01)
178 3.44 (0.038) 0.67 (0.016) 0.87 (0.008)
181 2.27 (0.067) 0.44 (0.025) 0.47 (0.026)
186 6.80 (0.001) 1.40 (0.0007) 1.32 (0.001)
187 5.17 (0.008) 1.01 (0.004) 0.97 (0.006)
3 200 3.26 (0.067) 0.68 (0.032) 0.91 (0.015)
238 3.47 (0.031) 0.77 (0.004) 0.64 (0.010)
(287) 5.46 (0.014) 1.28 (0.007) 1.88 (0.001)
281 6.26 (0.0005) 1.14 (0.0002) 1.32 (0.001)
310 4.44 (0.012) 0.91 (0.004) 1.35 (0.0009)
315 5.52 (0.003) 1.01 (0.002) 1.12 (0.002)
321 5.86 (0.004) 1.12 (0.002) 1.53 (0.0007)
C3 336 6.72 (0.019) 1.55 (0.003) 2.14 (0.001)
340 NS 1.04 (0.009) 1.28 (0.005)
350 4.22 (0.060) 0.92 (0.007) 1.27 (0.002)
354 5.98 (0.036) 1.22 (0.013) 2.24 (0.0006)
394 NS 0.39 (0.038) 0.52 (0.023)
400 NS 2.00 (0.030) 2.13 (0.030)
403 6.18 (0.041) 1.92 (0.048) 4.45 (0.0004)
405 7.81 (0.004) 1.77 (0.00007) 2.27 (0.00003)
407 NS 0.58 (0.025) 0.89 (0.008)
444 3.99 (0.044) 0.63 (0.021) 0.70 (0.019)
465 6.14 (0.047) 1.26 (0.053) 2.19 (0.009)
467 NS 0.62 (0.043) 0.96 (0.012)178
Table S2.1, Continued
HAD Lymphoid
Region Codon
a SLAC
b FEL
b IFEL
b
138 4.42 (0.044) 1.37 (0.021) 1.93 (0.008)
141 11.00 (0.023) 1.88 (0.040) 2.58 (0.021)
143 8.23 (0.050) NS 2.72 (0.014)
146 8.99 (0.015) 2.30 (0.014) 3.99 (0.002)
152 NS 0.80 (0.016) 0.95 (0.013)
167 3.48 (0.039) 0.86 (0.017) 1.02 (0.013)
168 3.12 (0.069) 0.74 (0.039) 0.91 (0.028)
181 3.14 (0.032) 0.76 (0.013) 0.57 (0.042)
(236) 3.93 (0.044) 1.03 (0.019) 1.19 (0.015)
190 3.42 (0.057) 0.082 (0.022) 1.05 (0.014)
3 200 4.96 (0.012) 1.43 (0.001) 1.42 (0.002)
236 3.97 (0.039) 1.07 (0.026) NS
238 2.87 (0.039) 0.72 (0.015) 1.25 (0.003)
240 7.26 (0.0009) 2.05 (0.0003) 2.18 (0.0006)
281 2.84 (0.042) 0.70 (0.015) 0.85 (0.012)
291 3.57 (0.018) 0.96 (0.005) 1.67 (0.0006)
C3 337 8.06 (0.001) 1.39 (0.008) 1.87 (0.003)
340 7.38 (0.003) 1.33 (0.003) 1.56 (0.003)
343 5.51 (0.011) 0.91 (0.026) 0.90 (0.035)
350 10.28 (0.0002) 1.37 (0.018) 1.90 (0.009)
363 7.46 (0.008) 0.91 (0.098) 1.33 (0.048)
391 NS 2.59 (0.010) 4.18 (0.002)
392 5.77 (0.019) 1.51 (0.013) 2.67 (0.002)
393 9.05 (0.005) 1.73 (0.003) 1.47 (0.009)
408 7.76 (0.003) 1.35 (0.003) 2.22 (0.0004)
409 3.45 (0.053) 0.64 (0.039) 1.17 (0.009)
417 5.41 (0.003) 0.95 (0.008) 1.24 (0.005)179
Table S2.1, Continued
non-HAD Brain
Region Codon
a SLAC
b FEL
b IFEL
b
143 10.54 (0.080) 4.34 (0.018) 6.24 (0.006)
183 5.85 (0.086) 2.18 (0.034) 2.22 (0.041)
238 NS 1.93 (0.045) 2.36 (0.034)
252 NS 1.96 (0.034) 2.34 (0.025)
283 8.43 (0.032) 3.41 (0.004) 3.19 (0.008)
290 8.11 (0.068) 3.43 (0.023) 4.50 (0.013)
310 7.53 (0.088) 3.81 (0.015) 7.22 (0.004)
C3 347 10.90 (0.033) 4.00 (0.033) 5.50 (0.017)
388 NS 2.62 (0.032) 3.91 (0.013)
396 NS 5.89 (0.043) 10.58 (0.008)
404 11.94 (0.043) 4.94 (0.008) 8.52 (0.002)
405 9.91 (0.087) 3.90 (0.019) 4.20 (0.020)
429 10.70 (0.045) 3.90 (0.029) 5.77 (0.011)
466 NS 5.72 (0.050) 9.74 (0.017)
non-HAD
Lymphoid
Region Codon
a SLAC
b FEL
b IFEL
b
C3 343 2.24 (0.096) 9.31 (0.047) 15.17 (0.020)
466 NS 13.40 (0.031) 23.24 (0.012)
aCodon: codons with p<0.05 by a minimum of 2 methods are numbered according to
codon env position for HIV-1 HXB2. Codons selected by all 3 methods are underlined.
bSLAC, FEL, and IFEL: the first numbers are the dN-dS differences (normalized and
scaled by total codon tree length), the numbers in parentheses are p-values for
corresponding test of non-synonymous rate being higher than synonymous rate
(dN>dS). Sites in the bridging sheet strands are indicated in bold.
NS, p>0.1180
Figure S2.2. Fusion and entry into cells
expressing low CD4 and CCR5 correlates
with macrophage entry. Percent wild-type
fusion (A) and entry (B, C) with cells
expressing low CD4 (A, B) and low CD4 and
CCR5 (C) were compared to percent wild-type
entry into MDM. P-values were calculated using
Spearman correlation (GraphPad Prism
software).181
Figure S2.3. Neutralization sensitivity of the parental and mutant Envs to sCD4 and 17b is
strain-dependent. HIV luciferase reporter viruses expressing the wild-type and mutant Envs
and the control ADA Env were incubated with sCD4 (A-B), mAb 17b (C-D), or a mix of sCD4
and 17b (E-F) for 1 hour prior to infection of TZM-bl cells. Cells were lysed 48 hours post-
infection and analyzed for luciferase activity. Results are expressed as percentages of maximum
infection for each virus when incubated with no sCD4 or 17b and are representative of 2 separate
experiments. Error bars represent standard deviations from duplicate wells in a single assay182
SUPPLEMENTAL FIGURES:
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Fig. S3.2. Levels of sgp120 detected in supernatants of transfected 293T cells are not
dependent on cell surface expression levels.
Mean band intensities of gp120 bands in cell lysates and supernatants analyzed by Western blot
in a single experiment were determined using Photoshop and compared using GraphPad Prism
software. P and R values were determined using Spearman correlation.
Fig. S3.1. Levels of sgp120
shedding are not associated with
env genetic diversity or tissue
viral load.
For brain and lymphoid Envs from
each patient, average % sgp120
shedding was compared with mean
genetic distance calculated from
env sequence alignments using
MEGA5.0 (A) or tissue viral load
represented as HIV copies per
million cells (B) (1-3). P values
were determined using Spearman
correlation (GraphPad Prism
software).184
Fig. S3.3. High levels of sgp120 shedding from primary Envs does not inhibit infectivity.
A) sgp120 shedding from a panel of mutants constructed in the YU2 Env was calculated as an
association index [(mutantcell x wtsup)/(mutantsup x wtcell)] and plotted against relative infectivity
of CF2-CD4/CCR5 cells as previously reported (7). Envs with high levels of sgp120 shedding
exhibited reduced infectivity (bottom left portion of the curve). B) Percent sgp120 shedding from
primary HIV Envs was calculated as a modified association index, with expression of the control
ADA Env in cell lysates and supernatants replacing wild type Env and compared to infectivity of
TZM-bl cells. Envs with high levels of shedding (left side of graph) exhibited comparable
infectivity to Envs with low levels of shedding (right side of graph).185
Fig. S3.4. Envs with high levels of spontaneous sgp120 shedding induce upregulation of
CD25 on CD4+ and CD8+ lymphocytes.
PBMCs were infected as described in Materials and Methods. Cells were collected on day 6
post-infection, stained for expression of cell surface markers, and analyzed by flow cytometry.
CD25 expression levels were analyzed for CD4+ T cells (A) and CD8+ T cells (B). Mock
infected cells are shown on the left. Order of sgp120 shedding is ADA>UK1br>UK7br.186
Fig. S3.5. Comparison of phylogenetic trees for Envs with high versus low shedding.
Primary brain and lymphoid Envs were characterized as high shedding (% sgp120 shedding
>20%; n=38 Envs from 13 patients) or low shedding (% sgp120 shedding <20%, n=29 Envs
from 9 patients). Nucleotide sequence alignments of each group were created using Clustal X2
Numbers associated with each branch are bootstrap values, which represent the number of trees,
out of 1000 replicates performed, in which the same branching order was found. Only values
above 800 for the major branches are shown. Branch lengths are proportional to the amount of
sequence divergence. Scale bars indicate 1% sequence divergence. Panels depict the
phylogenetic relationship among gp120 nucleotide sequences amplified from Envs with high
levels (A) and low levels (B) of % sgp120 shedding relative to gp120 in cell lysate by Western
blotting. High levels of sgp120 shedding= % sgp120 shedding >20%; low levels of sgp120
shedding = % sgp120 <20%.187
Table S3.1. Diversity and Compartmentalization Between Patients and Tissue
Compartments
Patient Tissue Viral
Load
a
Genetic
Distance
b
Slatkin-Maddison
P-value
c
MACS2 Brain 1234.5 0.002 0.0007
Lymphoid 2451.0 0.032
MACS3 Brain 658.0 0.002 0.0007
Lymphoid 100841.0 0.002
UK1 Brain 51539.0 0.017 0.002
Lymphoid 1444.0 0.013
UK7 Brain 27826.0 0.004 0.089
Lymphoid 301.0 0.035
MACS1 Brain 2018.1 0.014 0.397
Lymphoid 25267.0 ND
d
NA118 Brain NA
e ND
d ND
d
Lymphoid NA
e 0.057
NA20 Brain NA
e 0.029 0.086
Lymphoid NA
e 0.017
NA420 Brain NA
e 0.027 0.200
Lymphoid NA
e 0.015
A Brain NA
e 0.002 0.167
Blood NA
e 0.019
B Brain NA
e 0.005 0.333
Blood NA
e 0.012
C Brain NA
e 0.011 0.167
Blood NA
e 0.036
D Brain NA
e 0.001 0.238
Blood NA
e 0.018
aTissue viral load is represented as HIV copies per million cells.
bGenetic distance is the number of nucleotide substitutions per 100 sites calculated with the
maximum composite likelihood method in Mega 5.0 software. The average pairwise genetic
distances for brain and blood/lymphoid sequences within each patient are shown.
cThe Slatkin-Maddison test for gene flow between populations was used to measure genetic
compartmentalization between the brain and blood/lymphoid populations. Migration events
describe the number of env migration events between the brain and blood/lymphoid Env
populations for each phylogenetic tree. A P-value >0.05 indicates statistically significant genetic
compartmentalization between brain and b1ood/lymphoid populations.
dND, not determined because <2 sequences/tissue were available.
eNA, not available188
Table S3.2. Sgp120 detected in 293T cell lysates and supernatants
by Western blotting and ELISA
Patient Tissue Clone MBI
a % sgp120
b ng/ml
c
M2 BR 8-12 0 1.1 ± 0.8 94.6 ± 13.0
9-15 0 0 ± 0 50.9 ± 5.7
9-11 0 3.4 ± 4.8 51.7 ± 31.6
9-9 3.5 1.7 ± 1.2 1.6 ± 1.8
SP 6-18 32.2 4.1 ± 0.1 0 ± 0
10-15 34.1 0.8 ± 0.6 0 ± 0.5
6-11 11 2.5 ± 0.1
160.3 ±
23.0
M3 BR 5 50 30.4 ± 11.8 31 ± 1.5
12-27 42.2 39.3 5.1 ± 7.3
10 45.6 33.1 ± 9.2 94.2 ± 2.2
LN 20 66.7 23.7 40.3 ± 5.4
2 77.9 36.4 177.4 ± 0.5
2-6 37.6 20 ± 12.4 59.5 ± 28.1
UK1 BR 2-13b 24.9 13.9 ± 21.6 81.9 ± 6.1
3-13 71.3 69.1 ± 24.5 87.5 ± 16.2
2-14 2.9 16.4 ± 27.2 0 ± 6.6
1-8 0 30.3 ± 27.6 27.3 ± 0.07
2-15 0 23.4 ± 19.2
118.9 ±
26.8
SP 20 5.7 19.6 ± 2.1 0 ± 0
6-20 0 11.7 ± 14.6 92.8 ± 7.8
6-22 7.5 5 ± 7.1
119.7 ±
14.0
UK7 BR 1-4 0 0 ± 0 14.2 ± 21.3
34 0 0 ± 0 12.3 ± 13.0
6-24 0 0 ± 0 0 ± 1.5
1-8 54 0.1 ± 0.2 84 ± 3.7
10 61.5 0 ± 0 73.1 ± 30.9
LN 7-6 4.5 0 ± 0 92.2 ± 9.5
M1 BR 3b-6 5.2 38 ± 15.5 125 ± 26.1
7b-9 0 28.6 4.7 ± 6.7
6b-13 3.8 75.1
205.2 ±
103.8
6b-9 7 84.6 58.0 ± 39.4
SP 8a-2 0 0 0 ± 0
NA118 BR 12 98.7 47.5
710.5 ±
24.2
LN 27 109.5 59.7
735.7 ±
72.3
33 130 69.6 645.4 ± 6.2189
Table S3.2, Continued
Patient Tissue Clone MBI
a % sgp120
b ng/ml
c
NA20 BR 59 49.3 46.4 ± 19.3 410.6 ± 64.7
36 0 47.7 ± 24.8 480.9 ± 29.0
501 0 55.5 ± 30.1 0 ± 0
LN 3 38.7 75.4 ± 26.3 154.8 ± 61.6
8 63.3 78.0 ± 26.0 725 ± 74.3
10 95.1 70.6 ± 22.5 619.6 ± 39.1
14 15.6 29 ± 2.7 330.3 ± 27.9
16 36.6 62.9 ± 15.0 327.8 ± 67.3
NA420 BR 13 109.6 37.9 748.1 ± 61.1
33 0 54.6 510.1 ± 37.4
42 27.4 51.9 575.9 ± 42.8
LN 40 18.5 32.2 377.1 ± 14.1
85 14 11 570.9 ± 51.7
A BR 01 41.1 21.2 235.9 ± 97.7
04 58.8 32.8 ± 11.1 207.5 ± 47.5
BL 01 6.8 22.8 0 ± 0
03 8.2 11 194.9 ± 72.5
B BR 01 32.2 12.5 91.8 ± 69.4
03 73.2 20.6 105.7 ± 70.2
BL 05 26.5 11.9 260.7 ± 12.0
07 128.1 82.6 548.4 ± 42.5
C BR 06 44 14.1 128 ± 6.1
07 73.8 25.3 662.3 ± 47.6
BL 02 171.5 50.2 ± 30.6 1711.2 ± 48.6
03 27 0 22.5 ± 23.0
D BR 02 88 38.2 462.6 ± 64.4
BL 02 23.1 0 ± 0 62.9 ± 55.4
03 25 0 ± 0 19.1 ± 13.5
04 52.8 45.8 932.2 ± 71.8
07 0 0 ± 0 53.9 ± 18.8
08 0 15 73.9 ± 59.4
Control ADA 96.2 52 ± 14.5
1366.1 ±
284.5
JRFL 89.1 ± 20.8
2172.8 ±
476.2
JRCSF 97.8 6671.0 ± 94.4
HXB2 45.7 1315 ±
YU2 24.4
1391.0 ±
141.3
aMBI, mean band intensity of sgp120 in supernatant of 293T cells detected by Western blotting
b% sgp120 shedding calculated at [sgp120 (supernatant)/gp120 (cell lysate)] x 100. Detected by
Western blotting.
cng/ml sgp120 measured by ELISA against a standard curve of purified HIVIIIB.190
Table S3.3. Analysis of within group variation
Analysis Program Condition Region High
Shedding
d
Low
Shedding
d
Shannon’s
Entropy
Entropy One
a Average
a gp120 0.554 0.359
gp41 0.511 0.214
dN-dS SLAC/FEL/
IFEL
b
Positive
b gp120 21 24
gp41 24 5
Negative
b gp120 56 53
gp41 35 27
N-glycosylation
sites
Glycosite
c All
frequencies
c
gp120 55 47
gp41 8 5
>90%
c gp120 10 12
gp41 2 4
aShannon’s entropy for each codon in gp160 calculated using Entropy One from Los Alamos
National Laboratories online sequence analysis tools. Results are presented as Shannon’s entropy
values averaged across gp120 and gp41.
bSingle likelihood ancestor counting (SLAC), fixed effects likelikhood (FEL), and internal fixed
effects likelihood (IFEL) methods (HyPhy software package) were used to reconstruct ancestral
sequences at each node of a phylogenetic tree (method) (data not shown). Synonymous (dS) and
nonsynonymous (dN) substitutions are calculated at each branch and terminal node. Numbers of
sites estimated to be under positive or negative selection in gp120 and gp41 indicate codons with
P-values 0.1 using at least 2 methods.
cNumber of predicted N-glycosylation sites across gp120 and gp41 for each group were
calculated using Glycosite from Los Alamos National Laboratories online analysis tools. Total
sites represents all predicted N-glycosylation sites across each group (high and low shedding).
>90% represents N-glycosylation sites predicted to be present in >90% of sequences from each
group.
dPrimary brain and lymphoid Envs were characterized as high shedding (% sgp120 shedding
>20%; n=38 Envs from 13 patients) or low shedding (% sgp120 shedding <20%, n=29 Envs
from 9 patients).APPENDIX B
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Abstract
Background: The population of HIV replicating within a host consists of independently evolving and interacting
sub-populations that can be genetically distinct within anatomical compartments. HIV replicating within the brain
causes neurocognitive disorders in up to 20-30% of infected individuals and is a viral sanctuary site for the
development of drug resistance. The primary determinant of HIV neurotropism is macrophage tropism, which is
primarily determined by the viral envelope (env) gene. However, studies of genetic aspects of HIV replicating in the
brain are hindered because existing repositories of HIV sequences are not focused on neurotropic virus nor
annotated with neurocognitive and neuropathological status. To address this need, we constructed the HIV Brain
Sequence Database.
Results: The HIV Brain Sequence Database is a public database of HIV envelope sequences, directly sequenced
from brain and other tissues from the same patients. Sequences are annotated with clinical data including viral
load, CD4 count, antiretroviral status, neurocognitive impairment, and neuropathological diagnosis, all curated from
the original publication. Tissue source is coded using an anatomical ontology, the Foundational Model of Anatomy,
to capture the maximum level of detail available, while maintaining ontological relationships between tissues and
their subparts. 44 tissue types are represented within the database, grouped into 4 categories: (i) brain, brainstem,
and spinal cord; (ii) meninges, choroid plexus, and CSF; (iii) blood and lymphoid; and (iv) other (bone marrow,
colon, lung, liver, etc). Patient coding is correlated across studies, allowing sequences from the same patient to be
grouped to increase statistical power. Using Cytoscape, we visualized relationships between studies, patients and
sequences, illustrating interconnections between studies and the varying depth of sequencing, patient number,
and tissue representation across studies. Currently, the database contains 2517 envelope sequences from 90
patients, obtained from 22 published studies. 1272 sequences are from brain; the remaining 1245 are from blood,
lymph node, spleen, bone marrow, colon, lung and other non-brain tissues. The database interface utilizes a
faceted interface, allowing real-time combination of multiple search parameters to assemble a meta-dataset, which
can be downloaded for further analysis.
Conclusions: This online resource, which is publicly available at http://www.HIVBrainSeqDB.org, will greatly
facilitate analysis of the genetic aspects of HIV macrophage tropism, HIV compartmentalization and evolution
within the brain and other tissue reservoirs, and the relationship of these findings to HIV-associated neurological
disorders and other clinical consequences of HIV infection.
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192Introduction
The population of HIV replicating within a host consists
of independently evolving and interacting sub-popula-
tions, as demonstrated by the various degrees of phylo-
genetic compartmentalization seen across and within
anatomical compartments and various rates of decay in
viral load during HAART therapy [1,2]. Several factors
contribute to this genetic compartmentalization: (i) viral
target cell tropism–HIV infects CD4+ T cells and
macrophages in the periphery, and primarily infects
macrophages and microglia (and rarely, astrocytes) in
the brain [3]; (ii) viral adaptation in response to immune
selection pressures that differ between anatomical com-
partments [3,4]; (iii) physical barriers such as the blood-
brain barrier [5]; and (iv) variable antiretroviral drug
penetration into different tissues [6,7]. An important
viral sub-population is HIV replicating within the brain
[8-10]. HIV replicating in the brain causes neurocogni-
tive and neuropathological disorders in up to 20-30% of
infected individuals, particularly in later stages of dis-
ease; in the era of HAART, HIV-associated neurocogni-
tive disorders (HAND) have emerged as a significant
cause of mortality and morbidity [4,6]. Additionally, the
brain is a sanctuary site for the development of drug
resistance, because poor antiretroviral drug penetration
into the CNS leads to sub-therapeutic drug concentra-
tions and incomplete suppression of viral replication [6].
The primary determinant of HIV neurotropism is
macrophage tropism, which is primarily determined by
genetic variation in the viral envelope (env)g e n e[ 8 ] .
Phylogenetically related populations of macrophage-tro-
pic virus are found across brain and other macrophage-
rich tissues, such as lung and bone marrow [11,12].
Thus, studies of the genetics of HIV replicating in the
brain are pertinent to important clinical aspects of HIV,
as well as the biology of the virus replicating within spe-
cific anatomical compartments.
There are several excellent existing repositories of
HIV sequences in the public domain, two of the most
widely used being Genbank at the NCBI [13] and the
HIV Sequence Database at the Los Alamos National
Laboratory (LANL) (http://hiv.lanl.gov). However,
neither is focused on neurotropic virus nor contains
clinical annotations of neurocognitive and neuropatholo-
gical diagnosis. Though more than 20 publications have
clonally sequenced HIV env from the brain, assembling
a meta-dataset of these sequences presents significant
technical challenges. To address these challenges, we
constructed the HIV Brain Sequence Database (HBSD),
the first comprehensive database of HIV envelope
sequences clonally sequenced from brain and non-brain
tissues, which is publicly available at http://HIVBrain-
SeqDB.org
The HIV Brain Sequence Database
The HBSD contains 2517 envelope sequences from 90
patients. Sequences were obtained from 22 published
studies (Table 1) ranging in publication date from 1991
to 2009 and in number of sequences per publication
from 1 to over 700. 1272 of these sequences are brain-
derived; the remaining approximately 1245 are derived
from blood, lymph node, spleen, bone marrow, colon,
lung and other non-brain tissues. 44 independent tissue
types are represented within the database. These tissue
types are grouped into 4 categories: (i) brain, brainstem,
and spinal cord; (ii) meninges, choroid plexus, and CSF;
(iii) blood and lymphoid; and (iv) other (bone marrow,
lung, liver, etc) (Table 2). Figure 1 shows the database
sequence content aligned to the env gene of HXB2. V3
region and near full-length gp120 region sequences
comprise the majority of the database, with approxi-
mately 1100 and 800 sequences, respectively. There are
also approximately 200 near full-length env sequences,
150 V4-V5 region, and 100 V1-V2 region. As new publi-
cations emerge, facilitated by new sequencing technolo-
g i e s ,w ee x p e c tt h es i z eo ft h eH B S Dt of o l l o wt h e
Table 1 Publications describing the cloning of sequences
included in the HBSD
Publication Number of Sequences
Keele, Burton (2008) [19] 51
Power, Chesebro (1994) [20] 15
Peters, Clapham (2004) [21] 31
Mefford, Gabuzda (unpublished) 33
Mefford, Gabuzda (2008) [22] 10
Ohagen, Gabuzda (2003) [23] 35
Thomas, Gabuzda (2007) [24] 55
Liu, Gartner (2000) [25] 31
Martín-García, González-Scarano (2006) [26] 12
Shapshak, Goodkin (1999) [15] 65
Li, Hahn (1991) [27] 2
Gatanaga, Iwamoto (1999) [28] 17
Lamers, McGrath (2009) [29] 715
Salemi, McGrath (2005) [12] 88
Shah, Saksena (2006) [30] 30
Smit, Saksena (2001) [31] 11
Hughes, Simmonds (1997) [32] 87
McCrossan, Simmonds (2006) [18] 259
Morris, Simmonds (1999) [33] 252
Wang, Simmonds (2001) [11] 470
Monken, Srinivasan (1995) [34] 39
Korber, Wolinsky (1994) [17] 209
First author, last author and publication year of included publications, sorted
by last author is shown in the left column. Total number of sequences
included in the database from each publication is shown in the right column.
In some cases, publications may contain additional sequences that did not
meet our inclusion criteria–for example, sequences from isolates or patients
with no brain sequences–and were therefore omitted.
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193Table 2 Classification of tissues represented in the database, with their respective Foundational Model of
Anatomy (FMA) codes
Brain, brainstem, and spinal cord (n = 1272) FMA Code Number of sequences
Brain FMA:50801 171
Brainstem FMA:79876 16
Caudate nucleus FMA:61833 7
Cortex of frontal lobe FMA:242199 67
Cortex of occipital lobe FMA:242205 20
Cortex of temporal lobe FMA:242201 77
Frontal lobe FMA:61824 91
Left frontal lobe FMA:72970 214
Left hemisphere of cerebellum FMA:83877 1
Left occipital lobe FMA:72976 12
Left parietal lobe FMA:72974 5
Left temporal lobe FMA:72972 17
Middle frontal gyrus FMA:61859 10
Occipital lobe FMA:67325 25
Parietal lobe FMA:61826 3
Putamen FMA:61834 1
Right frontal lobe FMA:72969 43
Right hemisphere of cerebellum FMA:83876 1
Right occipital lobe FMA:72975 16
Right parietal lobe FMA:72973 18
Right temporal lobe FMA:72971 15
Set of basal ganglia FMA:84013 87
Spinal cord FMA:7647 12
Temporal lobe FMA:61825 41
White matter of frontal lobe FMA:256178 111
White matter of neuraxis FMA:83929 29
White matter of occipital lobe FMA:256188 140
White matter of temporal lobe FMA:256186 22
Meninges, choroid plexus, and CSF (n = 184)
Choroid plexus of cerebral hemisphere FMA:61934 44
CSF FMA:20935 1
Set of meninges FMA:76821 139
Blood and lymphoid (n = 776)
Blood FMA:9670 122
Infraclavicular lymph node FMA:14193 4
Lymph node FMA:5034 417
Mesenteric lymph node FMA:12795 28
Peripheral blood mononuclear cell FMA:86713 15
Spleen FMA:7196 129
T-lymphocyte FMA:62870 61
Other (n = 285)
Bone marrow FMA:9608 31
Colon FMA:14543 135
Epithelial lining fluid FMA:276456 5
Liver FMA:7197 34
Lung FMA:7195 78
Right lung FMA:7309 2
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194exponential expansion seen by other sequence databases
[13].
Collection and assembly of HIV sequences
The HBSD attempts to contain all available, published
HIV sequences meeting stringent inclusion criteria. For
inclusion in the HBSD, sequences must meet the follow-
ing criteria: (i) be deposited in Genbank; (ii) include
some portion of the HIV env region; (iii) be clonal,
amplified directly from tissue; and (iv) be sampled from
the brain, or sampled from a patient for which the
HBSD already contains brain sequences. We identified
sequences for inclusion both by searching the public
sequence databases–Genbank and the LANL
HIV sequence database–and by identifying publications
that sequenced HIV from the brain. In several cases, we
communicated directly with study authors to encourage
deposition of sequences that had not been previously
submitted to Genbank. Additionally, BLAST alignment
was used to screen for possible contamination with
commonly used lab strains (i.e., ADA, HXB2, JR-CSF,
NL4-3, SF2, BaL, IIIB, MN, SF162, and JR-FL)
Annotation Structure
The HIV Brain Sequence Database contains three
categories of annotations: publication references, patient
and sampling information, and sequence properties
(Table 3). The publication annotations include biblio-
graphic information identifying the study that generated
the sequences. Patient sampling annotations contain
information describing the individual patients, as well as
clinical information at the time of sampling. This infor-
mation was obtained by manual curation of the original
publications and in some cases direct communications
with the study authors. In cases where multiple studies
examined tissue samples from the same patient, the
resulting sequences are linked to the same patient code
to increase statistical power. Sample timepoint annota-
tions describe the patient’s clinical health status, neuro-
cognitive, neuropathological status, CD4 counts, viral
load, and anti-retroviral treatment history at the time of
sampling. Clone and sequence annotations describe the
individual sequences, the tissue from which they were
cloned, and the method of PCR amplification and clon-
ing. This includes the sequence start and end locations
numbered based on alignment to the HXB2 reference
genome, and tissue source coded using terms from a
formal anatomical ontology. Alignment to HXB2 was
performed using the HIV Sequence Locator tool located
at the LANL HIV Sequence Database (http://hiv.lanl.
gov). Currently, amplification and cloning methods
included in the database are: bulk PCR then cloning
(1736 sequences) and limiting-dilution PCR then cloning
(781 sequences). As new sequencing projects are
completed, we hope to expand the database to include
significant numbers of sequences cloned via single gen-
ome amplification.
Annotation of Tissue Type
Annotation of tissue source presented several challenges.
First, the granularity of tissue annotation varied by pub-
lication–we encountered tissue type annotations as gen-
eral as “Brain” and as specific as “White matter of
occipital lobe”. However, within the HBSD a search for
a more general tissue type, such as cerebrum should
also return sequences from sub-parts of the cerebrum,
such as caudate nucleus and putamen. Second, publica-
tions utilize non-standard tissue names that are human-
readable but difficult to parse in a database search. To
address these challenges, we utilized a formal anatomical
ontology, the Foundational Model of Anatomy (FMA) to
code tissue source [14]. The FMA defines terms for
approximately 75,000 human anatomical structures, ran-
ging in scale from biological macromolecules to whole
organ systems. These terms are linked by ontological
relationships defining subpart relationships, allowing the
calculation of transitive closure within the database. In
addition, we assigned sequences into one of four classes:
(i) Brain; (ii) Meninges, choroid plexus, and CSF;
( i i i )B l o o da n dl y m p h o i d ;a n d( i v )O t h e r .M e n i n g e s ,
choroid plexus, and CSF were grouped separately from
Brain because phylogenetic evidence suggests that the
CSF represents an intermediate compartment, contain-
ing virus from both the brain and periphery [8]. “Other”
includes organs such as lung, liver, stomach and pros-
tate, bone marrow, and fluid samples such as lung
epithelial lining fluid.
Annotation of Neurocognitive and Neuropathological
Diagnosis
Neurocognitive and neuropathological status were classi-
fied for each patient at the sampling timepoint, usually
perimortem (Table 4). Neuropathological and neurocog-
nitive disorders can be due either to virus replicating in
the brain or to non-HIV related causes such as toxo-
plasmosis, CMV encephalitis, or CNS lymphoma. Neu-
ropathological status was coded as HIV encephalitis
(HIVE) of varying severity, lymphocytic perivascular
cuffing, or “Other”, specifying the predominant non-
HIV neurological pathology. Neurocognitive diagnosis
was annotated using the nomenclature consensus pub-
lished in Antinori et al, 2007 [4]. We further classified
the HAD diagnosis into mild, moderate, and severe to
capture information included in the publication as mild,
moderate, or severe (most commonly) or MSK scores
(rarely). Additionally, there were several unique cases
that fell outside the AAN or HNRC criteria, but which
we felt were important to annotate within the database.
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195Diagnosis for patient 196 stated: “insufficient informa-
tion for patient 196 for the diagnosis of HAD, though
there was evidence for neuropsychiatric disease.”[15].
Given that we lacked the further information to meet
the strict criteria for an ANI or MND diagnosis, we
chose the more general NPI: unknown defined in
Woods et al. 2004 [16]. Diagnoses for patients 1 through
6 stated, “Clinical material was obtained from six HIV-1
infected patients with significant neurological signs and
symptoms requiring image-guided stereotactic brain
biopsy for definitive diagnosis. ... Neurological signs and
symptoms were consistent with the onset of global neu-
rological dysfunction, with clinical evidence supporting
acute rather than chronic HIV-1-associated neurological
disease.”[17]. As an acute diagnosis, this does not fit the
criteria for HAD, so it was annotated in the database as
acute HIV encephalopathy [17].
Design and Implementation
The HBSD structure is sequence-centric and uses NCBI
GI and Genbank accession numbers as identifiers, sim-
plifying correlations with other databases. The database
exists in two forms. The master version is kept intern-
ally as a relational SQL database utilized for sequence
management and curation. This is replicated to an
external interface that uses the Apache Solr search plat-
form to optimize for flexible search and data retrieval.
The search interface (Figure 2) is based on a filtering
paradigm; the user begins with the set of all sequences
and narrows by applying filtering criteria to the
sequence annotations. Filtering criteria are specified by
two means. A faceted search interface presents all values
for categorical annotations, such as tissue class or neu-
rocognitive status. Clicking on a value adds it to the
search criteria and filters for matching sequences. Addi-
tionally, a global search box allows direct entry of search
terms. Multiple searches in the global search box
sequentially add filtering criteria, allowing the construc-
tion of complex searches. Sequences are initially pre-
sented with a default set of annotations, however, users
can select to add or remove columns from the set of all
annotations available. The final filtered set of sequences
and annotations can be downloaded for local analysis in
tab-separated and FASTA formats.
Visualization of the contents of the database
To better understand the highly complex network of
publications, patients, and sequences, we used Cytoscape
to visualize the connections between patients and the
publications that sequenced virus from those patients
(Figure 3). This network visualization demonstrates that,
while most publications examine a unique set of
patients, there is an emerging network of patients from
the Edinburgh MRC HIV Brain and Tissue Bank (coded
as NA#) that are shared among multiple publications.
Additionally, Figure 3 illustrates the dramatic differences
in sequencing depth between patients, and in number of
patients between studies.
Many experimental designs examining compartmenta-
lization or tissue specific effects depend on overlap in the
viral regions sequenced and matched tissue source. In
order to quantify the power of the database to make
these comparisons, we visualized the total number of
across-tissue and within-tissue comparisons possible with
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196the current database content (Figure 4). Panel A visua-
lizes, for each tissue pair, how many patients contain
overlapping sequences. Each comparison is ontologically
inclusive–for example entries under Frontal lobe also
consider sequences from White matter of frontal lobe,
Cortex of frontal lobe, etcetera. This visualization reveals
structures within the dataset useful for experimental
design. For example, while a large number of patients
contain overlapping sequences from lymph node and
another tissue, in 8, 11, and 7 patients, respectively, it is
possible to compare frontal lobe to occipital, temporal, or
parietal lobes. Figure 4B is a complementary visualization
counting the number of pairwise patient to patient
comparisons possible within each tissue type. This illus-
trates, for example, that while many patients have over-
lapping sequences from the cerebrum, frontal lobe is a
particularly well-represented tissue. Conversely, though
the database contains sequences from the cerebellum,
there are no across patient comparisons that can be
made. The numbers in both A and B of Figure 4 do not
represent simple sums or permutations, because each
considers sequence overlap. If hypothetical patients A, B,
and C contained full-length env, V3 region, and V5
region sequences, respectively, then only 2 pair-wise
comparisons would be possible (A to B and A to C), not
the 3 given by a simple permutation.
Table 3 Annotation categories
Patient Column Definition
Patient code patient code
Sex gender
Risk factor HIV risk factor
Tissue bank tissue bank distributing samples
Patient year of death patient year of death
Sampling timepoint
Sampling geo-region patient geo-region at time of sampling
Sampling country patient country at time of sampling
Sampling city patient city at time of sampling
Patient age patient age at sampling
Health status patient health status at sampling
Subtype predominant subtype at time of sampling
Drug naïve (ART) has patient had ART
Antiretroviral treatment (ART) patient ART history
Viral load plasma (copies/mL) plasma viral load
Viral load brain (copies/million cells) brain viral load
Viral load lymphoid (copies/million cells) lymphoid viral load
CD4 count (cells/uL) CD4 count
Neurocognitive diagnosis neurocognitive diagnosis
Neuropathological diagnosis neuropathological diagnosis
Giant cells were giant cells present in the brain
Sequence
Genbank accession Genbank accession number
GI Genbank GI number
PubMed ID Pubmed ID for original publicaiton
Sequence length sequence length
Clone name publication assigned clone name
Cloning strategy methods of genome amplification and cloning
Sample tissue class global tissue class (Brain, Blood & Lymphoid, etc...)
Sample tissue name tissue source
Sample tissue FMA code tissue FMA code
Nucleic acid type was proviral DNA or viral RNA sequenced
Start and end coordinates sequence start and end referenced to HXB2
Sequence viral sequence
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197Discussion
The HBSD is a public database designed to facilitate the
assembly of a large meta-dataset of HIV env sequences
that will be invaluable to investigations into the different
patterns of viral evolution in the brain and other tissue
reservoirs, and the relationship of these findings to each
other and to clinical consequences of HIV infection,
particularly development of HAND. The database con-
tains 2517 env sequences cloned from 90 patients and
44 tissues sources. 1272 of these sequences are brain-
derived; the remaining 1245 are derived from blood,
lymph node, spleen, bone marrow, colon, lung, and
other non-brain tissues. The majority of these sequences
are from the V3 region (45%) or near full-length gp120
region (31%), with the remainder being near full-length
env (9%), V4-V5 region (6%),V 1 - V 2r e g i o n( 4 % )a n d
others (5%) (Figure 1). The HBSD is unique compared
to other sequence databases, such as the LANL HIV
Sequence Database or Genbank, because of its specific
focus on HIV in the brain, its stringent inclusion of only
clonal sequences from patients with brain sequences,
and its rigorous curation with detailed clinical, patient,
and HAND annotations.
An HIV env meta-dataset annotated with detailed
clinical information will allow studies that previously
have not been feasible. Combining datasets to increase
the number of sequences and tissue-types increases the
statistical power available. This increased statistical
power can be used to examine questions such as the
genetic variations within env important for macrophage
tropism, which is the primary requirement for HIV
replication in the brain, and nucleotide positions within
env under positive genetic selection during HIV replica-
tion in the CNS. Annotation of neurocognitive status,
neuropathological status, and AIDS progression will
facilitate correlation of viral genotype to clinical pheno-
types, and may help to reveal how viral genotypes affect
the development of HAND.
During the assembly and annotation of the HBSD, we
encountered a number of challenges. Non-uniform tis-
sue coding made consistent database annotation diffi-
cult. To overcome this obstacle, we utilized the FMA
anatomical ontology to convert various tissue source
descriptions into a set of defined terms with ontological
linkages. We encountered several instances of ambigu-
ous patient coding. Because tissue samples are shared
Table 4 Neurocognitive and neuropathological annotations in the database
Neurocognitive Diagnosis Number of Patients Number of Sequences
None 42 739
Acute HIV encephalopathy 6 209
HAD: mild 74 6
HAD: moderate 48
HAD: severe 11 424
HAD: severity not specified 19 810
NPI-unknown 11 0
No diagnosis 7 271
Neuropathological Diagnosis
None 37 369
HIVE: mild 5 276
HIVE: moderate 3 100
HIVE: severe 6 117
HIVE: severity not specified 17 938
Lymphocytic perivascular cuffing 1 31
Other: cerebral atrophy 13 9
Other: CMV encephalitis 15
Other: CNS lymphoma 7 242
Other: necrotizing encephalitis, not HIV-related 1 23
Other: progressive multifocal leukoencephalopathy 2 36
Other: toxoplasmosis 38 3
Other: widespread atherosclerosis 1 87
No diagnosis 12 171
An annotation of “none” indicates a diagnosis of no impairment or neuropathology, whereas “no diagnosis” indicates that clinical annotation information was not
available.
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198within laboratories, and tissue banks distribute samples
from the same patient to multiple laboratories, viruses
from one patient may be sequenced in multiple publica-
tions. By examining patient annotation data and corre-
sponding with study authors, we identified 3 patients
that were coded differently by multiple studies
(NA118_p5, NA420_p6 and NA21_UK1) and 2 cases of
separate patients that were coded identically by different
studies (NA20 and NA234). Combining sequences from
multiple publications and grouping by patient can
increase the diversity of tissue types and the depth of
sequencing available, while carefully tracking patient
coding can avoid incorrect grouping of non-identical
patients. Many publications included in the HBSD con-
tain duplicate sequences cloned from the same tissue
sample. These duplicate sequences could result either
from PCR resampling in studies utilizing bulk PCR
before cloning, or could represent valid cloning of
copies of a majority viral variant. Fifteen publications
utilized bulk PCR then cloning, 5 utilized limiting dilu-
tion then cloning, and 2 used both approaches, based
on patient. The database contains 490 repeated
s e q u e n c e si n1 6 1g r o u p s .H o w e v e r ,2 1 7o ft h e s e
repeated sequences were obtained by limiting dilution
PCR and therefore are unlikely to represent PCR resam-
pling. Comparison of the distribution of the percentage
of duplicated sequences between bulk PCR and limiting
dilution demonstrated that studies utilizing bulk PCR
then cloning did not show a higher rate of sequence
duplication than those utilizing limiting dilution (data
not shown). Thus duplicated sequences in the database
likely represent appropriate cloning of majority viral
variants.
The HBSD includes several unique datasets, which,
though previously available in the public domain, are
now collected in a standardized annotation format for
meta-analysis. 15 patients included in McCrossan, 2006
[18] are pre-symptomatic, having died from HIV-unre-
lated causes [alcohol/drug overdose (n = 11), cirrhosis
(n = 2), suicide (n = 1), and bronchopneumonia
(n = 1)]. During late-stage AIDS, declining CD4 counts
lead to immune deficiency and reduced selection pres-
sure, allowing viral population expansion that may alter
the distribution of sequence variants. Based on
Figure 2 Search interface of the HBSD. A. Database facets for filtering results. All possible values for each category are presented, along with a
count of the number of sequences for each value. Clicking on a value adds it to the search box (B), filters the results list (C), and updates the
facet list and sequence counts (A). B. Universal search box and search term list. Performs a global search across categories, for example, a search
for “right” returns sequences from both “Right frontal lobe” and “Right lung”. Upon searching, the facet list (A) and results (C) are updated. All
searches and faceting terms applied are placed in the Search Terms box and can be removed individually by clicking the “X” next to a term. C.
Results list. Displays the current list of sequences matching the filters within the Search Terms box (B). Columns can be added or removed
through the Add Columns button. Clicking the checkbox by a sequence adds it to the Selected Sequences box (D). D. Selected Sequences and
Downloads. Clicking the download button presents options to download: (i) Current Results–all sequences matching the search terms, (ii)
Current Selection–all selected sequences in box D, (iii) Entire Collection–the entire HBSD. Downloads consist of a zip file containing a FASTA
formatted file of all sequences, named by Genbank accession number, and a tab-separated file of all selected annotation columns, ready for
import to Excel.
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199treatment history and year of death, the majority of
patients in the HBSD died prior to the HAART era. 49
out of 90 patients have annotations for antiretroviral
treatment history. Of these 49 patients, 19 are drug
naïve and 30 received antiretroviral drugs. The majority
of antiretroviral treated patients were on pre-HAART
regimens, and 9 received only AZT. Different ART
drugs have differing CNS penetration, affecting selection
pressures on virus replicating in the brain [6]. Addition-
ally, the majority of neurocognitive diagnoses occurred
before the 2007 HNRC consensus document [4] that
defined criteria for asymptomatic neurocognitive impair-
ment (ANI). Future improvement of the quality and
relevance of the database to the current epidemic
requires generating more sequences sampled from the
brains of pre-symptomatic patients at earlier stages of
disease and HAART-treated patients.
Our laboratory will continue to maintain the HBSD as
new sequences are deposited in the public domain. We
expect the HBSD to expand in several ways. New deep
sequencing projects will increase the number of
sequences and expand the diversity of patients, sampling
a wider spectrum of stages of disease and HAART
treatment regimens. Curation of patient coding may
allow us to identify longitudinal sets of sequences
sampled from the periphery, which can be paired with
brain sequences sampled from the same patient at
autopsy. Finally, we chose to focus on env for the initial
database release because it plays a key role in brain
infection and provides a tractable scope for develop-
ment of a highly curated database. As we consider
further database additions,w ew i l lc o n t i n u et ow e i g h
the benefits of inclusion against the resources required
to maintain our high standards of database curation.
Figure 3 Network representation of interconnections between publications, the patients they sequenced, and the number and tissue
classes of sequences available for each patient. The network was constructed using Cytoscape. Black nodes, containing the name of the first
author, represent publications. Publication nodes are connected by edges to the patients they sequenced, represented by clear nodes with
patient code printed at the bottom. In cases where multiple publications sequenced virus from the same patient, multiple publication nodes
connect to a single patient node (patient NA118 in the upper right). Individual HIV sequences for each patient are represented by the colored
dots within patient nodes: Brain-red, Meninges, choroid plexus, and CSF-yellow, Blood and Lymphoid-green, Other-blue. The total number of
sequences for each patient scales the size of the patient node.
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200Tat and nef are two logical next steps, as these genes
influence brain infection and development of neurocog-
nitive disorders. Drug resistance mutations in pol and
RT would also be a useful addition that will be consid-
ered in the future.
Conclusions
The HBSD is a unique resource for the research com-
munity investigating unique genetic and biological char-
acteristics of HIV in the brain. Though nearly all the
sequences and annotations included were previously
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Figure 4 Heatmap representation and counts of all possible comparisons between sets of overlapping sequences within the database.
Counts of possible comparisons were generated using 2 custom Perl scripts and SQL statements, then visualized as a heatmap using R. A.
Number of patients for which within-patient comparisons across tissue-types can be made. For pairs of tissues from the X and Y-axis, numbers
indicate the number of patients for which overlapping sequences from both tissues are available. For example, there are 11 patients with
overlapping sequences from both Frontal lobe and Temporal lobe. B. Number of possible pair-wise comparisons across patients within each
tissue type. For each tissue on the Y-axis, numbers indicate the count of possible pair-wise comparisons between patients. For example, there
are 2 patients with overlapping sequences from White matter of neuroaxis, giving 1 possible comparison, and 4 patients with overlapping
sequence from Left occipital lobe, giving 6 possible pair-wise comparisons. Tissue definitions are ontologically inclusive, i.e. Frontal lobe also
includes White matter of frontal lobe, Cortex of frontal lobe, etc. Cells are colored as a heat map accentuating high values, and range from light
yellow (low values) to dark red (high values). Black indicates no comparisons possible.
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201available in the public domain, the data did not exist in
a well-annotated and accessible format and its assembly
and curation represented a significant hurdle. The
HBSD will be an invaluable resource for studying the
viral genetics of HIV evolution within the brain and
other tissue reservoirs, and the relationship of these
findings to each other and to the development of HIV-
associated neurocognitive disorders.
Acknowledgements
The authors wish to thank Mick Correll and Yaoyu Wang of The Center for
Cancer Computational Biology, Dana-Farber Cancer Institute, Boston, MA for
assistance with developing the database website and interface. We also
thank the National NeuroAIDS Tissue Consortium (NNTC) for providing
missing clinical data for some cases. The tissue source annotation is based
on the FMA developed at the University of Washington by the FMATM
Research Project and is provided under license from the University of
Washington.
This work was supported by an ARRA supplement NIH/NIMH #3ROI
MH83588-12S1 and the parent grant MH83588. MEM was supported in part
by NIH fellowship 1F31NS060611-01. Core facilities were supported by the
Harvard Center for AIDS Research and DFCI/Harvard Center for Cancer
Research grants. The NNTC was supported by NIH funding through the
NIMH and NINDS Institutes by the following grants: Manhattan HIV Brain
Bank U01MH083501, R24MH59724 Texas NeuroAIDS Research Center
U01MH083507, R24 NS45491 National Neurological AIDS Bank
5U01MH083500, NS 38841 California NeuroAIDS Tissue Network
U01MH083506, R24MH59745, Statistics and Data Coordinating Center
U01MH083545, N01MH32002. The funders and NNTC had no role in study
design, data analysis, or preparation and submission of the publication.
Author details
1Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute,
Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts, 02115,
USA.
2Center for Cancer Computational Biology, Dana-Farber Cancer
Institute, Dana-Farber Cancer Institute, 44 Binney Street, Boston,
Massachusetts, 02115, USA.
3Department of Neurology, Harvard Medical
School, 25 Shattuck Street, Boston, Massachusetts, 02115, USA.
Authors’ contributions
AH designed the sequence database, assembled and curated sequences,
performed all bioinformatic analysis, and drafted the manuscript. MM
assembled and curated sequences and clinical data. NO designed and
implemented the database interface. DG conceived of the study,
participated in its design and coordination, and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 9 November 2010 Accepted: 14 December 2010
Published: 14 December 2010
References
1. Simon V, Ho DD: HIV-1 dynamics in vivo: implications for therapy. Nature
Reviews Microbiology 2003, 1:181-190.
2. Frost SD, Dumaurier MJ, Wain-Hobson S, Brown AJ: Genetic drift and
within-host metapopulation dynamics of HIV-1 infection. Proc Natl Acad
Sci USA 2001, 98:6975-6980.
3. Stevenson M: HIV-1 pathogenesis. Nature medicine 2003, 9:853-860.
4. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB,
Cinque P, Epstein LG, Goodkin K, et al: Updated research nosology for
HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
5. Ivey NS, MacLean AG, Lackner AA: Acquired immunodeficiency syndrome
and the blood-brain barrier. J Neurovirol 2009, 15:111-122.
6. McGee B, Smith N, Aweeka F: HIV pharmacology: barriers to the
eradication of HIV from the CNS. HIV Clin Trials 2006, 7:142-153.
7. Saksena NK, Potter SJ: Reservoirs of HIV-1 in vivo: implications for
antiretroviral therapy. AIDS Rev 2003, 5:3-18.
8. Dunfee R, Thomas ER, Gorry PR, Wang J, Ancuta P, Gabuzda D:
Mechanisms of HIV-1 neurotropism. Curr HIV Res 2006, 4:267-278.
9. González-Scarano F, Martín-García J: The neuropathogenesis of AIDS. Nat
Rev Immunol 2005, 5:69-81.
10. van Marle G, Power C: Human immunodeficiency virus type 1 genetic
diversity in the nervous system: evolutionary epiphenomenon or disease
determinant? J Neurovirol 2005, 11:107-128.
11. Wang TH, Donaldson YK, Brettle RP, Bell JE, Simmonds P: Identification of
shared populations of human immunodeficiency virus type 1 infecting
microglia and tissue macrophages outside the central nervous system. J
Virol 2001, 75:11686-11699.
12. Salemi M, Lamers SL, Yu S, de Oliveira T, Fitch WM, McGrath MS:
Phylodynamic analysis of human immunodeficiency virus type 1 in
distinct brain compartments provides a model for the
neuropathogenesis of AIDS. J Virol 2005, 79:11343-11352.
13. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW: GenBank.
Nucleic Acids Res 2010, 38:D46-51.
14. Rosse C, Mejino JLV: A reference ontology for biomedical informatics: the
Foundational Model of Anatomy. J Biomed Inform 2003, 36:478-500.
15. Shapshak P, Segal DM, Crandall KA, Fujimura RK, Zhang BT, Xin KQ,
Okuda K, Petito CK, Eisdorfer C, Goodkin K: Independent evolution of HIV
type 1 in different brain regions. AIDS Res Hum Retroviruses 1999,
15:811-820.
16. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, Hinkin CH,
Lazzaretto D, Cherner M, Marcotte TD, et al: Interrater reliability of clinical
ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol
2004, 26:759-778.
17. Korber BT, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, Levy R,
Wolinsky SM: Genetic differences between blood- and brain-derived viral
sequences from human immunodeficiency virus type 1-infected
patients: evidence of conserved elements in the V3 region of the
envelope protein of brain-derived sequences. J Virol 1994, 68:7467-7481.
18. McCrossan M, Marsden M, Carnie FW, Minnis S, Hansoti B, Anthony IC,
Brettle RP, Bell JE, Simmonds P: An immune control model for viral
replication in the CNS during presymptomatic HIV infection. Brain 2006,
129:503-516.
19. Keele BF, Tazi L, Gartner S, Liu Y, Burgon TB, Estes JD, Thacker TC,
Crandall KA, McArthur JC, Burton GF: Characterization of the follicular
dendritic cell reservoir of human immunodeficiency virus type 1. J Virol
2008, 82:5548-5561.
20. Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Perryman S,
Chesebro B: Demented and nondemented patients with AIDS differ in
brain-derived human immunodeficiency virus type 1 envelope
sequences. J Virol 1994, 68:4643-4649.
21. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J,
Simmonds P, Clapham PR: Biological analysis of human
immunodeficiency virus type 1 R5 envelopes amplified from brain and
lymph node tissues of AIDS patients with neuropathology reveals two
distinct tropism phenotypes and identifies envelopes in the brain that
confer an enhanced tropism and fusigenicity for macrophages. J Virol
2004, 78:6915-6926.
22. Mefford ME, Gorry PR, Kunstman K, Wolinsky SM, Gabuzda D: Bioinformatic
prediction programs underestimate the frequency of CXCR4 usage by
R5X4 HIV type 1 in brain and other tissues. AIDS Res Hum Retroviruses
2008, 24:1215-1220.
23. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, Taylor J,
Levy R, Murphy RL, Wolinsky SM, Gabuzda D: Genetic and functional
analysis of full-length human immunodeficiency virus type 1 env genes
derived from brain and blood of patients with AIDS. J Virol 2003,
77:12336-12345.
24. Thomas ER, Dunfee RL, Stanton J, Bogdan D, Taylor J, Kunstman K, Bell JE,
Wolinsky SM, Gabuzda D: Macrophage entry mediated by HIV Envs
from brain and lymphoid tissues is determined by the capacity to use
low CD4 levels and overall efficiency of fusion. Virology 2007,
360:105-119.
25. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S: Analysis of human
immunodeficiency virus type 1 gp160 sequences from a patient with
HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol
2000, 6(Suppl 1):S70-81.
Holman et al. AIDS Research and Therapy 2010, 7:43
http://www.aidsrestherapy.com/content/7/1/43
Page 11 of 12
20226. Martín-García J, Cao W, Varela-Rohena A, Plassmeyer ML, González-
Scarano F: HIV-1 tropism for the central nervous system: Brain-derived
envelope glycoproteins with lower CD4 dependence and reduced
sensitivity to a fusion inhibitor. Virology 2006, 346:169-179.
27. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH: Molecular
characterization of human immunodeficiency virus type 1 cloned
directly from uncultured human brain tissue: identification of
replication-competent and -defective viral genomes. J Virol 1991,
65:3973-3985.
28. Gatanaga H, Oka S, Ida S, Wakabayashi T, Shioda T, Iwamoto A: Active HIV-
1 redistribution and replication in the brain with HIV encephalitis. Arch
Virol 1999, 144:29-43.
29. Lamers SL, Salemi M, Galligan DC, de Oliveira T, Fogel GB, Granier SC,
Zhao L, Brown JN, Morris A, Masliah E, McGrath MS: Extensive HIV-1 intra-
host recombination is common in tissues with abnormal histopathology.
PLoS ONE 2009, 4:e5065.
30. Shah M, Smit TK, Morgello S, Tourtellotte W, Gelman B, Brew BJ,
Saksena NK: Env gp120 sequence analysis of HIV type 1 strains from
diverse areas of the brain shows preponderance of CCR5 usage. AIDS Res
Hum Retroviruses 2006, 22:177-181.
31. Smit TK, Wang B, Ng T, Osborne R, Brew B, Saksena NK: Varied tropism of
HIV-1 isolates derived from different regions of adult brain cortex
discriminate between patients with and without AIDS dementia
complex (ADC): evidence for neurotropic HIV variants. Virology 2001,
279:509-526.
32. Hughes ES, Bell JE, Simmonds P: Investigation of population diversity of
human immunodeficiency virus type 1 in vivo by nucleotide sequencing
and length polymorphism analysis of the V1/V2 hypervariable region of
env. J Gen Virol 1997, 78(Pt 11):2871-2882.
33. Morris A, Marsden M, Halcrow K, Hughes ES, Brettle RP, Bell JE,
Simmonds P: Mosaic structure of the human immunodeficiency virus
type 1 genome infecting lymphoid cells and the brain: evidence for
frequent in vivo recombination events in the evolution of regional
populations. J Virol 1999, 73:8720-8731.
34. Monken CE, Wu B, Srinivasan A: High resolution analysis of HIV-1
quasispecies in the brain. AIDS 1995, 9:345-349.
doi:10.1186/1742-6405-7-43
Cite this article as: Holman et al.: HIVBrainSeqDB: a database of
annotated HIV envelope sequences from brain and other anatomical
sites. AIDS Research and Therapy 2010 7:43.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Holman et al. AIDS Research and Therapy 2010, 7:43
http://www.aidsrestherapy.com/content/7/1/43
Page 12 of 12
203APPENDIX C
Reprinted from Virology, Vol. 362, Gorry, P.R., R.L. Dunfee, M.E. Mefford, K.
Kunstman, T. Morgan, J.P. Moore, J.R. Mascola, K. Agopian, G.H. Holm, A. Mehle, J.
Taylor, M. Farzan, H. Wang, P. Ellery, S.J. Willey, P.R. Clapham, S.M. Wolinsky, S.M.
Crowe, and D. Gabuzda, Changes in the V3 region of gp120 contribute to unusually
broad coreceptor usage of an HIV-1 isolate from a CCR5 32 heterozygote, pp. 163-178,
© 2006, with permission from ElsevierChanges in the V3 region of gp120 contribute to unusually broad coreceptor
usage of an HIV-1 isolate from a CCR5 Δ32 heterozygote
Paul R. Gorry
a,b,1, Rebecca L. Dunfee
a,b, Megan E. Mefford
a,b, Kevin Kunstman
d,
Tom Morgan
e, John P. Moore
e, John R. Mascola
f, Kristin Agopian
a,b, Geoffrey H. Holm
a,b,
Andrew Mehle
a,b, Joann Taylor
d, Michael Farzan
a,b, Hui Wang
a, Philip Ellery
g,h,
Samantha J. Willey
i, Paul R. Clapham
i, Steven M. Wolinsky
d,
Suzanne M. Crowe
g,h, Dana Gabuzda
a,c,⁎
a Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
b Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
c Department of Neurology, Harvard Medical School, Boston, MA 02115, USA
d Department of Medicine, Northwestern University Medical School, Chicago, IL 60611, USA
e Weill Medical College of Cornell University, New York, NY 10021-4896, USA
f Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
g Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
h Department of Medicine, Monash University, Melbourne, Victoria, Australia
i Program in Molecular Medicine, Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester, MA 01655, USA
Received 6 October 2006; returned to author for revision 30 October 2006; accepted 16 November 2006
Available online 18 January 2007
Abstract
Heterozygosity for the CCR5 Δ32 allele is associated with delayed progression to AIDS in human immunodeficiency virus type 1 (HIV-1)
infection. Here we describe an unusual HIV-1 isolate from the blood of an asymptomatic individual who was heterozygous for the CCR5 Δ32
allele and had reduced levels of CCR5 expression. The primary virus used CCR5, CXCR4, and an unusually broad range of alternative
coreceptors to enter transfected cells. However, only CXCR4 and CCR5 were used to enter primary T cells and monocyte-derived macrophages,
respectively. Full-length Env clones had an unusually long V1/V2 region and rare amino acid variants in the V3 and C4 regions. Mutagenesis
studies and structural models suggested that Y308, D321, and to a lesser extent K442 and E444, contribute to the broad coreceptor usage of these
Envs, whereas I317 is likely to be a compensatory change. Furthermore, database analysis suggests that covariation can occur at positions 308/317
and 308/321 in vivo. Y308 and D321 reduced dependence on the extracellular loop 2 (ECL2) region of CCR5, while these residues along with
Y330, K442, and E444 enhanced dependence on the CCR5 N-terminus compared to clade B consensus residues at these positions. These results
suggest that expanded coreceptor usage of HIV-1 can occur in some individuals without rapid progression to AIDS as a consequence of changes in
the V3 region that reduce dependence on the ECL2 region of CCR5 by enhancing interactions with conserved structural elements in G-protein-
coupled receptors.
© 2006 Elsevier Inc. All rights reserved.
Keywords: HIV-1; CCR5 Δ32; Env; V3; CCR5
Introduction
Human immunodeficiency virus type 1 (HIV-1) enters cells
via interaction of the viral envelope glycoproteins (Env) with
CD4 and a coreceptor. Macrophage (M)-tropic HIV-1 viruses
primarily use CCR5 (R5) as a coreceptor, whereas T cell line-
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205tropic HIV-1 viruses use CXCR4 (X4) (Berger et al., 1999;
Doms and Trono, 2000; Moore et al., 2004). Dual-tropic viruses
(R5X4) use both coreceptors. A subset of viruses can also use
alternative coreceptors including CCR3, CCR2b, CCR8, Apj,
Strl33 (BONZO/CXCR6), Gpr1, Gpr15 (BOB), CX3CR1,
ChemR23, or RDC1 for entry (Berger et al., 1999; Doms and
Trono, 2000; Moore et al., 2004). However, usage of core-
ceptors other than CCR5 and CXCR4 by primary viruses in
vitro is rare (Zhang et al., 1998), and infection of primary cells
occurs, with few exceptions, exclusively via CCR5 or CXCR4
(Cilliers et al., 2005; Moore et al., 2004). R5 strains pre-
dominate during primary infection and the asymptomatic phase,
whereas expansion of viral coreceptor usage and emergence of
X4 or R5X4 strains is frequently associated with rapid disease
progression.
Delayed or slow HIV-1 disease progression can be defined
by the lack of development of an AIDS defining illness for at
least 10 years after infection with a slowly declining CD4+ T
cell count. Viral genetic factors associated with slow
progression or nonprogression include mutations in the HIV-
1 gag, rev, vif, vpr, vpu, env and nef genes (Churchill et al.,
2004, 2006; Deacon et al., 1995; Kirchhoff et al., 1995;
Michael et al., 1997; Shioda et al., 1997; Wang et al., 2000).
Host genetic factors linked to a delay in the onset of AIDS and
prolonged survival include the CCR5 Δ32 mutation, CCR2b-
V64I polymorphism, and certain HLA haplotypes (Dean et al.,
1996; Eugen-Olsen et al., 1997; Huang et al., 1996; Smith et
al., 1997) (reviewed in O'Brien and Moore, 2000; Roger,
1998). The CCR5 Δ32 mutation, which results in a 32-
nucleotide deletion, is common in Caucasians, with heterozy-
gosity in 15 to 20% and homozygosity in 1%. Individuals
homozygous for the CCR5 Δ32 allele are highly resistant to
HIV-1 transmission (O'Brien and Moore, 2000), whereas
heterozygotes are susceptible but typically have delayed CD4+
Tcell decline and prolonged survival compared to CCR5 wt/wt
individuals (Dean et al., 1996; Eugen-Olsen et al., 1997;
Huang et al., 1996; Michael et al., 1997). Among CCR5 Δ32/
wt heterozygotes, there is large variation in levels of CCR5
expression (Cohen et al., 1997; de Roda Husman et al., 1999).
Slow progression of HIV-1 disease has been correlated with
reducedlevelsofCCR5expressiononCD4+Tlymphocytesand
monocytes compared to levels in CCR5 wt/wt individuals
(Cohen et al., 1997; de Roda Husman et al., 1999). Nonetheless,
thereisconsiderableoverlapbetweenCCR5expressionlevelsin
CCR5 Δ32/wt heterozygotes and individuals with the CCR5
wt/wt genotype (de Roda Husman et al., 1999).
In this study, we isolated and characterized HIV-1 from the
blood of an asymptomatic individual who was heterozygous for
the CCR5 Δ32 allele and had reduced levels of CCR5 cell
surface expression. In addition to using CCR5 and CXCR4, the
virus has highly expanded utilization of alternative coreceptors
that is broader than that of any previously described HIV-1
virus. Mutagenesis studies and structural models suggested
Y308 and D321 in the V3 region of gp120, and to a lesser extent
K442 and E444 in the C4 region, contribute to the broad
coreceptor usage of Envs cloned from the viral isolate. Fur-
thermore, studies using mutant CCR5 coreceptors indicated that
Y308, D321, Y330, K442, and E444 alter dependence on the N-
terminal and extracellular loop 2 (ECL2) regions of CCR5. The
results suggest that expanded coreceptor usage of HIV-1 can
occur in some individuals without rapid progression to AIDS as
a consequence of changes in the V3 region that enhance
interactions with conserved structural elements in G-protein-
coupled receptors (GPCRs).
Results
Clinical history and isolation of HIV-1
The subject is a homosexual male who was infected with
HIV-1 via sexual contact and first tested seropositive for HIV-1
in May 1989. As of 2006, the subject remained asymptomatic
with no AIDS defining illness. His antiretroviral therapy (ART),
plasma HIV-1 RNA levels, and CD4 counts are summarized in
Supplementary Table 3. The subject was seropositive for cyto-
megalovirus, hepatitis A, hepatitis C, and Toxoplasma gondii.
Genetic analysis of CCR5 alleles by PCR demonstrated hetero-
zygosity for the CCR5 Δ32 deletion (data not shown). Two-
color FACS staining of peripheral blood mononuclear cells
(PBMC) collected in October 2003 demonstrated that the mean
percentage of CCR5+ cells in the CD4+ T lymphocyte fraction
was 0.9% (n=2, SD=0.08) as compared with 19.3% in healthy
HIV-1-negative control subjects (n=7, SD=10.15). HIV-1 was
isolated from PBMC collected in August 2000 by coculture
with CD8-depleted donor PBMC as described (Gorry et al.,
2001). Attempts to isolate HIV-1 from cryopreserved PBMC
collected in October 1998 and March 1999 were unsuccessful.
Coreceptor usage
The ability of the primary virus isolate to utilize CCR5,
CXCR4, or alternative coreceptors for virus entry was first
determined in canine Cf2-Luc cells (Gorry et al., 2001)( Fig.
1A). The X4 NL4-3, R5 ADA, and R5X4 89.6 HIV-1 viruses
were used as positive controls (Gorry et al., 2001, 2002b). The
primary virus used both CCR5 and CXCR4 for virus entry.
Efficient usage of CCR2b, CCR3, CCR8, Gpr1, Gpr15, Strl33
and Apj was also demonstrated. Compared to 89.6, usage of
CCR2b, Gpr1, and Apj by the primary virus was approximately
5-, 20- and 2-fold greater, respectively. Compared to ADA,
usage of CCR8, Gpr15 and Strl33 by the primary virus was
approximately 5-, 6- and 2-fold greater. The virus could also
enter canine Cf2-Luc cells transfected with CD4 alone, albeit at
low levels. Coreceptor usage in human U87 astrocytoma cells
was similar to that in Cf2-Luc cells with the exception that virus
entry was not detected in U87 cells transfected with CD4 alone
(data not shown), suggesting that entry in Cf2-Luc cells
expressing CD4 alone was mediated by an endogenous canine
coreceptor. The promiscuous pattern of coreceptor usage
resembles that of some SIV and HIV-2 virus strains (Edinger
et al., 1998; Morner et al., 1999; Reeves et al., 1997, 1999;
Rucker et al., 1997), which can infect certain cell types lacking
CD4. However, virus entry mediated by CCR3, CCR5,
CXCR4, or the endogenous coreceptor expressed on Cf2-Luc
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206cells was strictly CD4-dependent (data not shown). We next
tested whether the primary virus could utilize other GPCRs as
coreceptors. Virus entry was detected in Cf2-Luc cells
coexpressing CD4 and the promiscuous CC-chemokine recep-
tor D6 (Nibbs et al., 1997), but not in cells coexpressing CD4
and CX3CR1, Rdc1, CCR7, CXCR1, CXCR2, CXCR3,
complement 5a anaphylatoxin receptor (C5aRC9), dopamine
receptor 2-short form (D2DrsC9), duffy antigen/receptor for
chemokines (DARC), or formyl-methionine–leucine–phenyl-
alanine receptor (FMLP-R) (Fig. 1B). Cell surface expression of
these GPCRs was readily detected (M. Farzan and H. Choe,
unpublished observations). Preincubation with zidovudine
(AZT) abolished infection (data not shown). The broad and
efficient usage of alternative coreceptors by the patient virus
was unique by comparison to over 50 other primary HIV-1
viruses analyzed in similar assays (Gorry et al., 2001, 2002b;
Gray et al., 2005; Lawson et al., 2004; Solomon et al., 2005 and
data not shown). Thus, the patient virus demonstrates unusually
broad and efficient usage of alternative coreceptors compared to
other HIV-1 strains.
Replication kinetics
We examined the capacity of the primary virus to replicate in
PBMC, CEMx174 cells, and monocyte-derived macrophages
(MDM) (Fig. 2A). The ADA and NL4-3 viruses were used as
positive controls for replication in PBMC; NL4-3 was used as a
positive control for replication in CEMx174 cells; ADA, the R5
YU2 strain, and the X4 NDK strain (Ancuta et al., 2001; Gorry
et al., 2001) were used as positive controls for replication in
MDM. In PBMC, the primary virus replicated to low levels
compared to NL4-3 and ADA, reaching peak levels of repli-
cation at day 10 post-infection compared to days 4 and 7 for
NL4-3 and ADA, respectively. In CEMx174 cells, the primary
virus reached peak levels of virus replication at day 24 post-
infection compared to day 7 for NL4-3. In MDM, the primary
virus replicated at low levels compared to ADA, YU2 and
NDK. These results, together with experiments showing that the
same primary virus stock had similar infectivity on Cf2-Luc
cells coexpressing CD4 and CCR5 or CXCR4 compared to the
control viruses (Fig. 1), suggest that the primary virus has
reduced replication capacity in PBMC, CEMx174, and MDM
compared to several laboratory and primary HIV-1 strains.
Sensitivity to CCR5 and CXCR4 inhibitors
The efficient usage of alternative coreceptors in transfected
cells raised the possibility that infection of primary CD4+ cells
by the primary virus might be mediated by alternative
coreceptors. Therefore, sensitivity to small molecule inhibitors
of CCR5 or CXCR4 (TAK-779 and AMD3100, respectively)
was tested in PBMC and MDM. We first determined sensitivity
to AMD3100 and TAK-779 in PBMC at a range of concentra-
tions previously shown to be effective at inhibiting infection by
other primary HIV-1 viruses (Gorry et al., 2002a). AMD3100 or
AMD3100 and TAK-779 in combination abolished infection of
Fig. 1. Coreceptor usage. (A) Cf2-Luc cells were transfected with pcDNA3-CD4 alone or cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR2b, CCR3,
CCR5, CCR8, CXCR4, Gpr1, Gpr15, Strl33 or Apj and infected with equivalent amounts of each control HIV-1 virus (left panel) or patient-derived virus (right panel).
Control cells were transfected with pcDNA3 plasmid only. Mock-infected cells were treated with culture medium. Cell lysates were prepared at 48 h post-infection and
assayed for luciferase activity. (B) Cf2-Luc cells transfected with pcDNA3-CD4 alone or cotransfected with pcDNA3-CD4 and plasmids expressing CCR5, CX3CR1,
RDC1, CCR7, CXCR1, CXCR2, CXCR3, C5aRC9, D2DRsC9, DARC, D6 or FMLP-R were infected with equivalent amounts of each HIV-1 virus. HIV-1 entry was
measured as above.Data are represented as means from duplicateinfections. Error bars represent standard deviations.Similar results were obtained in two independent
experiments.
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207PBMC at day 14 post-infection, whereas treatment with TAK-
779 alone had only a modest inhibitory effect (Fig. 2B). Similar
results were obtained at days 7 and 10 post-infection (data not
shown). The 50% inhibitory concentration (IC50) and IC90 of
AMD3100 at day 14 post-infection was 0.65 μM and 5.5 μM,
respectively, whereas the IC50 and IC90 of TAK-779 at day 14
was 58 μM and>100 μM, respectively. PBMC from a donor
homozygous for the CCR5 Δ32 allele supported replication
of the primary virus, which was completely abolished by
AMD3100 (data not shown). These results demonstrate that the
virus primarily uses CXCR4 for infection of PBMC. We then
determined sensitivity to AMD3100 and TAK-779 in MDM at
concentrations previously shown to completely inhibit infection
of MDM or microglia (Gorry et al., 2001; Simmons et al., 1998)
(Fig. 2C). AMD3100 abolished infection of MDM by NDK, but
had no inhibitory effect on the primary virus. TAK-779
abolished infection of MDM by the primary virus, but had no
inhibitory effect on NDK. AMD3100 and TAK-779 in com-
bination abolished infection of MDM by either virus. These
results demonstrate exclusive use of CCR5 for infection of
MDM. Thus, despite broad coreceptor utilization in transfected
cells, infection of PBMC and MDM was mediated only by
CXCR4 and CCR5, respectively.
We previously showed that primary human adult astrocytes
transduced with CD4 via an adenovirus vector and primary
brain microvascular endothelial cells (BMVECs) that express
low levels of CD4 can support infection by a subset of HIV-1,
HIV-2 and SIV isolates in a CCR5- and CXCR4-independent
manner (Willey et al., 2003). To further investigate whether the
primary virus can use alternative coreceptors for virus entry in
Fig. 2. Replication kinetics and sensitivity to coreceptor inhibitors and antibody neutralization. (A) PBMC, CEMx174 cells and MDM were infected with equivalent
amounts of each HIV-1 virus, as described in Materials and methods, and cultured for 28 days. Virus production in culture supernatants was measured by RTassays.
(B) PBMC were treated with concentrations of CCR5 (TAK-779) or CXCR4 inhibitors (AMD3100), or both inhibitors increasing 10-fold from 0.01 to 100 μM, and
infected with the patient virus in the presence of each concentration of inhibitor. Virus production in culture supernatants at day 14 post-infection was measured by
quantitation of soluble HIV-1 p24 Ag. Production of p24 Ag was calculated as a percentage of the amount produced in the absence of inhibitors, and then expressed as
the percentage of inhibition relative to cultures containing no inhibitor. (C) MDM were treated with TAK-779 (100 nM), AMD3100 (1.2 μM) or both for 1 h prior to
infection. Untreated cells contained no inhibitor. Cells were infected with equivalent amounts of HIV-1 NDK or the patient isolate and cultured for 21 days in the
presence of each inhibitor. HIV-1 production in culture supernatants was measured by RTassays. (D) Virus stocks were treated with concentrations of MAbs or CD4-
IgG2 increasing 10-fold from 0.01 to 100 μM for 30 min, and used to infect PBMC. Virus production in culture supernatants and calculation of percent neutralization
was determined as per panel (B). Values shown are means from duplicate infections. Error bars represent standard deviations (A, C). Results are representative of two
independent experiments using cells obtained from different donors.
166 P.R. Gorry et al. / Virology 362 (2007) 163–178
208primary human cells, we infected these cells with the primary
virus, as previously described (Willey et al., 2003). No evidence
of infection of CD4-expressing astrocytes or BMVECs by the
primary virus was observed, whereas both cell types supported
productive virus replication by the R5X4 HIV-1 viruses GUN-
1v and HAN-2, the HIV-2 strain TER, and the SIV strain 17Efr
(data not shown). These studies provide further evidence that
infection of primary cells by the virus is unlikely to be mediated
by alternative coreceptors.
Sensitivity to antibody neutralization
We next measured the sensitivity of the primary virus to
neutralization by Env monoclonal antibodies (MAbs) and CD4-
IgG2, as previously described (Trkola et al., 1995)( Fig. 2D).
The neutralizing reagents were human MAbs 2F5 (Muster et al.,
1994; Trkola et al., 1995), 2G12 (Trkola et al., 1995, 1996),
IgG1b12 (Burton et al., 1991, 1994), and the tetrameric CD4-
IgG2 molecule (Allaway et al., 1995). The virus was moderately
sensitive to neutralization by IgG1b12 and CD4-IgG2, but
showed a high level of resistance to neutralization by 2F5 and
2G12, similar to that of 2 other primary viruses studied in
parallel (Fig. 2D and data not shown). Thus, the primary virus is
relatively resistant to neutralization by Env MAbs and CD4-
IgG2, similar to the majority of primary HIV-1 viruses.
Neutralization of heterologous viruses by the subject’s plasma
We determined the ability of the subject’s plasma (obtained
in September 2001; see Supplementary Table 3) to inhibit
infection of PBMC by 6 clade B and 2 clade A HIV-1 viruses as
compared with HIVIG and MAbs IgG1b12, 2F5, and 2G12, as
previously described (Mascola et al., 2002). The IC50s and
IC90s are summarized in Table 1. The subject’s plasma and
HIVIG neutralized infection by 6 diverse clade B and 1 of 2
clade A HIV-1 viruses at plasma dilutions increasing 5-fold
from 1:5 to 1:625, or HIVIG concentrations increasing 10-fold
from 10 μg/ml to 10 mg/ml (Mascola et al., 2002). In contrast,
the MAbs IgG1b12, 2F5 and 2G12, at concentrations increasing
from 0.05 μg/ml to 50 μg/ml, neutralized infection by a subset
of the viruses tested. Compared to plasma and sera from other
HIV-1-infected individuals, the potency and breadth of the
cross-neutralizing activity of the patient’s plasma were in the
top 10% of HIV-1-positive plasma/sera (J. Mascola, unpub-
lished data). Together, these studies suggest that the subject’s
plasma has high levels of cross-neutralizing antibodies.
Characterization of full-length gp160 Env clones
The gp160 coding region of HIV-1 Env was cloned into the
pCR3.1-Uni expression vector. Full-length, functional Env
clones were identified by Western blot analysis of gp120/gp160
in transfected 293Tcells and by fusion assays. Four Env clones
that express distinct gp160 and gp120 proteins detected by
Western blot analysis of transfected 293T cells (Fig. 4A) were
sequenced (Fig. 3). Env gp160 amino acid sequences were
uninterrupted in Env clones 6, 16 and 30, but contained a
premature truncation of 4 amino acids in the gp41 cytoplasmic
region in clone 12. The net charge of the V3 variable loops was
+5 in all 4 Env clones. The Env clones contained an asparagine-
rich insertion of 10 amino acids at positions 131 to 140 in the
V1 variable region, which is unique among 207 clade B Envs
screened in the Los Alamos database. Two similar asparagine-
rich insertions of 11 and 6 amino acids were identified at
positions 192 to 202 and 208 to 213, respectively, in the V2
variable region. These insertions result in a net gain of one
potential N-linked glycosylation site in V1, and 3 potential N-
linked glycosylation sites in V2. The total number of potential
N-linked glycosylation sites in gp120 was 20 to 21 compared to
25 in the clade B consensus sequence.
To determine whether the Env clones are representative of
the predominant HIV-1 variants in the viral quasispecies, fusion
and single round entry assays were performed (Figs. 4B, C).
293T cells expressing each Env (Fig. 4A) were fused with Cf2-
Luc cells cotransfected with CD4 and a coreceptor as described
(Gorry et al., 2002a)( Fig. 4B). 293T cells expressing a non-
functional Env or expressing the ADA, HXB2 or 89.6 Env were
used as negative and positive controls, respectively. The
Table 1
Virus neutralization studies
Plasma or Ab Clade B HIV-1 Clade A HIV-1
SF162 BaL 89.6 dBR07 aBL01 6101 UG031 RW020
Patient
a IC50 255 220 261 553 90 105 187 32
IC90 42 31 64 256 18 27 10 7
b12
b IC50 0.4 1.1 0.3 0.6 12 >50 >50 >50
IC90 2.7 12 5.5 22 >50 >50 >50 >50
2F5 IC50 2.9 1.1 0.1 1.1 3.1 50 9 0.3
IC90 >50 >50 2 >50 >50 >50 >50 4
2G12 IC50 17 0.1 >50 >50 >50 29 >50 0.6
IC90 >50 10 >50 >50 >50 >50 >50 5
HIVIG IC50 40 320 13 140 685 850 5420 2004
IC90 680 6590 430 2610 >10000 8700 >10000 6050
a IC50 and IC90 values of patient plasma neutralization are expressed as the reciprocal of plasma dilution required to inhibit 50 or 90%, respectively, of viral infection
of CD8-depleted PBMC. The patient plasma was obtained in September, 2001 (see Supplementary Table 3).
b IC50 and IC90 values of Env MAbs and HIVIG are expressed as the concentration (μg/ml) required to inhibit 50 or 90%, respectively, of viral infection of CD8-
depleted PBMC.
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209primary Env clones functioned in fusion assays with Cf2-Luc
cells coexpressing CD4 and CCR2b, CCR3, CCR5, CCR8,
CXCR4, Gpr1, Gpr15, Strl33, Apj or D6. A low level of fusion
was also observed with Cf2-Luc cells expressing CD4 only. We
performed single round entry assays in Cf2th cells expressing
CD4 only or coexpressing CD4 and each of the coreceptors
(Fig. 4C). HIV-1 pseudotyped with Env clones 6 and 30 entered
cells expressing CD4 alone, or coexpressing CD4 and CCR2b,
CCR3, CCR5, CCR8, CXCR4, Gpr1, Gpr15, Strl33, Apj or D6.
In contrast, HIV-1 pseudotyped with Env clones 12 and 16
entered cells coexpressing CD4 and CCR2b, CCR3, CCR5,
CXCR4, Gpr15, Strl33 or Apj, but not cells expressing CD4
alone or coexpressing CD4 and CCR8, Gpr1 or D6. The levels
of virus entry mediated by Env clones 12 and 16 were lower
than those mediated by Env clones 6 and 30. Together, these
results demonstrate broad coreceptor usage by 4 Env clones in
fusion and single round entry assays, similar to the pattern of
coreceptor usage of the primary virus isolate (Fig. 1).
Analysis of Env determinants contributing to broad coreceptor
usage
To investigate mechanisms underlying the broad coreceptor
usage of these primary Envs, we analyzed sequences of the V3
Fig. 3. Env amino acid sequences.Amino acid sequences were obtainedfrom gp160 env genes cloned from genomicDNA of PBMC infected with the primary virus as
described in Materials and methods. Amino acid alignments of Envs from the patient virus are compared to the clade B consensus sequence. Dots indicate residues
identical to the clade B consensus and dashes indicate gaps.
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210region, which modulates coreceptor usage (reviewed in Hartley
et al., 2005), and the conserved coreceptor binding site on the
Env core (Rizzuto et al., 1998) to identify amino acid variants
that might influence Env–GPCR interactions. In the V3 region,
patient Envs had Y308,a rare amino acid variant (1.5% of Clade
B Envs, n=23,470) at a position implicated in modulating
resistance to neutralizing antibodies (Zhang et al., 2002) and a
small molecule CCR5 inhibitor (Kuhmann et al., 2004); I317,
an amino acid that contributed to the ability of JR-CSF to use an
N-terminal deletion mutant of CCR5 (Platt et al., 2001); D321
(or E321) and Y330, amino acid changes that affect the overall
charge of V3 and thus may alter interactions with the tyrosine-
sulfated N-terminal region of GPCRs; and T332, a change that
results in the loss of a potential N-linked glycosylation site
relative to the Clade B consensus (Fig. 5A). In the conserved
coreceptor binding site on the Env core, patient Envs had K442
and E444 in the β22 strand near the base of V3, amino acid
variants that could potentially affect electrostatic interactions at
the Env–GPCR interface.
To investigate the contribution of these amino acid variants
to broad coreceptor usage, we used site-directed mutagenesis to
change each of these amino acids to the Clade B consensus
residue in patient Env-30. The parental and mutant Envs were
expressed at similar levels as determined by Western blotting
(Fig. 5B, inset). The ability of Envs to use CCR5, CXCR4, and
alternate coreceptors Gpr1, Gpr15, Strl33, and D6 was analyzed
in cell-to-cell fusion and single round virus entry assays (Fig.
5B and data not shown). The Y308H mutation resulted in an
increased ability to use CCR5, and to a lesser extent CXCR4,
but reduced the capacity of Env-30 to use Gpr1, Gpr15, Strl33,
and D6 (p=0.001, 0.02, 0.02, and 0.04, respectively; Student’s
t test). Additionally, a D321G mutation in Env-30 resulted in an
increased utilization of CCR5, CXCR4, and D6 (p=0.002,
0.049, and 0.006, respectively), but decreased utilization of
Gpr1 and Gpr15 (p=0.006 and 0.048, respectively). In contrast,
a I317F mutation drastically reduced the capacity of Env-30 to
use all coreceptors tested (p<0.01). A K442Q mutation resulted
in a significant decrease in utilization of Gpr1 and Strl33
(p=0.001 and 0.01, respectively) and a minor decrease in
utilization of D6 that did not reach statistical significance, while
a E444R change reduced utilization of CXCR4 and Gpr15
(p<0.01). A Y330H mutation reduced the ability of Env-30 to
Fig. 4. Expression andfunction offull-lengthEnv clones in cell–cell fusionand infectionassays. (A) 293Tcellswere cotransfected with 15 μg pCR3.1 Env-expressing
plasmid (Envs 6, 12, 16 and 30) or pSVIII Env-expressing plasmid (ADA, HXB2 and 89.6 Envs) and 2 μg pLTR-Tat. At 72 h post-transfection, cell lysates were
analyzed by Western blotting using rabbit anti-gp120. The positions of gp160 and gp120 are indicatedon the right. (B) 293Teffector cells transfected with Env and Tat
as above were mixed with Cf2-Luc cells transfected with pcDNA3-CD4 only or cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR2b, CCR3, CCR5,
CCR8, CXCR4, Gpr1, Gpr15, Strl33, Apj or D6 and incubated at 37 °C for 12 h. Control 293Tcells were transfected with ΔKS Env. Mock-transfected Cf2-Luc cells
were transfected with pcDNA3 only. Cell lysates were then prepared and assayed for luciferase activity. (C) HIV-1 luciferase reporter viruses pseudotyped with each
Env were generated and used to infect Cf2th cells transfected with pcDNA3-CD4 only or cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR2b, CCR3,
CCR5, CCR8, CXCR4, Gpr1, Gpr15, Strl33, Apj or D6. Control virus was produced by pseudotyping with a non-functional Env (ΔKS Env). Cell lysates were
prepared at 60 h post-infection and assayed for luciferase activity. Data are represented as means from duplicate wells in one experiment. Error bars represent standard
deviations. Results are representative of two independent experiments, each performed in duplicate.
169 P.R. Gorry et al. / Virology 362 (2007) 163–178
211use Gpr1 (p=0.04), but enhanced utilization of Gpr15
(p=0.01) and had no significant effect on utilization of
Strl33 and D6. A T332N mutation had no significant effect on
entry efficiencies and patterns of coreceptor usage compared
to the parental Env-30 (Fig. 5B). These results suggest that
Y308, D321, and to a lesser extent K442 and E444, contribute
to enhanced gp120 interactions with alternate coreceptors, and
raise the possibility that I317 may be a compensatory change
in patient Env-30.
Molecular modeling of V3 determinants
To elucidate a mechanism for enhanced gp120–coreceptor
interactions in Env-30, we used Swiss PDB viewer to model the
amino acids at positions 308, 317, and 321 on the JRFL gp120-
CD4-X5 CD4i Ab crystal structure (2B4C) (Huang et al., 2005).
The Clade B consensus amino acids at positions 308 and 317 in
the V3 tip region are His and Phe, respectively (Fig. 6A). If the
His at 308 is changed to Tyr, there is an increased potential for
steric clashing when the aromatic ring of Phe is present at
position 317 (Fig. 6B), whereas the smaller side chain of Ile at
this position can accommodate the Tyr at 308 (Fig. 6C). This
finding suggests that the loss of Env function in the I317F
mutant may be due to the lack of a compensatory change at
position 308. Consistent with this prediction, when Y308 is
present in Clade B Envs (n=360), there is a decreased
frequency of amino acids with bulky aromatic side chains
such as Phe and Trp, but an increased frequency of amino acids
with small hydrophobic chains such as Ile and Val at position
317 compared to Clade B Envs (n=23,470) (Table 2), sug-
gesting that covariation may occur at positions 308/317 in vivo.
In Envs with Y308 (n=360 Env sequences from 77 patients),
I317 appeared in 23.9% (n=86 Env sequences from 11 patients)
compared to 4.1% (n=959) of Clade B Envs in the database
(n=23,470) (Table 2). At position 321, Gly may increase the
flexibility of the V3 stem, allowing increased gp120 binding to
GPCRs. An Asp at this position may decrease the flexibility of
the stem, but may also enhance the ability of Env-30 to interact
with some GPCRs that contain positive charges in the N-
terminus, such as Gpr1 and Gpr15. In Envs with Y308, there is
an increased frequency of charged amino acids at position 321
compared to Clade B Envs, raising the possibility that
covariation may also occur at 308/321 (Table 2).
Analysis of Env interactions with attenuated CCR5 coreceptors
GPCRs are 7-transmembrane receptors with an extracellular,
post-translationally modified acidic N-terminal region and three
Fig. 5. Analysis of Env determinants contributing to broad coreceptor usage (A) V3 and C4 amino acid sequences of the Clade B consensus and patient Env clones
were aligned with Clustal X. Dots represent amino acids identical to the Clade B consensus sequence. Residues important for CCR5 binding (Rizzuto et al., 1998)i n
the C4 region are indicated. Amino acid variants analyzed in mutagenesis studies are highlighted in gray. (B) HIV-1 luciferase reporter viruses pseudotyped with each
Env were generated and used to infect Cf2th cells cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR5, CXCR4, Gpr1, Gpr15, Strl33, or D6. Control
virus was produced by pseudotyping with ΔKS Env. Cell lysates were prepared at 60 h post-infection and assayed for luciferase activity. Data were normalized to
parental Env-30 activity and are represented as means from two to three independent experiments, each performed in duplicate. Error bars represent standard error of
the mean. *, p<0.05; **, p<0.01, Student's t test. Inset, 293T cells were cotransfected with 15 μg Env-expressing plasmids and 2 μg pLTR-Tat. At 72 h post-
transfection, cell lysates were analyzed by Western blotting using goat anti-gp120. The positions of gp160 and gp120 are indicated on the left.
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212extracellular loops (ECLs). The N-terminal region and ECL2
contain the major determinants for gp120 binding and core-
ceptor activity (Dragic et al., 1998; Farzan et al., 1998, 1999;
Kuhmann et al., 1997; Lee et al., 1999; Olson et al., 1999; Rabut
et al., 1998; Rucker et al., 1996). The N-terminus of CCR5 has
Tyr sulfation modifications at several sites that are important for
mediating HIVentry (Farzan et al., 1999). Todetermine whether
amino acid variants in Env-30 influence interactions with the N-
terminus or ECL2 regions of GPCRs, Cf2 cells expressing CD4
and either wild-type CCR5 (CCR5 (wt)), CCR5 (Y14N) which
has a point mutation in the N-terminal region that changes a Tyr
sulfation site important for mediating HIV-1 entry to an N-
linked glycosylation site (Farzan et al., 1999; Kuhmann et al.,
2000), CCR5 (Δ18) which contains a deletion of the first 18
amino acids of the N-terminal region, or CCR5 (G163R) which
contains a point mutation in the transmembrane region asso-
ciated with a conformational change in ECL2 that is detrimental
to HIV-1 entry (Platt et al., 2001; Siciliano et al., 1999), were
infected with viruses expressing wild-type or mutant Envs.
Primary, macrophage tropic R5 viral isolates use CCR5 (Y14N)
and CCR5 (G163R) at low efficiencies (1.5% and 10–20%
compared to CCR5 (wt), respectively) (Kuhmann et al., 2000;
Platt et al., 2001) and are unable to use CCR5 (Δ18) (Platt et al.,
2005). In contrast to primary R5 Envs, Env-30 used CCR5 (wt)
and CCR5 (G163R) with similar efficiencies (Fig. 7). Y308H
and D321G had reduced utilization of CCR5 (G163R) relative
to CCR5 (wt) compared to Env-30 (Fig. 7), suggesting that
amino acid variants at these positions in patient Env-30 reduce
dependence on the ECL2 region of CCR5. The Y308H,
Y330H, K442Q, and E444R mutants used CCR5 (Y14N) for
entry more efficiently compared to Env-30 (Fig. 7). None of
the Envs could use CCR5 (Δ18) efficiently, consistent with
the critical role of the N-terminal region of GPCRs in binding
and entry (Dragic et al., 1998; Farzan et al., 1998, 1999;
Kuhmann et al., 1997; Rabut et al., 1998; Rucker et al., 1996).
However, the Y308H, D321G, T332N, and E444R mutations
resulted in an increase in the ability of Env-30 to use CCR5
(Δ18), albeit at very low efficiencies. Cell surface expression
levels of CD4 and CCR5 on transfected Cf2th cells were
similar based on staining with CD4-FITC (RPA-T4) and
CCR5-PE (2D7) and FACS analysis (data not shown). Toge-
ther, these results suggest that Y308 and D321 reduce depen-
dence on the ECL2 region of CCR5, while these residues
along with Y330, K442, and E444 increase dependence on the
Fig. 6. Structural modeling of Env V3 determinants contributing to broad coreceptor usage. Swiss PDB viewer was used to model amino acid changes at positions 308,
317, and 321 on the V3 region of the JRFL gp120-CD4-X5 CD4i Ab crystal structure (2B4C) (Huang et al., 2005). JRFLV3 has a single amino acid change relative to
the clade B consensus (N301Q). Red, position 308. Gray, position 317. Cyan, position 321. (A) V3 region of JRFL with H308, F317, and G321. (B) AY308 change in
JRFL results in steric clashing with F317 (dotted lines). (C) Changes Q301N, K305R, S306G, Y308H, F317I, G321D, E322K, I324V, Q328K, H330Y, and N332T
were introduced in JRFL to produce a model of the V3 region of Env-30. Positions Y308, I317, and D321 are indicated.
Table 2
Frequency and co-variation of unusual amino acid variants in vivo
Position Amino
Acid
Clade B Envs
(n=23470)
a
Envs with Y308 (n=360)
Frequency
(%)
b
n Frequency
(%)
n Significance
c
317 F 78.6 18446 23.6 85 **
W 6.4 1500 0.6 2 **
L 5.1 1194 5.0 18
I 4.1 959 23.9 86
d **
V 2.7 644 45.3 163 **
Y 1.8 411 0.0 0 **
Other 1.3 316
e 1.7 6
f
321 G 79.8 18740 36.7 132 **
E 4.1 970 19.7 71 **
D 2.8 667 7.5 27 **
K 2.0 460 26.9 97 **
R 1.7 389 8.1 29 **
Other 9.6 2244
g 1.1 4
h
a V3 sequence alignment was obtained from the Los Alamos database in
October 2005. Sequence data for Envs with Y308 are from 77 patients.
b Frequency was calculated as [(n/total number of sequences)×100].
c Differences between groups were significant as calculated by Fisher's Exact
Test. **, p<0.005.
d Envs with Y308/I317 are from 11 patients.
e Other indicates amino acids M, S, K, R, C, Q, H, P, T, G, A, D, and E (in
descending order of frequency), or could not be determined.
f Other indicates amino acids M, S, K, E, and P (in descending order of
frequency).
g Other indicates amino acids T, A, Q, N, S, I, and V (in descending order of
frequency), a gap in the alignment, or could not be determined.
h Other indicates amino acid Q or could not be determined.
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213CCR5 N-terminus compared to clade B consensus residues at
these positions.
Discussion
In this study, we isolated and characterized an unusual HIV-1
strain from the blood of an asymptomatic individual who was
heterozygous for the CCR5 Δ32 allele and had reduced levels
of CCR5 expression. The primary virus is dual-tropic and
exhibits unusually broad and efficient utilization of alternative
coreceptors. The repertoire of alternative coreceptors used is
greater than that of any previously described HIV-1 virus, and
more closely resembles that of some SIVand HIV-2 viruses than
that of HIV-1 viruses (Morner et al., 1999; Rucker et al., 1997;
Siciliano et al., 1999). However, in contrast to some SIV and
HIV-2 strains that can infect cells in the absence of CD4
(Reeves et al., 1997, 1999), CCR5- and CXCR4-mediated entry
by the primary virus is strictly CD4-dependent. Previous studies
suggest that expanded use of alternative coreceptors is
associated with rapid HIV-1 disease progression (Bjorndal et
al., 1997; Connor et al., 1997). However, the virus we described
here was isolated from an individual who was asymptomatic for
18 years and had slow disease progression, suggesting that
expanded tropism of HIV-1 can occur in some individuals who
do not have rapid disease progression.
Despite efficient usage of many alternative coreceptors in
transfected cells, the virus exclusively used CXCR4 or CCR5 to
enter primary T cells and monocyte-derived macrophages, res-
pectively.Asimilarpatternofcoreceptorpreferenceforinfection
of these primary cells was described for the R5X4 89.6 isolate.
CD4-expressing astrocytes and BMVECS were not infected by
theprimaryvirus,whereasbothcelltypessupportedinfectionby
other unusual HIV-1 and HIV-2 strains. Thus, infection of
primary cells was mediated only by CXCR4 and CCR5.
In addition to using CCR2b, CCR3, CCR5, CCR8, CXCR4,
Gpr1, Gpr15, Strl33 and Apj, the patient virus also utilized the
promiscuous CC-chemokine receptor D6 (Nibbs et al., 1997).
Only two previous studies demonstrated HIV-1 entry mediated
via D6 (Choe et al., 1998; Neil et al., 2005). D6 is expressed on
lymphatic endothelial cells, but not on peripheral blood cells or
vascular endothelial cells (Nibbs et al., 2001). In addition to
entry mediated by D6, entry mediated by an endogenous canine
coreceptor was demonstrated, albeit at very low levels. This
property was not observed for over 50 other primary HIV-1
isolates tested in similar assays (data not shown). The identity of
the endogenous canine coreceptor is unknown. However, entry
via this coreceptor was not inhibited by AMD3100, suggesting
it most likely is not CXCR4 (data not shown).
CCR5 cell surface expression levels were very low on the
study subject’s PBMC compared to other CCR5 Δ32 hetero-
zygotes (Cohen et al., 1997; de Roda Husman et al., 1999).
Previous studies demonstrated an increased frequency of R5X4
viruses in CCR5 Δ32 heterozygotes compared to CCR5 wt/wt
individuals (Lathey et al., 2001; Zhang et al., 1998). We
speculate that structural features that enhance interaction of the
primary virus Env described herein with conserved structural
elements in GPCRs may have resulted from adaptive evolution
in the setting of very low levels of CCR5 cell surface expres-
sion. However, validation of this hypothesis would require
longitudinal analysis of Env sequences in the patient’s plasma
and their functional characterization. The primary virus did not
show enhanced sensitivity to antibody neutralization, but the
subject’s plasma had potent neutralizing activity against a wide
variety of HIV-1 strains. This finding raises the possibility that
the Env from the subject’s virus may express epitopes that are
immunogenic and neutralization functional, and may be
responsible for at least some of the cross-reactive neutralizing
activity of his plasma. A better understanding of these epitopes
and their relationship to expanded coreceptor usage may
provide insights relevant for improving HIV-1 immunogenicity
and the elicitation of anti-HIV-1 neutralizing antibodies.
ThebroadusageofalternatecoreceptorssuggeststhattheEnv
of this primary virus has unique structural features that enhance
interaction with conserved structural elements in GPCRs. In the
V3 region, patient Envs had the unusual amino acid variants
Y308 (present in 1.5% of Clade B Envs, n=23,470), I317
(4.1%), and D321 (2.8%). Y308H and D321G mutations
increased the capacity of Env-30 to use CCR5 and to a lesser
extent CXCR4, but decreased the utilization of alternate
coreceptors, and an I317F mutation drastically decreased the
capacity of the Env to use any coreceptor. Structural modeling
suggests that a Y308 change in the JRFL crystal structure results
in steric clashing with F317 (the clade B consensus residue),
whereas the smaller side chain of Ile at this position is accom-
modated. Thus, I317 is likely to be a compensatory change for
Y308. D321 may enhance electrostatic interactions with the
positively charged N-terminus of CCR5 and other GPCRs.
These observations, together with evidence for covariation of
amino acids at positions 308/317 and 308/321 in vivo based on
database analysis, suggest that Y308, I317, and D321 may act
cooperatively to enhance Env–GPCR interactions. Env-30 used
Fig. 7. Env interactions with attenuated CCR5 coreceptors. HIV-1 luciferase
reporter viruses pseudotyped with each Env were generated and used to infect
Cf2th cells cotransfected with pcDNA3-CD4 and pcDNA3 expressing CCR5
(Y14N), CCR5 (Δ18), or CCR5 (G163R). Control virus was produced by
pseudotyping with ΔKS Env. Cell lysates were prepared at 60 h post-infection
and assayed for luciferase activity. Results for each mutant CCR5 were
normalized to levels of luciferase activity in cells expressing CCR5 (wt) for each
Env and are represented as means from two independent experiments, each
performed in duplicate. Error bars represent standard deviations.
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214CCR5(G163R), a mutant CCR5 which does not affect entry of
SIVmac251 but reduces entry of primary macrophage tropic
isolates such as ADA and SF162 (Kuhmann et al., 1997), for
entryatlevelscomparabletothosemediatedbyCCR5(wt).This
finding is consistent with the promiscuous coreceptor usage of
the patient isolate and Env-30, which resembles that of SIVor
HIV-2 (Edinger et al., 1998; Morner et al., 1999; Reeves et al.,
1997, 1999; Rucker et al., 1997). In addition to enhancing
utilization of alternative coreceptors, Y308 and D321 reduced
the dependence of Env-30 on the ECL2 region of CCR5, while
introducing the clade B consensus residues H308, H330, K442,
and E444 resulted in reduced dependence on the CCR5 N-
terminus.Thesefindingsareconsistentwithaproposedmodelin
which the tip of V3 interacts with ECL2 of GPCRs, while the
moreconservedstemandbaseofV3interactwiththeN-terminal
region(Huangetal.,2005;Xiangetal.,2005).K442andE444in
the C4 region may work in concert with the changes in V3 by
facilitating interactions with the highly acidic N-terminal region
of CCR5 and other GPCRs. Changes in other regions of Env,
such as those in the V1/V2 region that cooperatively modulate
coreceptor usage with V3 (Nabatov et al., 2004; Pastore et al.,
2006; Sullivan et al., 1993), may further enhance Env–core-
ceptor interactions. Based on our results, we propose that
changes in the V3 region of Env-30 cooperatively enhance
interactionswithconservedstructuralelementsinGPCRs,while
changes in the base of V3 and the C4 region may enhance
electrostatic interactions with the N-terminus of GPCRs.
AnalysisofpatientEnvsequencesrevealedauniqueinsertion
of 10 amino acids in the V1 region, and two asparagine-rich
insertions of 11 and 6 amino acids in the V2 region. Similar
extensionsintheV2regionhavebeenassociatedwithslowHIV-
1 progression or nonprogression (Shioda et al., 1997; Wang et
al., 2000). The V1 insertion in this subject is unusual compared
toothercladeBEnvs,andtheV1/V2regionislongerthanthatof
other Envs in the database. Changes in Env that reposition the
V1/V2 loops can increase exposure of the coreceptor binding
site(Kolchinskyetal.,2001).Thesefindingsraisethepossibility
that the unusually long V1/V2 region may reposition the V1/V2
loops, resulting in a conformation that enhances interaction of
gp120 with conserved elements in GPCRs. Conserved elements
in GPCRs important for HIV-1 entry include the tyrosine-rich
sulfated regions in the N-terminus, which are important for
CCR5-mediated HIV-1 entry (Farzan et al., 1999). GPCRs that
mediate entry by the primary virus have many tyrosine residues
within the N-terminus that are probably sulfated in close
proximity, similar to the pattern of sulfated tyrosine residues in
CCR5. Thus, the tyrosine-rich region in the N-terminus is likely
tobeoneoftheconservedelementsinGPCRsinvolvedinHIV-1
binding and virus entry.
The subject’s slow disease progression despite harboring a
dual-tropic HIV-1 strain with highly expanded coreceptor usage
may reflect additional viral and/or host factors that can in-
fluence HIV-1 progression. The primary virus had attenuated
replication kinetics in PBMC, CEMx174, and MDM compared
to several laboratory strains (Fig. 3A) and other primary viruses
(Gorry et al., 2001). However, we did not determine whether the
virus studied here was one of the majority sequences present in
the patient. Mutations in the nef gene can cause viral attenuation
and reduced pathogenicity of HIV-1 strains (Deacon et al.,
1995; Kirchhoff et al., 1995). However, we found no deletions
or other obvious defects in nef genes cloned from the primary
virus, which were fully functional for CD4 and MHC-I down-
regulation (K. Agopian and D. Gabuzda, unpublished data).
Further studies are required to determine whether the primary
virus contains any mutations in other viral genes that might be
associated with slow disease progression, and whether it is a
major variant in the patient viral quasispecies in vivo.
In summary, we describe an unusual dual-tropic HIV-1 strain
with highly expanded coreceptor usage isolated from an
asymptomatic individual who was heterozygous for the CCR5
Δ32 allele and had low CCR5 cell surface expression. In this
subject, highly expanded coreceptor usage of HIV-1 occurred
without progression to AIDS, suggesting that R5X4 HIV-1
strains with broadened coreceptor usage can be harbored by
some individuals without rapid disease progression. Our results
suggest that changes in the V3 and C4 regions, possibly a
consequence of adaptive evolution in the setting of very low
levels of CCR5 expression and viral escape from neutralizing
antibodies, act cooperatively to broaden coreceptor usage by
enhancing interactions with conserved structural elements in
GPCRs. These results lead to a better understanding of HIV
Env–GPCR interactions and provide insights that may faci-
litate development of vaccines and therapeutics that target virus
entry.
Materials and methods
Cells
Peripheral blood mononuclear cells were purified from blood
of healthy HIV-1-negative donors by Ficoll-Hypaque density
gradient centrifugation, stimulated with 2 μg/ml phytohemag-
glutinin (PHA) for 3 days and cultured in RPMI 1640 medium
supplemented with 10% (v/v) fetal bovine serum (FBS) and 20
U/ml interleukin-2 (IL-2; Boehringer Mannheim, Germany).
CD8+ T cells were depleted by magnetic separation with anti-
CD8-conjugated magnetic beads (Miltenyi Biotech, Auburn,
CA). Monocyte-derived macrophages were purified from
PBMC by plastic adherence and cultured for 5 days in RPMI
1640 medium supplemented with 10% (v/v) human AB+ serum
and 12.5 ng/ml M-CSF. Cf2-Luc cells (Etemad-Moghadam et
al., 2000), derived from the Cf2th canine thymocyte cell line
(Choe et al., 1996), stably express the luciferase gene under the
control of the HIV-1 LTR. Cf2-Luc cells were cultured in
DMEM medium supplemented with 10% (v/v) FBS, and
0.7 mg/ml G418. Cf2th cells were cultured in the same medium
without G418. CEMx174 cells were cultured in RPMI 1640
medium supplemented with 10% (v/v) FBS.
Isolation of HIV-1
HIV-1 was isolated from patient PBMC by coculture with
CD8-depleted donor PBMC as described previously (Gorry
et al., 2001). Briefly, 2×10
6 patient cells were added to
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6 CD8-depleted PBMC from a normal uninfected donor,
incubated at 37 °C for 1 h, and then cultured in 10 ml growth
media containing 20 U/ml IL-2. Fifty percent media changes
wereperformedtwiceweekly.FivemillionfreshPHA-activated,
CD8-depletedPBMCfromadifferentdonorwereaddedatevery
second media change. Supernatants were tested for reverse
transcriptase (RT) activity using [
3H]dTTP incorporation.
Supernatants testing positive for RT were filtered through
0.45 μm filters and stored at −80 °C.
Coreceptor usage
To determine coreceptor usage by the patient HIV-1 isolate,
Cf2-Luc cells were cotransfected with 10 μg of plasmid
pcDNA3-CD4 and 20 μg of plasmid pcDNA3 containing
CCR2b, CCR3, CCR5, CCR8, CXCR4, CX3CR1, Gpr1,
Gpr15, Strl33, Apj, CX3CR1, Rdc1, CCR7, CXCR1, CXCR2,
CXCR3, C5aRC9, D2DrsC9, DARC, D6 or FMLP-R using the
calcium phosphatemethod,andinfected48hlaterbyincubation
with10,000
3HcpmRTunitsofHIV-1inthepresenceof2μg/ml
polybrene as described previously (Gorry et al., 2001). Mock-
infected cells were treated with culture medium. Cf2-Luc cells
mock-transfected or transfected with pcDNA3-CD4 alone were
used as negative controls. After overnight infection, virus was
removed and the cells were cultured for an additional 48 h prior
to lysis in 200 μl cell lysis buffer. Cell lysates were cleared by
centrifugation, and assayed for luciferase activity according to
the manufacturers’ protocol (Promega).
HIV-1 replication kinetics
Five million PHA-activated PBMC were infected by
incubation with 50,000
3H cpm RT units of virus supernatant
in a volume of 2 ml for 3 h at 37 °C. Virus was then removed
and PBMC were washed 3 times with PBS and cultured in
media containing 20 U/ml IL-2 for 28 days. Monocyte-derived
macrophages were isolated from PBMC by plastic adherence
and allowed to mature for 5 days prior to seeding in 6-well
tissue culture plates at approximately 90% confluence. Virus
equivalent to 50,000
3H cpm RT units in a volume of 2 ml was
allowed to adsorb to the cell monolayers for 3 h at 37 °C. Virus
was then removed and cells were rinsed 3 times with PBS prior
to addition of 2 ml culture medium. Five million CEMx174
cells were infected by incubation with 50,000
3H cpm RT units
of virus supernatant in a volume of 2 ml for 3 h at 37 °C. Virus
was then removed and cells were washed 3 times with PBS and
cultured for 28 days. Fifty percent media changes were
performed twice weekly and supernatants were tested for
HIV-1 by RT assays.
Virus inhibition studies
The effects of the coreceptor inhibitors TAK-779 (Baba et
al., 1999) and AMD-3100 (Donzella et al., 1998; Schols et al.,
1997) on virus replication in PBMC were assayed as described
elsewhere (Gorry et al., 2002a; Trkola et al., 1998). Briefly,
PBMC were incubated for 30 min with a range of concentra-
tions of each inhibitor (0.01 to 100 μM) prior to infection with
the patient virus isolate. Virus replication was measured by
production of HIV-1 p24 antigen in culture supernatants for
14 days (Trkola et al., 1995). The production of p24 antigen in
the presence of an inhibitor was expressed as a percentage of the
amount producedin control cultures containing no inhibitor. For
virus inhibition studies in MDM, cells were preincubated with
100 nM TAK-779 or 1.2 μM AMD3100 for 1 h prior to
infection with HIV-1 isolates containing the same concentration
of inhibitor, as described previously (Gorry et al., 2001).
Infected cells were cultured for 21 days in the presence of each
inhibitor. Fifty percent media changes were performed weekly
and supernatants were tested for HIV-1 by RT assays.
Neutralization assays
Human monoclonal antibodies (MAb) against HIV-1 gp120
(IgG1b12 and 2G12) and gp41 (2F5), the tetrameric CD4-
immunoglobulin (CD4-IgG2) molecule, and purified polyclonal
anti-HIV immunoglobulin (HIVIG) have been described
previously (Allaway et al., 1995; Burton et al., 1991, 1994;
Mascola et al., 2002; Muster et al., 1994; Trkola et al., 1995,
1996). Neutralization of replication of the patient virus isolate in
PBMC was assessed as described previously (Trkola et al.,
1995). Briefly, virus was incubated for 30 min with a range of
concentrations of each Mab or CD4-Ig2 (0.01 to 100 μg/ml)
prior to infection. Virus replication and calculation of percent
neutralization were measured as described above. Neutraliza-
tion of heterologous viruses by the subject’s plasma was
assessed as described by Mascola et al. (2002).
PCR amplification, HIV-1 Env cloning and sequence analysis
Genomic DNA was extracted from PBMC infected with the
patient virus isolate using the DNeasy DNA extraction kit
(Qiagen). Full-length Env genes were amplified from genomic
DNA with RTth XL polymerase and nested primers using hot
s t a r tA m p l i W a xP C RG e m5 0( A p p l i e dB i o s y s t e m s ) ,a s
described previously (Gorry et al., 2002a). Env PCR-product
DNAwas gel purified and cloned into pCR3.1-Uni (Invitrogen).
Functional full-length Env clones were identified by Western
blot analysis of gp120/gp160 in transfected 293T cells and by
fusion assays. Env clones were sequenced using a model 3100
Genetic Analyzer (Applied Biosystems). Y308H, I317F,
D321G, Y330H, T332N, K442Q, and E444R mutant Env
plasmids were created by PCR-based mutagenesis and changes
were verified by DNA sequencing.
Western blot analysis
For analysis of Env expression, 293T cells were transfected
with 15 μg of different pCR3.1 Env clones, or 15 μg pSVIII
plasmid expressing ADA, HXB2 or 89.6 Env plus 2 μg pLTR-
Tat plasmid. At 72 h after transfection, cells were rinsed twice in
PBS and resuspended in 400 μl of ice-cold lysis buffer for
20 min, followed by centrifugation at 15,300×g for 10 min to
remove cellular debris. Cell lysates were separated in 8.5%
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216SDS-PAGE gels, and analyzed by Western blotting using rabbit
anti-gp120 polyclonal antisera (American Biotechnologies Inc.)
orgoat anti-gp120 polyclonal antisera (NIH AIDS Research and
Reference Reagent program). Env proteins were visualized
using horseradish peroxidase-conjugated anti-rabbit or anti-goat
immunoglobulin G antibodies and enhanced chemilumines-
cence (Perkin Elmer).
Fusion assays
293Tcells (1×10
5) cotransfected with 15 μg Env-expressing
plasmid and 2 μg pLTR-Tat were mixed with Cf2-Luc cells
(1×10
6) that had been cotransfected with 10 μg pcDNA3-CD4
and 20 μg pcDNA3 expressing an alternative coreceptor as
indicated, then incubated at 37 °C in 0.75 ml culture medium.
Mock-transfected Cf2-Luc cells were transfected with pLTR-
Tat only. Control 293T cells were cotransfected with pLTR-Tat
and a non-functional Env (pSVIII-ΔKS Env). Twelve hours
later, cells were harvested and assayed for luciferase activity as
described above.
Single round entry assays
AnEnvcomplementation assay was used to quantitate HIV-1
entryasdescribed(Choeetal.,1996).Briefly,recombinantHIV-
1 luciferase reporter viruses were generated by cotransfection of
293T cells by the calcium phosphate method with 16 μgo f
pNL4-3env
− Luc, which contains an HIV-1 provirus with a
deletion in the env gene and a replacement of the nef gene with a
luciferase gene, and 6 μg of pCR3.1Env or pSVIIIEnv plasmid.
Cf2th cells intended for use as target cells were cotransfected
with 10 μg pcDNA3-CD4 and 20 μg pcDNA3 expressing an
alternative coreceptor as indicated. Plasmids expressing CCR5
(Y14N), CCR5 (Δ18), and CCR5 (G163R) were kindly
provided by D. Kabat. Approximately 48 h after transfection,
these cells were infected by incubation with 20,000
3H cpm RT
unitsofrecombinantluciferasereporterviruses.Reporterviruses
pseudotyped with a non-functional Env (pSVIII-ΔKSenv) were
used as negative controls. Sixty hours later, cells were harvested
and assayed for luciferase activity.
Nucleotide sequence accession numbers
Nucleotide sequences were submitted to GenBank (acces-
sion numbers AY624304 through AY624307).
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Abstract
Binding to the CD4 receptor induces conformational changes in the human immunodeficiency virus (HIV-1) gp120 exterior
envelope glycoprotein. These changes allow gp120 to bind the coreceptor, either CCR5 or CXCR4, and prime the gp41
transmembrane envelope glycoprotein to mediate virus–cell membrane fusion and virus entry. Soluble forms of CD4 (sCD4)
and small-molecule CD4 mimics (here exemplified by JRC-II-191) also induce these conformational changes in the HIV-1
envelope glycoproteins, but typically inhibit HIV-1 entry into CD4-expressing cells. To investigate the mechanism of
inhibition, we monitored at high temporal resolution inhibitor-induced changes in the conformation and functional
competence of the HIV-1 envelope glycoproteins that immediately follow engagement of the soluble CD4 mimics. Both
sCD4 and JRC-II-191 efficiently activated the envelope glycoproteins to mediate infection of cells lacking CD4, in a manner
dependent on coreceptor affinity and density. This activated state, however, was transient and was followed by
spontaneous and apparently irreversible changes of conformation and by loss of functional competence. The longevity of
the activated intermediate depended on temperature and the particular HIV-1 strain, but was indistinguishable for sCD4
and JRC-II-191; by contrast, the activated intermediate induced by cell-surface CD4 was relatively long-lived. The
inactivating effects of these activation-based inhibitors predominantly affected cell-free virus, whereas virus that was
prebound to the target cell surface was mainly activated, infecting the cells even at high concentrations of the CD4
analogue. These results demonstrate the ability of soluble CD4 mimics to inactivate HIV-1 by prematurely triggering active
but transient intermediate states of the envelope glycoproteins. This novel strategy for inhibition may be generally
applicable to high–potential-energy viral entry machines that are normally activated by receptor binding.
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Introduction
The entry of human immunodeficiency virus type 1 (HIV-1) into
target cells is mediated by the trimeric envelope glycoprotein
complex, which consists of three gp120 exterior envelope
glycoproteins and three gp41 transmembrane envelope glycopro-
teins [1]. Binding of gp120 to the receptor, CD4, on the target cell
surface induces major conformational changes in the envelope
glycoproteins [2]. These changes allow gp120 to bind the viral
coreceptor, either CXCR4 or CCR5 [3–7]. CD4 binding also
induces the formation of a gp41 pre-hairpin intermediate, in which
three hydrophobic grooves on the surface of a coiled coil formed by
the heptad repeat 1 (HR1) region of gp41 are exposed [8–10].
These hydrophobic grooves are subsequently occupied by helices
from the gp41 heptad repeat 2 (HR2) region, during the formation
of an energetically stable six-helix bundle that is thought to drive the
fusion of the viral and target cell membranes [9,11,12].
In contrast to the activating effect of cell-surface CD4 on HIV-1
entry, the soluble form of CD4 (sCD4) demonstrates opposing
effects on HIV-1 infectivity at different concentrations. At high
concentrations, sCD4 neutralizes most HIV-1 strains [13]; at
lower sCD4 concentrations, the infectivity of some HIV-1 strains
can be modestly enhanced [14]. This enhancing effect of sCD4 is
more prominent in some strains of the related primate
immunodeficiency viruses, HIV-2 and simian immunodeficiency
virus (SIV), where sCD4 can efficiently replace cell-surface CD4 to
drive infection of CD4
2CCR5
+ cells [15,16].
Based on the potential of sCD4 to inhibit HIV-1 infection in
vitro, this protein was tested for clinical efficacy in HIV-1-infected
individuals; however, no effect on plasma viral loads was observed
[13]. Further examination revealed that doses of sCD4 that were
significantly higher than those achieved in the clinical trial were
required to neutralize primary clinical isolates of HIV-1, in
contrast to the relatively sensitive, laboratory-adapted strains [17].
Interest in improving the therapeutic potential of sCD4 has
prompted investigation of the mechanistic basis for sCD4-induced
neutralization. Competitive inhibition of envelope glycoprotein
binding to the cell-surface CD4 receptor was suggested as a major
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222mechanism of sCD4 neutralization [17,18]. Resistance to sCD4
may thus arise by a decreased affinity of the envelope glycoprotein
complex for sCD4 [13]. However, sCD4 sensitivity cannot always
be predicted by measurements of affinity [17,19–21]. Binding of
sCD4 to the envelope glycoprotein trimer can induce detachment
(shedding) of the gp120 subunit from the envelope glycoprotein
trimer [17,18,22–24]. However, the sCD4 concentrations that are
required to elicit shedding are significantly higher than those
required to neutralize the virus [25,26]. In addition, for some
HIV-1 strains, the temperature dependence of sCD4-induced
gp120 shedding and virus neutralization differs [26]. The mode of
sCD4-mediated inhibition thus remains incompletely understood.
Targeting the functionally important and therefore conserved
CD4-binding site on HIV-1 gp120 represents an attractive
potential approach to therapy or prophylaxis. CD4-mimicking
peptides and oligomeric forms of sCD4 that target this site on
primary HIV-1 isolates have been developed [27–30]. Recently, a
new class of small-molecule CD4 mimics was identified [31,32].
These compounds, which include the prototypic compound NBD-
556 and its derivatives, mimic the effects of CD4 by inducing the
exposure of the coreceptor-binding site on gp120 [31,33].
Although NBD-556 inhibits HIV-1 infection of CD4
+CCR5
+
cells, it can replace CD4 and thus enhance HIV-1 infection of
CD4
2CCR5
+ cells [31]. In view of their capacity to enhance
infectivity, any potential application of CD4-mimetic compounds
and sCD4 derivatives, herein referred to as soluble CD4 mimics
(SCMs), would benefit from a mechanistic understanding of these
activating and inhibitory effects.
The study of receptor-induced conformational changes of the
HIV-1 envelope glycoprotein complex is still limited by the lack of
tools that enable monitoring of this dynamic multi-step process.
Detection of conformational intermediates is largely based on the
use of conformation-specific fusion/entry inhibitors, which are
added at different times after initiation of the fusion process [34–
38]. Although such assays have provided insights into the
mechanisms of gp41-directed inhibitors, they fail to detect
transitions to conformations that are inactive and do not
differentiate between lack of inhibitor binding and lack of
inhibition. Furthermore, because formation of the ternary
complex between the envelope glycoproteins, CD4 and coreceptor
constitutes a major rate-limiting step in the membrane fusion
process, these approaches are limited in their capacity to define the
progression of subsequent events [39]. Finally, due to the low
temporal resolution of most systems, mainly steady-state confor-
mations are detected, while intermediate states of the complex
may be missed.
To overcome these limitations, we developed new systems that
allow us to monitor the dynamic changes in conformation and
function of the HIV-1 envelope glycoproteins, immediately after
engagement of the activating molecules. Using these tools, we
found that SCMs inactivate envelope glycoprotein function by an
activation-triggered inhibition process, through induction of a
metastable activated state.
Materials and Methods
Reagents and Antibodies
Four-domain sCD4 (molecular weight 50 kDa) was expressed in
293F cells after stable transfection. The protein was secreted into
the cell culture medium and then purified by using the C-terminal
His6 tag, as previously described [40]. The structure of compound
JRC-II-191 (herein referred to as 191) is reported in reference
[33]. The CCR5 antagonist ‘Compound A’ [4-nitrobenzyl 1-(3-
(N-methylphenylsulfonamido)-3-phenylbutyl)piperidin-4-yl(vinyl)-
carbamate] [41,42] was kindly provided by Dr. Martin Springer
at Merck Research Laboratories, Rahway, NJ.
The anti-gp120 monoclonal antibody 48d, which recognizes an
epitope that overlaps the coreceptor-binding site, was kindly
provided by Dr. James Robinson (Tulane University Medical
Center) [43]. The monoclonal antibodies IgG1 b12 and 39F
recognize the CD4-binding site and the V3 loop of gp120,
respectively [44,45]. The C34-Ig fusion protein consists of the Fc
region of human IgG1 linked to the HR2 region of the HXBc2
envelope glycoprotein (amino acid residues 628–661, numbered
according to current convention [46]). C34-Ig was produced and
purified as previously described [47]. The CD4-Ig fusion protein
consists of the first two N-terminal domains of the CD4 molecule
and the Fc region of human IgG1. Purification was carried out as
described for the C34-Ig molecule [47].
Envelope Glycoprotein Constructs
The primary viruses UK7br and UK7br34 were isolated from
autopsy brain tissue from an AIDS patient with HIV-1 associated
dementia [48]. These envelope glycoproteins were expressed from
the pcDNA 3.1 backbone vector. All other envelope glycoproteins
described were expressed from the pSVIIIenv vector [49]. The
YU2, AD8, JR-FL, 89.6 and KB9 env sequences from Asp 718 (Kpn
I) to BamH I were substituted for the corresponding HXBc2 env
sequences in the original pSVIIIenv vector. The DKS construct,
whichcontains anHIV-1HXBc2 envgene with a large deletion,was
used as a negative control. The YU2(Dct) protein has a truncated
cytoplasmic tail of 17 amino acids, with a stop codon introduced
after Ala 710 (numbered according to current convention [46]).
The YU2-GS8 construct is a cleavage-defective form of the
YU2 HIV-1 envelope glycoproteins that contains an 8-amino acid
glycine-serine linker at the gp120/gp41 junction. Starting with the
cytoplasmic tail-deleted YU2 envelope glycoproteins, both Arg
508 and Arg 511 near the furin cleavage site were altered to Ser to
render the protein cleavage-defective. The 8-amino acid linker,
Gly-Gly-Gly-Ser-Gly-Gly-Gly-Ser, was then inserted between Ser
511 (the C-terminal residue of gp120) and Ala 512 (the N-terminal
residue of gp41) using the overlapping PCR method.
Cell-Based Enzyme-Linked Immunosorbent Assay (ELISA)
A sensitive cell-based ELISA with high temporal resolution was
developed to measure the binding of antibodies to HIV-1 envelope
Author Summary
Human immunodeficiency virus type 1 (HIV-1) is the cause
of the global AIDS epidemic. HIV-1 gains entry into its
target cells by fusing with the cell membrane, a process
that begins with the interaction of the viral envelope
glycoproteins with cell-surface receptors. HIV-1 uses two
receptors on the target cell: CD4 and CCR5/CXCR4. Binding
of the virus to the primary receptor, CD4, primes the viral
envelope glycoproteins to mediate the fusion of the viral
membrane and the membrane of the target cell. Soluble
forms of the CD4 receptor and small molecules that mimic
the effects of CD4 can inhibit virus infection; however, how
this inhibition occurs is still unknown. In this report, we
show that soluble mimics of CD4 inhibit HIV-1 infection by
prematurely triggering the viral envelope glycoproteins.
The unstable activated state of the virus lasts only a few
minutes, after which the virus loses the ability to infect
cells. This novel strategy for inhibition may be generally
applicable to other viruses besides HIV-1, some of which
are also activated by binding to their receptors.
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223glycoprotein trimers expressed on cells. COS-1 cells were seeded
in 96-well plates (2.4610
4 cells per well) and transfected the next
day with 0.1 mg of a plasmid expressing the envelope glycoproteins
and 0.01 mg of a Tat-expressing plasmid per well using the
Effectene transfection reagent (Qiagen). Two days later, cells were
washed twice with blocking buffer (35 mg/ml BSA, 10 mg/ml
non-fat dry milk, 1.8 mM CaCl2, 1 mM MgCl2, 25 mM Tris,
pH 7.5 and 140 mM NaCl). For pulse activation experiments, the
COS-1 cells were incubated with sCD4 (40 mg/ml, 0.8 mM) or
191 (360 mM) suspended in blocking buffer for three minutes,
washed three times with blocking buffer and incubated for
different time periods until the C34-Ig or 48d antibodies were
added (at 40 mg/ml or 1 mg/ml, respectively, for 30 minutes). To
study the temperature dependence of HR1 groove exposure, the
sCD4-pulsed cells were incubated at the requisite temperature for
different lengths of time; the cells were subsequently returned to
room temperature for incubation with C34-Ig. Cells were then
washed four times with blocking buffer and four times with
washing buffer (140 mM NaCl, 1.8 mM CaCl2, 1 mM MgCl2 and
20 mM Tris, pH 7.5). A horseradish peroxidase-conjugated
antibody specific for the Fc region of human IgG was then
incubated with the samples for 45 minutes at room temperature.
Cells were washed 5 times with blocking buffer and 5 times with
washing buffer. HRP enzyme activity was determined after the
addition of 33 ml per well of a 1:1 mix of Western Lightning
oxidizing and luminol reagents (Perkin Elmer Life Sciences)
supplemented with 150 mM NaCl. Light emission was measured
with a Mithras LB 940 luminometer (Berthold Technologies). For
experiments that measure the rate of decay of C34-Ig or 48d
antibody binding, the indicated values for the amount of antibody
bound were obtained by subtracting binding measured in the
absence of sCD4 from the binding measured at each time point
after the sCD4 pulse.
HR1 Groove Exposure Induced by Cell-Surface CD4
293T cells cultured in 6-well plates were transfected with the
pcDNA3.1-CD4 or DKS constructs (1 mg per 1.8610
6 cells) using
the Effectene reagent (Qiagen). COS-1 cells cultured in 96-well
plates were transfected with plasmids expressing the HIV-1
envelope glycoproteins as described above. Two days later, the
293T cells were harvested using 5 mM EDTA in PBS and added
at 4uC to the monolayer of COS-1 cells (3610
5 293T cells per
well). Cells were subsequently centrifuged at 1,0006g for two
minutes to increase contact and incubated at 4uC for 75 minutes.
Samples were then washed once with blocking buffer and rapidly
equilibrated to 25uC. C34-Ig was then added at different times.
Detection of C34-Ig binding was performed as described above.
Fluorescence-Activated Cell Sorting (FACS) Analysis of
Ligand Binding to Cell-Surface HIV-1 Envelope
Glycoproteins
Flow cytometry was used to detect the binding of C34-Ig to
293T cells that express the cytoplasmic tail-deleted (Dct) HIV-1
envelope glycoproteins [47]. Cells were cultured in 6-well plates
(1.5610
6 cells per well) and transfected with 0.6 mg of a plasmid
expressing the HIV-1 envelope glycoproteins and 0.06 mgo fa
Tat-expressing plasmid using the Effectene transfection reagent
(Qiagen). Two days later, cells were detached using PBS
supplemented with 5 mM EDTA and resuspendend in FACS
buffer (PBS supplemented with 10 mg/ml BSA and 0.5 mg/ml
sodium azide). Cells were then incubated with C34-Ig suspended
in FACS medium, with or without sCD4, at the indicated
temperature for 45 minutes. Following three washes with FACS
buffer, cells were incubated at room temperature for 45 minutes in
FACS buffer containing a phycoerythrin-conjugated goat anti-
human IgG antibody (Sigma) and an anti-CD4 fluorescein-
conjugated antibody (OKT4, eBioscience) to measure C34-Ig
and sCD4 binding, respectively. Cells were subsequently washed
three times with FACS buffer and analyzed with a FACScan
analyzer (Becton Dickinson) using Cellquest software for data
acquisition and analysis.
Generation and Preparation of Recombinant Luciferase-
Expressing Viruses
Single-round, recombinant HIV-1 viruses that express the
luciferase reporter gene were generated by transfection of 293T
cells using the calcium phosphate transfection method (Promega).
Cells were seeded in 100-mm tissue culture dishes (approximately
4610
6 cells per dish) and transfected the next day with 10 mgo f
the HIV-1 packaging construct pCMVDP1DenvpA [50], 10 mgo f
the firefly luciferase-expressing construct pHIvec2.luc and 2.5 mg
of the plasmid expressing the HIV-1 Rev and envelope
glycoproteins. Sixteen hours following transfection, the medium
was changed to culture medium (Dulbecco-modified Eagle
medium supplemented with 10% fetal calf serum, DMEM/FCS
10%); 12 hours later, the medium was changed to DMEM/FCS
1%. Virus-containing supernatants were collected 12 hours later,
cleared of cell debris by low speed centrifugation and filtered
through 0.2 mm filters. Preparations were subsequently loaded
onto Float-A-Lyzer dialysis cassettes (molecular weight cutoff
100 kDa, Spectrum Labs) and dialyzed against HS buffer
(140 mM NaCl, 10 mM HEPES, pH 7.3) for 24 hours at 4uC.
Viral preparations were subsequently aliquoted and stored at
280uC until use.
Magnetically Controlled Infection by sCD4-Activated HIV-
1
To minimize the time interval between activation of the virus
and attachment to the cells, we magnetically controlled the
attachment step. As a magnetically controllable carrier, we used
magnetite nanoparticles (50 nm in diameter) that are coated by a
starch polymer with phosphate end groups (FluidMag PD,
Chemicell). Viruses were preincubated with magnetite nanopar-
ticles (1.2 mg/ml) for 7 minutes at room temperature, followed by
incubation with sCD4 (40 mg/ml) for different time periods.
Preparations were then added to a confluent monolayer of cells
cultured in a 96-well plate, to which was applied a magnetic field
using a Nd-Fe-B permanent magnet (OZ Biosciences). Canine
thymocyte Cf2Th cells that express CCR5 or both CD4 and
CCR5 were used as target cells (approximately 7610
4 cells per
well). After a one-minute incubation at room temperature, cells
were washed twice with DMEM/FCS 10% and cultured for an
additional 14 hours. Cells were then detached with trypsin-EDTA
and seeded again at a 1:6 dilution. Forty-eight hours after
infection, cells were lysed with passive lysis buffer (Promega) and
lysates were assayed for luciferase activity. To each well was added
100 ml of luciferin buffer (15 mM MgSO4, 15 mM KPO4
[pH 7.8], 1 mM ATP, and 1 mM dithiothreitol) and 50 mlo f
1 mM D-luciferin potassium salt (BD Pharmingen). Luminescence
was recorded using a Berthold LB 960 microplate luminometer.
Decay Rate of Virus Infectivity after Pulse Activation with
sCD4
The decay rate of virus infectivity after activation by sCD4 was
measured using magnetically-immobilized viruses. This method
allows rapid pulsing and washing of the virus before addition of
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224target cells; thus, virus infectivity shortly after activation can be
measured. Virus preparations were preincubated with magnetite
nanoparticles (1.2 mg/ml, suspended in HS buffer) for 7 minutes
and then added to 96-well plates placed over a permanent Ne-Fe-
B magnet (OZ Biosciences). After a 4-minute incubation at room
temperature, wells were washed twice with culture medium.
Immobilized viruses were then pulsed with 40 mg/ml (0.8 mM)
sCD4 for 3 minutes, washed twice with culture medium and then
incubated at room temperature for different time periods. Cf2Th-
CCR5 cells suspended in culture medium (,1610
5 cells) were
then added to the wells and centrifuged at 1,0006g for 2 minutes
to expedite contact between cells and viruses. Luciferase activity
was measured two days later.
Decay Rate of Virus Infectivity after Pulse Activation with
Compound 191
The affinity of NBD-556 analogues, including 191, for the
HIV-1 gp120 envelope glycoprotein is significantly lower than that
of sCD4 [31,33]. Measured by isothermal titration calorimetry,
the Kd of 191 binding to the YU2 gp120 envelope glycoprotein is
760 nM, compared with a Kd of approximately 2 nM for the
sCD4-gp120 interaction. At achievable concentrations, 191
induced significantly lower levels of HIV-1 activation than sCD4
(see Results section); levels of infectivity were consequently too low
to be monitored for decay. We therefore introduced a number of
modifications to the method described above for measuring
infectivity decay. Briefly, viruses were incubated with 180 mM 191
at 37uC for 10 minutes. Activation was then halted by a 20-fold
dilution of the virus-compound mix in HS buffer equilibrated to
26uC. After dilution, no additional activation of HIV-1 infection
was induced by 191 during the time frame of the experiment (data
not shown). Samples were then incubated for different time
periods, associated with magnetite nanoparticles and magnetically
adsorbed to confluent cultures of Cf2Th-CCR5 cells, as described
above.
Infectivity of Cell-Bound Virus Activated by sCD4
Cf2Th cells cultured in 6-well plates (6610
5 cells per well) were
transfected with different amounts of the pcDNA3.1-CCR5
plasmid, which expresses human CCR5, using the Effectene
transfection reagent. Two days later, cells were detached using
5 mM EDTA in PBS and re-seeded in 96-well plates (7610
5 cells
per well). Viruses were then magnetically adsorbed to the
transfected cells in the presence of 20 mg/ml (400 nM) sCD4 in
the culture medium and infectivity was measured two days later.
Results
Rescue of the Infectivity of sCD4-Treated HIV-1 by Rapid
Attachment to Cells
Soluble CD4 mimics (SCMs) can exert varied effects on HIV-1
infection of CD4
+ and CD4
2 target cells. Although soluble CD4
(sCD4) typically inhibits HIV-1 infection of CD4
+CCR5
+ cells,
enhancement of HIV-1 infection of CCR5
+ cells lacking CD4 is
sometimes seen after sCD4 treatment [14]. Sensitivity to these
effects varies among different HIV-1 strains [49]. We examined
the sensitivity to sCD4 of recombinant HIV-1 viruses (designated
HIV-1(AD8) and HIV-1(YU2), respectively) pseudotyped with the
envelope glycoproteins of the primary HIV-1 isolates AD8 and
YU2, which have similar binding affinities for sCD4 [51,52]. In
CD4
+CCR5
+ target cells, sCD4 inhibited the infectivity of HIV-
1(AD8) and HIV-1(YU2) with IC50 values of 80 nM (4 mg/ml)
and 12 nM (0.6 mg/ml), respectively (Figure 1A). In CD4
2CCR5
+
cells, sCD4 activated infection of HIV-1(AD8) much more
efficiently than that of HIV-1(YU2).
A similar pattern of HIV-1 activation and inactivation was
observed for the NBD-556 analogue, JRC-II-191, herein referred to
as 191. The affinity of 191 for the HIV-1YU2 gp120 envelope
glycoprotein (Kd=760 nM) is significantly lower than that of sCD4
(Kd=,2 nM). Nevertheless, at proportionately higher concentra-
tions, 191 resembled sCD4, inhibiting HIV-1 infection of
CD4
+CCR5
+ cells and enhancing infection of CD4
2CCR5
+ cells
(Figure 1B). For both sCD4 and 191, the enhancement of infection
of cells lacking CD4 became progressively less efficient at higher
concentrations; in some cases, decreases in viral infectivity were
associated with escalating doses. These characteristics of HIV-1
envelope glycoproteins differ from those observed with several SIV
envelope glycoproteins, which demonstrate increasingly efficient
infection of CD4
2CCR5
+ cells with increasing sCD4 concentra-
tions (data not shown, and ref. [15]). These observations suggested
the existence of a concentration-dependent, virus-inhibitory process
superimposed on the HIV-1 activation process.
Because virus attachment to cells in culture progresses in a slow,
diffusion-dependent manner [53,54], significant time intervals can
elapse between virus binding by SCMs and the association
between virus and cell. Thus, the diminished capacity of the SCMs
Figure 1. Inhibition and activation of infection by sCD4 and the CD4-mimetic compound 191. Recombinant HIV-1(YU2) or HIV-1(AD8)
strains were incubated with CD4
2CCR5
+ or CD4
+CCR5
+ Cf2Th cells for 48 hours in the presence of sCD4 (A) or 191 (B). Infectivity was determined by
measurement of luciferase activity. (C) HIV-1(YU2) was incubated for three minutes in the presence or absence of sCD4 (40 mg/ml, 0.8 mM) and then
adsorbed by diffusion or magnetically to cultures of the indicated cell type. Measured luciferase activity is presented as mean relative light units
(RLU)6standard error of the mean (s.e.m.) of three replicate samples.
doi:10.1371/journal.ppat.1000360.g001
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225to enhance HIV-1 infection of CD4
2CCR5
+ cells at higher
concentrations might reflect the involvement of time-dependent as
well as concentration-dependent processes that abrogate infectivity
after activation occurs. To test this possibility, we examined the
effect of neutralizing concentrations of sCD4 on HIV-1(YU2)
infection when the time interval between sCD4-virus binding and
virus-cell attachment was reduced. For this purpose, we applied a
system that magnetically controls virus motion to eliminate viral
dependence on passive diffusion for cell attachment; this system
allows near-complete transfer of the virus inoculum to the cell-
bound state within one minute [53,55]. When HIV-1(YU2) was
briefly incubated with a high concentration of sCD4 and then
added to CD4
2CCR5
+ cells, infection occurred only when the
virus was magnetically adsorbed to the cells (Figure 1C). These
results suggested the possibility of a time-dependent process that
decreases HIV-1 infectivity after activation by sCD4, and
prompted us to measure the stability of the sCD4-activated
intermediate form of the HIV-1 envelope glycoproteins.
Conformational Stability of the CD4-Activated
Intermediate
Engagement of CD4 induces a major structural rearrangement
of the HIV-1 envelope glycoproteins [2]. Two functionally
important regions of the HIV-1 envelope glycoproteins are formed
and exposed as a result of CD4 binding: i) the coreceptor-binding
site on the gp120 envelope glycoprotein [3–7,56]; and ii) the
trimeric coiled coil composed of the N-terminal heptad repeat
(HR1) regions of the three gp41 subunits [8–10,47]. To investigate
the conformational stability of the sCD4-activated envelope
glycoprotein intermediate, we monitored changes over time in
the exposure of the coreceptor-binding site on gp120 and the HR1
coiled coil on gp41 after pulse activation by sCD4.
To measure the progression of conformational changes that
immediately follow HIV-1 envelope glycoprotein activation, we
developed a novel enzyme-linked immunosorbent assay (ELISA)-
based system that utilizes live cells as a platform for expression of
membrane-bound trimeric envelope glycoprotein complexes The
system allowed sensitive detection of ligand binding to full-length
envelope glycoproteins at high temporal resolution. COS-1 cells
that express the HIV-1YU2 envelope glycoproteins were pulse-
activated with sCD4 at 37uC for 3 minutes and incubated at 37uC
for different time periods. The following probes were then added:
i) monoclonal antibody 48d, which binds to a gp120 epitope that
overlaps the coreceptor-binding site [43]; or ii) the C34-Ig protein,
which is composed of the C34 peptide corresponding to the gp41
HR2 region linked to the Fc constant region of human IgG1 [47].
C34-Ig binds to the hydrophobic groove formed at the interface of
the HR1 coiled-coil helices [10,47]. The sCD4 pulse significantly
enhanced the binding of the C34-Ig protein and the 48d antibody
to the HIV-1 envelope glycoproteins (Figure 2A and 2B). The time
interval between the sCD4 pulse and addition of the 48d antibody
did not affect the level of 48d binding observed (Figure 2B). Thus,
after the sCD4-induced conformational change, the epitope of the
48d antibody remains stably exposed over the time period
examined.
In contrast to the above results, the exposure of the C34-Ig
binding site after the sCD4 pulse was transient at 37uC (Figure 2C).
Stability of the HR1-exposed state was highly dependent on the
temperature of incubation (Figure 3A). Although sCD4 efficiently
bound to the envelope glycoprotein complex and induced the
formation/exposure of the HR1 groove at 4, 25 and 37uC, this
state was stable only at lower temperatures (Figure 3B). The loss of
exposure of the HR1 groove was not reversible by repeated
pulsing of the envelope glycoprotein complexes with saturating
concentrations of sCD4 (data not shown). At the different
temperatures examined, in the absence of sCD4, C34-Ig binding
was similar to that measured for the negative control cells
transfected with the DKS plasmid. No correlation was observed
between the temperature of incubation and the binding of C34-Ig
in the absence of sCD4.
Given the constant level of 48d antibody binding to the sCD4-
pulsed envelope glycoprotein-expressing cells, the observed time-
dependent decrease in C34-Ig binding cannot be attributed to
changes in cell-surface levels of the envelope glycoproteins, as
might occur due to gp120 shedding [17]. Moreover, we observed
that sCD4 binding to the cells remained constant over the time
period examined. We performed a kinetic experiment to measure
the decay of HR1 exposure using FACS analysis. The binding of
sCD4 and C34-Ig to the envelope glycoprotein-expressing cells
was measured simultaneously at different time points after the
sCD4 pulse, using phycoerythrin- and fluorescein-conjugated
secondary antibodies. We observed a gradually decreasing
capacity of C34-Ig to bind despite constant levels of bound
sCD4 (Figure S1).
In summary, after engagement of sCD4, the HIV-1 envelope
glycoprotein complex undergoes conformational changes that
result in formation/exposure of the gp120 coreceptor-binding site
and the gp41 HR1 groove. However, despite continued
engagement of sCD4 and stable exposure of the 48d epitope on
gp120, the induced envelope glycoprotein intermediate undergoes
a spontaneous temperature-dependent and apparently irreversible
change of conformation.
Decay of Exposure of the HR1 Groove on Envelope
Glycoproteins from Different HIV-1 Strains
The decay profile of sCD4-induced HR1 groove exposure was
determined for a panel of envelope glycoproteins from primary and
laboratory-adapted HIV-1 strains. Measurements were conducted
at room temperature (24–26uC) to slow the rate of decay, allowing
greater accuracy. Interestingly, a wide range of stabilities of the
HR1 groove-exposed state was observed in the different HIV-1
envelopeglycoproteins(Figure 4A). For example,theYU2and AD8
envelope glycoproteins exhibited half-lives of 5 and 100 minutes,
respectively. The different decay rates of HR1 groove exposure
could not be explained by differences in the affinity of the trimeric
envelope glycoprotein complexes for sCD4 (Figure S2A), or in
kinetic differences in CD4-Ig binding to these complexes (Figure
S2B). We also found that the deletion of the gp41 cytoplasmic tail
had no effect on the stability of the CD4-activated intermediate
(Figure S2C), even though the cell-surface level of envelope
glycoprotein expression was increased, as expected [57].
Envelope glycoproteins from HIV-189.6 and HIV-1KB9 exhib-
ited highly stable sCD4-induced intermediates that did not
appreciably decay at room temperature for up to 1 hour after
the sCD4 pulse. For these envelope glycoproteins, the half-lives of
the HR1-exposed state measured at 37uC were 16 and
17 minutes, respectively (Figure S2D).
Correlation between Stability of the HR1 Groove and
Functional Stability of the HIV-1 Envelope Glycoproteins
after sCD4 Exposure
Does the sCD4-induced conformational instability in the HIV-1
envelope glycoproteins have consequences for virus infectivity? To
examine this question, we devised a strategy to measure changes
over time in the capacity of sCD4-activated virus to infect
CD4
2CCR5
+ cells. First, recombinant, luciferase-expressing
viruses were associated with magnetite nanoparticles and immo-
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226bilized on tissue-culture plates by constant application of a
magnetic field. Next, the immobilized viruses were pulsed with
sCD4 for 3 minutes and incubated at 25uC for different time
periods. Then, CD4
2CCR5
+ cells were added and immediately
pelleted onto the immobilized viruses. Infectivity was assessed by
measuring luciferase activity in the cells 48 hours later. The levels
of initial infectivity for viruses pseudotyped with the different HIV-
1 envelope glycoproteins were significantly increased by incuba-
tion with sCD4 (data not shown). However, infectivity subse-
quently declined at different rates for viruses with different
envelope glycoproteins (Figure 4B). Similar to the stability of HR1
groove exposure, the rate of decay of infectivity was highly
dependent upon temperature (Figure S3). At room temperature,
the half-life of infectivity exhibited by the sCD4-treated viruses
pseudotyped with different HIV-1 envelope glycoproteins corre-
lated well with the half-life of the HR1 groove-exposed state
following incubation with sCD4 (R
2=0.9374, Figure 4C).
Assuming that the linear regression model generated using the
data obtained at 25uC applies to the situation at 37uC, we first
estimated the half-lives of HIV-1 infectivity by fitting the half-lives
of HR1 groove exposure measured at 37uC to the model. For the
most stable envelope glycoproteins (derived from HIV-189.6 and
HIV-1KB9), we estimated a maximal half-life of infectivity of 5–
7 minutes at 37uC. In accordance with the predicted values, the
measured half-lives of infectivity at 37uC for viruses containing the
KB9 and 89.6 envelope glycoproteins were 7 and 8 minutes,
respectively, after the sCD4 pulse (Figure S2E).
We compared the infectious half-lives of viruses with different
HIV-1 envelope glycoproteins following incubation with sCD4
(using CD4
2CCR5
+ cells, as described above) and without sCD4
treatment (using CD4
+CCR5
+ cells). Incubation of the viruses at
37uC for increasing time periods in the absence of sCD4, followed
by infection of CD4
+CCR5
+ cells, revealed a gradual reduction of
infectivity, with half-lives ranging from 6.9 to 12.1 hours (Figure
Figure 2. Soluble CD4-induced changes in the gp120 coreceptor–binding region and gp41 HR1 region. (A) A cell-based ELISA was used
to measure the binding of C34-Ig, which detects the HR1 gp41 region [38,47], to the trimeric HIV-1 envelope glycoproteins. COS-1 cells were
transfected with the negative control DKS plasmid or plasmids expressing the full-length YU2 envelope glycoproteins (left) or the cytoplasmic tail-
deleted (Dct) YU2 envelope glycoproteins (right). Two days later, cells were incubated with C34-Ig (20 mg/ml), in the presence or absence of sCD4
(20 mg/ml). C34-Ig binding was measured using a secondary horseradish peroxidase-conjugated antibody. (B,C) Change over time in the exposure of
CD4-induced epitopes. Cells that express the YU2(Dct) envelope glycoproteins were pulsed for three minutes with sCD4 (40 mg/ml). Cells were then
washed three times and incubated for different time periods at 37uC. The monoclonal antibody 48d (B) or C34-Ig (C) was then added. The bound 48d
or C34-Ig molecules were detected using a horseradish peroxidase-conjugated anti-human IgG Fc antibody, as described in Materials and Methods.
Values represent the mean RLU (6s.e.m.) of two replicate samples.
doi:10.1371/journal.ppat.1000360.g002
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227S4). However, no correlation between the functional stability of
the native and sCD4-bound states of each of the envelope
glycoproteins was observed.
We conclude that after engagement of sCD4, HIV-1 undergoes
a transient phase of activation, during which attachment to cells
that express CCR5 will allow entry to occur. However, this
activated state is short-lived and is followed by apparently
irreversible structural rearrangements and loss of infectivity. Thus,
at any given time point after exposure to sCD4, HIV-1 infectivity
represents the combined result of an activation process and
progression through the activated intermediate state to inactiva-
tion (Figure S5).
Figure 3. Temperature dependence of the decay of HR1 groove
exposure. (A) Decay of HR1 groove exposure at different temperatures
after pulse activation with sCD4 (40 mg/ml; 0.8 mM) was measured by a
cell-based ELISA, as described in Materials and Methods. The indicated
values for C34-Ig binding were obtained by subtracting the values of
C34-Ig binding in the absence of sCD4 from the binding measured at
each time point after the sCD4 pulse. Mean background levels of C34-Ig
binding (in the absence of sCD4) were 10316, 21413, and 19028 RLU for
the experiments performed at 4uC, 25uC, and 37uC, respectively. (B)
Binding of C34-Ig and sCD4 to the HIV-1 envelope glycoproteins was
measured at different temperatures. Cells that express the YU2(Dct)
envelope glycoproteins were incubated simultaneously with both C34-
Ig (20 mg/ml) and sCD4 (20 mg/ml; 0.4 mM) at the indicated tempera-
ture. Binding of sCD4 and C34-Ig was detected by FACS analysis using a
fluorescein-conjugated anti-CD4 antibody and a phycoerythrin-conju-
gated goat anti-human IgG antibody, respectively (see Materials and
Methods). The mean fluorescence intensity (MFI) of the cells in both
channels is shown.
doi:10.1371/journal.ppat.1000360.g003
Figure 4. Relationship between infectivity decay and loss of
HR1 groove exposure. (A) Decay of HR1 groove exposure of different
HIV-1 envelope glycoproteins was studied at 25uC after pulse activation
with sCD4. COS-1 cells expressing the indicated HIV-1 envelope
glycoproteins were pulsed with sCD4 (40 mg/ml; 0.8 mM) for 3 minutes,
followed by assessment of HR1 groove exposure using the cell-based
ELISA method, as described in the Figure 2 legend. (B) Recombinant
HIV-1 virions carrying the indicated envelope glycoproteins were pulsed
with sCD4 (40 mg/ml; 0.8 mM) for 3 minutes and incubated at 25uC.
After the indicated times, CD4
2CCR5
+ Cf2Th cells were added to the
viruses. For the sample marked as control, HIV-1(YU2) was pulsed with
buffer and then CD4
+CCR5
+ cells were added. Two days later, virus
infectivity was assessed by measuring luciferase activity in the target
cells. (C) The relationship between the decay rate of HR1 groove
exposure and the decay rate of infectivity, both measured at 25–27uC
after pulse activation with sCD4, is shown for the panel of HIV-1
envelope glycoproteins. Half-lives were determined by fitting a model
function to the data using nonlinear regression. Values represent half-
lives (6s.e.m. for both variables) derived from two to four separate
experiments for each envelope glycoprotein variant.
doi:10.1371/journal.ppat.1000360.g004
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228Metastable Activation Induced by a Small-Molecule CD4
Mimic
CD4-mimetic compounds exemplified by NBD-556 and 191
induce conformational changes in the HIV-1 envelope glycopro-
teins similar to those induced by sCD4 [31,33]. These changes
include formation/exposure of both the coreceptor-binding site on
gp120 and the HR1 groove on gp41 (Figure 5). The similarity
between the effects of 191 and sCD4 on HIV-1 infection of CD4
+
and CD4
2 cells (Figure 1) suggested that 191 may also induce
transiently activated intermediate states in the HIV-1 envelope
glycoproteins. To examine this possibility, we compared the decay
profiles associated with sCD4 and 191. We examined the YU2
and AD8 envelope glycoproteins, which exhibit dramatic
differences in the decay rate of the sCD4-induced intermediate.
For each of these envelope glycoproteins, sCD4 and 191 induced
identical decay profiles, both for HR1 groove exposure and for
infectivity (Figure 6). These results suggest that sCD4 and 191
induce a similar, transient intermediate state in the HIV-1
envelope glycoproteins. Moreover, the differences in decay rates
between the AD8 and YU2 envelope glycoproteins were evident
for both sCD4 and 191, suggesting that the stability of the induced
state is determined by intrinsic properties of the envelope
glycoproteins rather than by the activating agent.
A More Stable Envelope Glycoprotein Intermediate
Induced by Cell-Surface CD4
To examine the longevity of the activated intermediate induced
during the normal HIV-1 entry process, we examined the stability
of HR1 groove exposure after the binding of the envelope
glycoproteins to cell-surface CD4. For this purpose, 293T cells that
express CD4 (but not CCR5) were used to activate the HIV-1
envelope glycoproteins expressed on COS-1 cells. Pilot experi-
ments demonstrated that the observed increases in C34-Ig binding
to the envelope glycoproteins-expressing cells depended on the
presence of CD4 on the activating cell, and were not observed for
a mutant envelope glycoprotein (YU2-GS8), which binds CD4
efficiently but does not expose the HR1 groove in response (see
Figure S6 and Materials and Methods). Relative to the effects of
treatment with sCD4 or 191, the HR1 groove exposure
consequent to activation by cell-surface CD4 was surprisingly
long-lived (Figure 7A). The AD8 and YU2 envelope glycoproteins,
which exhibited significant differences in the half-lives of HR1
groove exposure after activation by sCD4, both formed stable
intermediates following activation by cell-surface CD4.
During HIV-1 entry, CCR5 binding to the CD4-induced
envelope glycoprotein intermediate promotes progression along
the path to virus entry [58]. Differences in the longevity of the
CD4-induced state would be predicted to manifest themselves as
an altered dependency on the density of target cell CCR5. To test
this, the CCR5 available on CD4-expressing cells for interaction
with the HIV-1 envelope glycoproteins was varied in two ways: 1)
the addition of increasing amounts of Compound A, a CCR5
inhibitory compound [41,42,59], to cells expressing both CD4 and
CCR5; and 2) transfection of different amounts of a CCR5-
expressing plasmid into cells expressing CD4. The latter method is
based on the direct relationship between the amount of CCR5
DNA transfected and the cell-surface density of the expressed
Figure 5. Effect of compound 191 on exposure of the gp41 HR1
groove. COS-1 cells transfected with a plasmid expressing the
YU2(Dct) envelope glycoproteins or with the control DKS plasmid,
which does not express an envelope glycoprotein on the cell surface,
were incubated with the indicated molecules in the presence or
absence of C34-Ig (20 mg/ml). The data represent the means (6s.e.m.)
of two replicate samples.
doi:10.1371/journal.ppat.1000360.g005
Figure 6. Longevity of the HIV-1 envelope glycoprotein intermediate at room temperature after activation by sCD4 or 191. (A) The
decay of HR1 groove exposure for cell-surface–expressed YU2 and AD8 envelope glycoproteins is compared after pulse activation with 191 (360 mM)
or sCD4 (40 mg/ml, 0.8 mM). (B) The decay of the ability to infect CD4
2CCR5
+ Cf2Th cells after pulse activation with 191 or sCD4 is compared.
doi:10.1371/journal.ppat.1000360.g006
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229CCR5 molecule (Figure S7). The cells were then exposed to HIV-
1(AD8) or HIV-1(YU2) and the efficiency of infection measured.
HIV-1(AD8) and HIV-1(YU2) behaved indistinguishably in
response to variations in the CCR5 available on target cells
expressing CD4 (Figure 7B and 7C). In contrast, when sCD4 was
used to activate infection of Cf2Th cells expressing different levels
of CCR5, entry by HIV-1(AD8) was significantly better than that
of HIV-1(YU2) (Figure 7D). These results are consistent with the
existence of a relatively long-lived envelope glycoprotein interme-
diate being induced by CD4 expressed on the target membrane.
Discussion
Clinical testing of the inhibitory efficiency of sCD4 revealed no
reduction of viral loads in HIV-1-infected individuals [13]. Failure
of treatment was attributed to the resistance to sCD4-mediated
inhibition of primary HIV-1 isolates, relative to laboratory-
adapted isolates [13]. However, lower sCD4-binding affinity could
not be consistently correlated with resistance of HIV-1 isolates to
inhibition [17,19]. Furthermore, in vitro observations of sCD4-
mediated enhancement of infection [14] remained largely
unexplained. More recently, small-molecular-weight compounds
have been developed that target the highly conserved CD4-
binding site of the gp120 envelope glycoprotein [31,32]. NBD-556
and its derivatives bind to the gp120 envelope glycoprotein and
induce structural changes similar to those promoted by sCD4.
Although currently NBD-556 and analogues are only interesting
tools to study the entry process, with improvement, they could
prove useful therapeutically or prophylactically. However, in view
of their potential to enhance HIV-1 infection, an understanding of
the mechanisms underlying the effects of SCMs is essential for the
safe application of these inhibitors.
In this study, we apply a new approach to define the dynamics of
conformational changes that occur in the trimeric membrane-
bound form of the HIV-1 envelope glycoproteins. The binding of
conformation-specific probes was directly measured at high
temporal resolution, allowing us to monitor transiently exposed
structures and thus to define the longevity of specific activated
intermediates. The lack of dependence on indirect methods, such as
the use of conformation-specific inhibitors, and the capacity to
detect conformational intermediates permitted identification of an
SCM-induced transitionto the inactive state. In contrast to previous
observations based on the interactions of envelope glycoprotein-
and receptor-expressing cells [26,60], we detected no lag in the
formation/exposure of either the gp120 coreceptor-binding site or
the gp41 HR1 groove, two key signatures of the SCM-activated
state. Even at low temperatures, both sites were immediately
exposed after binding of the SCMs to gp120. This is consistent with
a model in which conformational changes in the envelope
glycoproteins associated with SCM binding are tightly coupled, or
perhaps coincide, with the structural transitions that shape and
expose the coreceptor-binding site and the HR1 coiled coil.
Except for its lower affinity for the envelope glycoproteins, the
NBD-556 analogue 191 [31,33] exerted effects that were
remarkably similar to those exerted by sCD4. Thus, the properties
of the SCM-induced intermediate defined in this study are
intrinsic to the envelope glycoproteins of the particular HIV-1
strain rather than being dependent on the individual SCMs.
During HIV-1 infection of CD4
+ cells, SCMs compete for cell-
associated CD4. Competition for the cell-surface CD4 receptor
was previously suggested as a major mechanism of HIV-1
inhibition by sCD4 [17,18]. In this work, we show that SCMs
can efficiently substitute for cell-surface CD4. In this context, some
inhibition of infection may result from the difference in the
efficiency with which membrane-anchored CD4 and SCMs
promote HIV-1 entry. Importantly, we demonstrate that SCMs
inhibit HIV-1 infection by a novel mechanism that is initiated by
activation of the viral envelope glycoproteins. Similar to the
envelope glycoprotein intermediate that results from binding cell-
surface CD4, the SCM-induced activated state is characterized by
the exposure of the coreceptor-binding site on gp120 and the HR1
groove on gp41. Moreover, the SCM-activated envelope glyco-
proteins are able to mediate virus entry into CCR5
+ cells lacking
CD4. However, in contrast to the stable activation induced by cell-
surface CD4, the SCM-activated intermediate decays rapidly, in a
manner dependent upon temperature and envelope glycoprotein
Figure 7. HIV-1 activation by native CD4 and sCD4. (A) The stability of HR1 groove exposure was measured after activation of the YU2 or AD8
envelope glycoproteins by cell-surface CD4. Background was defined as C34-Ig binding to cells transfected with the YU2-GS8 construct, which
engages sCD4 with an affinity similar to that of the wild-type YU2 envelope glycoproteins but does not expose the HR1 groove (see Figure S6). The
background was subtracted from all measurements, which are presented as percent (6s.e.m.) of C34-Ig binding measured at the initial time point. (B)
The effect of the CCR5 antagonist ‘‘Compound A’’ [41,42] on infectivity of recombinant HIV-1 pseudotyped with the indicated envelope glycoproteins
was investigated. Cf2Th-CD4/CCR5 cells were infected with HIV-1(AD8) or HIV-1(YU2) in the presence of increasing concentrations of Compound A.
Data are presented as the percentage (6s.e.m.) of infection measured in the absence of the compound. (C) The effect of CCR5 expression on the
infection of CD4-expressing cells by HIV-1(AD8) or HIV-1(YU2) was examined. Cf2Th-CD4 cells were transfected with different amounts of a plasmid
that expresses human CCR5. Two days later, transfected cells were incubated with HIV-1(AD8) or HIV-1(YU2). Infectivity is expressed as the
percentage (6s.e.m.) of infectivity measured for cells transfected with the highest amount of the CCR5-expressing plasmid. (D) The graph shows
infection by cell-bound virus of CD4
2 Cf2Th cells transfected with different amounts of the CCR5-expressing plasmid in the presence of 20 mg/ml
sCD4. Infectivity is expressed as the percentage (6s.e.m.) of infection measured in cells transfected with plasmids expressing CD4 and CCR5 (0.6 and
0.9 mg, respectively, of each plasmid per well).
doi:10.1371/journal.ppat.1000360.g007
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230strain. In the process, both exposure of the HR1 groove and
membrane-fusing potential are irreversibly lost.
The SCM-induced exposure of the hydrophobic HR1 groove
may be energetically unfavorable in the context of free virus,
favoring a transition to a more stable but nonfunctional state.
Whether this nonfunctional state involves a prematurely triggered
six-helix bundle in gp41 or another, possibly off-pathway,
conformation requires further investigation. Arguing against the
former possibility is the expectation that six-helix bundle
formation in gp41 would be incompatible with maintaining the
non-covalent association with gp120. In fact, even for the most
unstable envelope glycoprotein intermediate studied, no evidence
of gp120 shedding after SCM treatment was observed. Despite
rapid loss of function, the SCM-inactivated envelope glycoproteins
retained gp120, which remained associated with the SCM and
stably attached to the expressing cell surface. This finding is
consistent with previous studies of dose response, temperature
dependence, timing and HIV-1 strain specificity that show a lack
of correlation between the HIV-1-inhibitory activity of sCD4 and
the degree of gp120 shedding induced [14,17,19,21,25].
By contrast, the kinetics of the decay of SCM-induced HR1
groove exposure and the decay of HIV-1 infectivity correlate, and
the ranges of SCM concentrations required for induction of the
labile envelope glycoprotein intermediate and for virus neutrali-
zation overlap. These observations support the important
contribution that induction of the metastable activated interme-
diate makes to SCM-mediated inhibition of virus infectivity.
Achieving inhibition by initiating the targeted process is unusual,
but two properties of the HIV-1 envelope glycoproteins render
them susceptible to this strategy of inhibition: 1) initial folding and
assembly into a high-potential-energy form that is prone to
transform into energetically more favorable states; and 2)
triggering of these conformational transitions by receptor binding,
allowing a receptor mimic to take advantage of the built-in
propensity of the viral envelope glycoproteins to engage the
receptor and undergo global conformational changes.
The efficiency of an activation-based mechanism of inhibition is
determined by the change over time in the distribution of the
HIV-1 envelope glycoproteins among three states: 1) unliganded/
non-activated; 2) bound/activated; and 3) post-activation decayed.
This distribution is influenced by the following factors: 1) rate of
SCM engagement; 2) the time interval between SCM-induced
activation and progression to a step of infection that is unaffected
by the decay process; and 3) the intrinsic stability of the SCM-
induced activated intermediate. Forces that determine the
distribution between these three states dictate the balance between
enhancement and inhibition of infection, as detailed below.
Infection by cell-free virus is rate-limited by the slow diffusion-
dependent attachment of the virus to the cell surface [53,54].
Activation of the diffusing virus by a soluble molecule is thus
characterized by an extended lag period between activation and
the next step of the infection sequence. Half-maximal productive
adsorption of diffusing HIV-1 virions to a cell monolayer (i.e.,
attachment that culminates in an infection event) occurs after
approximately 5 hours at 37uC [55]. By contrast, the half-life of
infectivity of the most stable activated intermediate examined in
this study at 37uC was less than 8 minutes. As the longevity of the
SCM-activated intermediate is significantly shorter than the
duration of the attachment step, SCM-mediated inhibition of
cell-free virus is primarily determined by the rate of activation (i.e.
by both the on-rate and effective concentration of the compound).
Activating effects on HIV-1 infection predominate at low
concentrations of SCMs. The dependence of virus activation and
inactivation on SCM concentration was particularly evident in the
biphasic dose-effect curves associated with HIV-1(YU2) infection
of CD4
2 CCR5
+ target cells (Figure 1A and 1B and Figure S5).
The stoichiometry of SCM binding to the HIV-1 envelope
glycoprotein trimers may influence the propensity of the activated
intermediate(s) to proceed along entry or post-activation decay
pathways. For example, the binding of two SCMs to the envelope
glycoprotein trimer may be more efficient in promoting inactiva-
tion/decay than the binding of a single SCM. Such a model would
explain the exceptionally long-lived sCD4 activation of SIV
[15,61], the envelope glycoproteins of which have been reported
to bind only one CD4 molecule per trimer [62,63].
Retrovirus transmission is significantly more efficient when virus
is transferred through direct physical interaction between cells
(cell-cell transmission) than by diffusion of virions in cell-free
transmission [64]. During cell-cell transmission, where HIV-1
virions emerging from the infected cell rapidly achieve proximity
to the target cell [65,66], SCMs are more likely to enhance
infection than in the case of cell-free infection. Indeed, HIV-1 that
was pre-bound to the surface of CD4
2CCR5
+ cells, perhaps
mimicking the conditions of cell-cell transmission, infected the cells
efficiently after incubation with SCM concentrations that were
highly neutralizing for cell-free virus. In cell-cell transmission, the
time interval between SCM-induced activation and the next step
committed to the infection pathway exerts a dominant influence
on the efficiency of HIV-1 inhibition by SCMs. Several
observations suggest that the engagement of the coreceptor plays
a major role in moving the SCM-activated HIV-1 envelope
glycoproteins along the entry pathway. First, the sCD4-mediated
enhancement of HIV-1 infection of CD4
2 cells is highly
dependent on the level of CCR5 expression (Figure 7D). Second,
a study of activation of infection of CD4
2CCR5
+ cells by NBD-
556 indicated a contribution of CCR5-binding affinity to
susceptibility to enhancement [33]. Finally, although SCMs
allowed CCR5-using viruses to infect CD4
2CCR5
+ cells, SCMs
did not stimulate the infection of CD4
2CXCR4
+ cells by
CXCR4-using viruses. The lack of enhancement of CXCR4-
using viruses was not due to greater lability of the activated state.
The half-life of the sCD4-induced, HR1-groove-exposed state on
the CXCR4-tropic HXBc2 envelope glycoproteins was 55 min-
utes at 26uC, and was significantly longer on the dual-tropic KB9
envelope glycoproteins. Despite this, neither of these envelope
glycoproteins supported infection of CD4
2CXCR4
+ cells after
incubation with sCD4 or 191 [ref. 33 and data not shown].
However, 191 did allow viruses with the KB9 envelope
glycoproteins to infect CD4
2CCR5
+ cells. The apparent inability
of SCM-activated viruses to utilize CXCR4 for entry may be a
consequence of the significantly lower affinity of CXCR4 for the
HIV-1 envelope glycoproteins, relative to that of CCR5 [67].
Together, these observations support the importance of efficient
coreceptor binding to the susceptibility of HIV-1 to SCM-induced
activation of infection of CD4
2 cells. Further work will be
required to assess whether this type of enhancement can occur on
primary CD4
2CCR5
+ cells following SCM treatment.
The mechanism of inhibition elucidated here suggests that
SCMs will be most effective in settings, such as sexual
transmission, in which HIV-1 is fully dependent on diffusion for
successful infection. Efforts to develop small-molecule SCMs with
improved rates of engaging the HIV-1 envelope glycoproteins are
therefore warranted.
Binding of the HIV-1 envelope glycoproteins to native,
membrane-anchored CD4 resulted in the stable exposure of the
HR1 groove on gp41, in contrast to the labile structure induced by
SCMs. Although additional studies will be needed to address the
basis of this difference, our data rule out the contribution of CCR5
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231or CXCR4 on the target cell. The stable nature of the activated
HIV-1 envelope glycoprotein intermediate induced by cell surface
CD4 facilitates engagement of additional CD4 molecules and the
coreceptor, and creates a ‘‘window of opportunity’’ for inhibition
of downstream events in virus entry.
Supporting Information
Figure S1 Decay of HR1 groove exposure measured by FACS.
Cells that express the YU2(Dct) envelope glycoproteins were
incubated at room temperature with sCD4 (40 mg/ml; 0.8 mM) for
20 min, washed, and further incubated at room temperature for
the indicated time periods. Then the C34-Ig protein (40 mg/ml)
was added. Binding of sCD4 and C34-Ig was detected by
fluorescein- and phycoerythrin-conjugated antibodies, respective-
ly, as described in the Figure 3 legend. Note that the decrease in
the mean fluorescence intensity of C34-Ig binding (right panel) was
more modest than the decrease in the percentage of the double-
positive cell population.
Found at: doi:10.1371/journal.ppat.1000360.s001 (0.44 MB TIF)
Figure S2 The kinetics, affinity, and consequences of soluble
CD4 binding to the HIV-1 envelope glycoproteins. (A) Binding of
sCD4 to the YU2 and AD8 envelope glycoprotein complexes on
the surface of expressing cells was examined. COS-1 cells
expressing the YU2 and AD8 full-length envelope glycoproteins
were incubated with the indicated concentrations of sCD4 for 1 h
at room temperature. Cells were then washed four times and
incubated with the anti-CD4 monoclonal antibody OKT4 (10 mg/
ml) for 30 min. Cells were subsequently washed, and binding was
detected using a horseradish peroxidase-conjugated goat-anti-
mouse polyclonal antibody. Results are presented as mean RLU
(6s.e.m.) of two replicate samples. (B) The kinetics of CD4-Ig
binding to full-length YU2 and JR-FL envelope glycoproteins
expressed on the surface of COS-1 cells was measured by the cell-
based ELISA method. CD4-Ig was added at 0.5 mg/ml. Results
are presented as the percentage of binding measured at the final
time point examined. (C) Decay of gp41 HR1 groove exposure for
the indicated envelope glycoproteins at 25uC after pulse-activation
with sCD4. (D) Decay of gp41 HR1 exposure at 25uC and 37uC
after pulse activation by sCD4 (40 mg/ml; 0.8 mM). (E) Decay of
HIV-1(KB9) and HIV-1(89.6) infectivity at 37uC after pulse
activation by sCD4 (40 mg/ml; 0.8 mM).
Found at: doi:10.1371/journal.ppat.1000360.s002 (0.68 MB TIF)
Figure S3 Decay of HIV-1 infectivity at different temperatures
after pulse activation with sCD4. (A) HIV-1(JR-FL) virions were
magnetically immobilized on tissue-culture plates and pulsed with
sCD4 (40 mg/ml; 0.8 mM) for three minutes at 26uC. Samples
were then washed and incubated at the indicated temperatures for
20 min. Cf2Th-CCR5 cells were subsequently added and pelleted
onto the viruses. Two days later, infectivity was measured by
luciferase assays. (B) As a control, viruses were pulsed with buffer,
incubated at the different temperatures, and then Cf2Th-CD4/
CCR5 cells were added. Infectivity was measured two days later
and is presented as mean RLU (6s.e.m.) of three replicate
samples.
Found at: doi:10.1371/journal.ppat.1000360.s003 (0.31 MB TIF)
Figure S4 Decay of infectivity of viruses bearing different HIV-1
envelope glycoproteins. Recombinant, luciferase-expressing virus-
es that contain the indicated envelope glycoproteins were
incubated in culture medium at 37uC for different time periods
and then added to Cf2Th-CD4/CCR5 cells. 48 h later, luciferase
activity in the target cells was measured to estimate the level of
infection. Data are presented as the percentage of infectivity
observed in samples not incubated at 37uC. The inset shows a
comparison between the infectivity half-lives of the non-activated
viruses (measured at 37uC with CD4+CCR5+ cells) and the sCD4-
activated viruses (measured at 26uC with CD42CCR5+ cells).
Found at: doi:10.1371/journal.ppat.1000360.s004 (0.43 MB TIF)
Figure S5 Change in cell-free HIV-1 infectivity after engage-
ment of sCD4. HIV-1(YU2) or HIV-1(JR-FL) virions were
associated with magnetite nanoparticles and then incubated with
the indicated concentrations of sCD4 for different time periods at
26uC. Complexes were then added to confluent cultures of Cf2Th-
CCR5 cells to which a magnetic field was applied. After
incubation for 1 min, cells were washed and further cultured for
two days. As a control, complexes of viruses and magnetite
nanoparticles were incubated with buffer and then adsorbed to
Cf2Th-CD4/CCR5 cells. Results are presented as mean RLU
(6s.e.m.) of three replicate samples.
Found at: doi:10.1371/journal.ppat.1000360.s005 (0.66 MB TIF)
Figure S6 Activation of the HIV-1 envelope glycoproteins by
cell-surface CD4. (A) The abilities of the YU2 and YU2-GS8
envelope glycoproteins to bind different ligands were compared,
using the cell-based ELISA. COS-1 cells transfected with plasmids
expressing the indicated envelope glycoproteins were incubated
with the monoclonal antibodies 39F or IgG1b12 (both at 0.5 mg/
ml), or C34-Ig (20 mg/ml), with or without sCD4 (20 mg/ml;
0.4 mM). Data are presented as mean RLU (6s.e.m.) of two
replicate samples. (B,C) 293T cells transfected with a plasmid
expressing wild-type human CD4 or with the control DKS plasmid
were added to COS-1 cells transfected with plasmids expressing
DKS, wild-type YU2, or the YU2-GS8 envelope glycoproteins.
Cells were pelleted to increase approximation and incubated at
4uC for 75 minutes to allow CD4 engagement. Samples were then
incubated with C34-Ig (20 mg/ml) to measure HR1 groove
exposure (B) or the anti-CD4 antibody sc-70660 (Santa Cruz
Biotechnology) to measure association of the 293T-CD4 cells with
the COS-1 cell monolayer. Antibody binding was detected using
HRP-conjugated antibodies. Data are presented as mean RLU
(6s.e.m.) of two replicate samples. (D) The experiments described
in (B) were repeated, expressing CD4 and the HIV-1 YU2
envelope glycoproteins (or the DKS control) in either COS-1 or
293T cells.
Found at: doi:10.1371/journal.ppat.1000360.s006 (0.56 MB TIF)
Figure S7 Relationship between the amount of transfected
CCR5-expressing plasmid DNA and the density of CCR5 on the
surface of the transfected cells. (A) COS-1 cells cultured in 96-well
plates (2.4610
4 cells per well) were transfected using Effectene
reagent (Qiagen) with the indicated amounts of the pcDNA3.1-
CCR5 plasmid, which expresses the CCR5 gene under the control
of the hCMV-IE promoter. Each well was transfected with the
same total amount of DNA (0.1 mg) by supplementing the
pcDNA3.1-CCR5 plasmid with the DKS plasmid. Two days
later, CCR5 expression was measured using the cell-based ELISA
method with the anti-CCR5 monoclonal antibody 2D7 (1 mg/ml),
detected with a horseradish peroxidase-conjugated goat-anti-
mouse IgG2a antibody. Data are presented as mean RLU
(6s.e.m.) of two replicate samples. (B) Cf2Th cells cultured in
10-cm plates were transfected using Lipofectamine 2000 reagent
(Invitrogen) with the indicated amounts of the pcDNA3.1-CCR5
plasmid. Three days later, cells were analyzed for CCR5
expression with a phycoerythrin-conjugated 2D7 antibody using
an EPICS XL flow cytometer (Beckman-Coulter). Data were
analyzed using WinMDI 2.9 software.
Found at: doi:10.1371/journal.ppat.1000360.s007 (0.18 MB TIF)
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